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Summary 
 
In this thesis project, we studied the pharmacology of long-known psychostimulants 
and of novel amphetamine-type designer drugs in vitro. On the basis of the 
pharmacological characterization, we focused on the drug effects in humans, 
investigating the pharmacological effects of the widely used amphetamine derivative 
3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”). Furthermore, we 
investigated potential antagonistic treatments for methamphetamine dependence.  
 
In vitro, we characterized the pharmacology of a comprehensive set of drugs, 
determining their action at targets found in monoaminergic synapses. We used 
HEK-293 cells transfected with the respective genes for the three monoamine 
reuptake transporters and post-synaptic receptors. We performed pharmacological 
assays with radiolabeled substrates or ligands to determine drugs’ transport 
modulation properties and receptor affinities. We classified novel designer drugs that 
were cathinone-derivatives according to their pharmacology and discriminated 
between three groups. Cocaine-MDMA-mixed cathinones were drugs that inhibited 
the dopamine (DA) and serotonin (5-HT) uptake with equal potencies to cocaine, but 
preferentially released transporter-mediated 5-HT like MDMA. Methamphetamine-
like cathinones inhibited DA uptake preferentially over 5-HT uptake and released 
DA, comparable to methamphetamine. Pyrovalerone-cathinones were extremely 
potent DA uptake inhibitors, but non-releasers. Additionally, we found methedrone as 
only serotonergic cathinone, similar to MDMA and other para-methoxylated 
amphetamines. We described key findings upon blood-brain-barrier characteristics 
and differences between β-ketonated and non-β-ketonated amphetamines in receptor 
binding and DA/5-HT preferences. All amphetamine-type drugs inhibited 
norepinephrine (NE) uptake, which indicated the importance of the norepinephrine 
system as contributor to the effects of psychostimulants.  
 
In humans, we assessed the role of NE and 5-HT in the mechanism of action of 
MDMA in two placebo-controlled, double-blind, crossover studies. To elucidate the 
contribution of the respective monoamines, we attenuated the MDMA-induced 
psychotropic and cardiovascular effects with the NE-transporter (NET) inhibitor 
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reboxetine and also with the mixed 5-HT transporter (SERT)/NET inhibitor 
duloxetine. We found that 5-HT primarily mediates empathogenic mood effects 
whereas NE is primarily involved in the MDMA’s cardiostimulant effects. PK-PD 
relationships combining subjective- or cardiostimulant effects with MDMA’s 
pharmacokinetics in relation to time depicted the tolerance of the drug’s effects. 
Predicting drug effects with in vitro 5-HT and NE release characteristics, we 
highlighted the role of NE in MDMA’s mode of action.  
We also showed that 5-HT and/or NE play a role in the MDMA-induced 
inappropriate secretion of antidiuretic hormone, which is involved in the development 
of potentially serious complications such as brain edema evolving from hyponatremia. 
In one of the aforesaid clinical studies, duloxetine attenuated the MDMA-induced 
increase of antidiuretic hormone, which was more distinctive in female than male 
subjects. 
 
Finally, we addressed our research to the possibilities of pharmacological modulation 
of amphetamine-type drug dependence by antagonizing DA-related effects. We 
assessed in vitro the potencies of three DA transporter (DAT) inhibitors to block 
methamphetamine-induced DA release, which is a known mechanism for drug 
dependence. The DA uptake inhibition potencies of the three assessed drugs 
correlated linearly with their potencies to inhibit methamphetamine-induced DA 
release. The strong action on the DA system and the associated abuse potential of the 
most potent release blocker, 3,4-methylenedioxypyrovalerone, depicts the difficulty to 
find unproblematic pharmacological treatment for drug dependence.  
 
Taken together, we characterized 5-HT, NE, and DA in amphetamine-type drug 
action in vitro and also illustrated their relevance for drugs’ effects in humans. 
INTRODUCTION_________________________________________________________________ 1!
Introduction 
1. Designer drugs - definitions 
Designer drugs are, to date, an unclear and opulent accumulation of different 
substances, which are ingested weekend for weekend all over the world in order to 
change one’s state of perception or to party all night. To look for an exact definition 
of the term designer drug is almost as confusing as trying to get an overview over the 
different molecules that are available as designer drugs.  
Designer drugs are substances that were designed from the example of illegal drugs 
by slight modification of the molecule in order to obtain uncontrolled substances with 
similar effects than the controlled exemplary drugs [1]. This is the definition of the 
authority that surveys the European illegal drug market, namely the European 
Monitoring Center for Drugs and Drug Addiction (EMCDDA). German Wikipedia is 
consistent with the EMCDDA definition and points out that the key feature of a 
designer drug is its design for narcotic drug purpose, which would not include 
substances such as amphetamine or MDMA, as they were first designed for medical 
purposes [2]. The Meyer’s encyclopedia is more general in their definition. It explains 
designer drugs as “synthetic narcotic drugs, chemical derivatives of known addictive 
drugs” and gives Ecstasy as example [3]. Sometimes designer drugs is used as 
synonym for synthetic drugs, which includes all drugs synthetically and not naturally 
derived [2]. Due to the inconsistency of definitions, I take here the freedom to define 
the term designer drug in our way of understanding. We understand designer drugs in 
this thesis as substances that were synthetically produced and currently abused as 
stimulant and/or recreational drugs. 
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Figure 1: Graphical definition of the term amphetamine-type drugs as it is referred to in this thesis. Amphetamine-
type drugs unify structural similarities (upper left circle), similar molecular mechanism of action (upper right 
circle), and comparable psychostimulant effects in humans (lower circle). MA = monoamine, MAT = 
MA-transporter. 
 
The term amphetamine-type drugs or shortly amphetamines, is use here for 
substances that resemble amphetamine in their chemical structure, in their molecular 
mechanism of action, and in the experienced effects in drug users. Derivatives of 
amphetamine can be derived from modification on the benzene ring, the amino group, 
and the α- or β-position of the carbon chain. A key characteristic of amphetamine 
pharmacology is the induction of monoamine release mediated by their respective 
uptake transporters [4]. Also, amphetamine inhibits reuptake of the monoamines 
dopamine (DA), norepinephrine (NE), and serotonin (5-HT) [5]. Characteristic 
psychotropic effects of amphetamines are euphoria and stimulation, but no 
hallucinations at the doses typically used [6, 7]. 
 
 
2. Novel designer drugs 
In chapter 1 of this thesis, our research is strongly focused on novel amphetamine-
type designer drugs. It is therefore worth to say some words about this kind of novel 
drugs. Within the last few years there was a massive increase in the diversity of 
available designer drugs (see Figure 2). Since many of these designer drugs were, or 
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still are, uncontrolled substances, they are also known as “legal highs” [8]. 
Mephedrone (also “Meow”, “MCAT”, “bath salt”, “research chemical”) is one of the 
most popular examples of novel designer drugs, which was set under control in the 
UK in April 2010 [9]. Many other substances followed to be controlled, while new 
structures emerged. In order to react quickly to newly emerged designer drugs, Swiss 
legislation for example, now allows for scheduling substances several times per 
annum into Verzeichnis e, which contained in December 2012 seven substance classes 
including cathinones and 52 single substances [10]. Media reports about “zombie 
drugs” in summer 2012 pointed out the relevance and actuality for research on this 
topic. These worldwide published stories associated psychotic cannibalism with the 
consumption of “bath salt” that most likely contained the novel designer drugs 
mephedrone, 3,4-methylenedioxypyrovalerone (MDPV), and/or methylone [11]. 
Dealing with novel designer drugs in this thesis, we mainly focus on cathinone-
derivatives, which have become a very popular class of designer psychostimulants 
and include mephedrone, MDPV, methylone and many others. From the 40 designer 
drugs newly emerged on the EU illicit drug market in 2010, 15 were cathinone-
derivatives [12]. Cathinones are synthetic derivatives of cathinone, which is found in 
Catha edulis. The fresh leaves of this tree, so-called Kath, are chewed in many 
African and Arab countries. Khat and the synthetic cathinones have stimulant 
amphetamine-type effects in humans [8]. Since the reported psychostimulant effects 
produced by cathinones are similar to those of other amphetamines like MDMA or 
methamphetamine, it was nearby to compare the pharmacology and mechanism of 
action of cathinones to these well-known and thoroughly investigated designer drugs. 
We assessed the novel designer drugs in vitro only, and for mechanistic studies that 
were partially conducted in humans we used the model substances MDMA and 
methamphetamine. The findings and conclusions based on the experiments with 
MDMA and methamphetamine in this study should also be expanded to our novel 
designer drugs, since the in vitro findings in chapter 1 build the bridge between the 
pharmacology of novel drugs and the classical stimulants, and the studies in chapter 2 
and 3 correlate relevant effects in humans with in vitro characteristics. 
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Figure 2: Number of newly detected substances sold as recreational designer drugs as presented by EMCDDA in 
their annual report 2012 [1]. Cathinones represent the second largest group of chemically defined substances. 
 
3. Molecular mechanism of action of amphetamines 
The molecular mechanism of action of amphetamine and its derivatives 
methamphetamine and MDMA is well investigated. The main site of action of 
amphetamine-type drugs is at the synapse of monoaminergic neurons located in the 
brain mainly in the reticular formation [13]. All amphetamine-type drugs inhibit DA, 
NE, and 5-HT reuptake from monoaminergic synapses, although with different 
potencies. Typically for amphetamines, they also induce reverse transport (also 
referred to as release or efflux) of neurotransmitter not exocytotically, but through 
monoamine transporters [4]. Since the reuptake transporters are the only targets that 
clear the monoaminergic neurotransmitters from the synapses and thus regulate signal 
transmission, inhibition of reuptake and induction of reverse transport result in 
profound changes of signal transmission [14, 15].  
For the understanding of the pharmacological assays with which we assessed all drugs 
in this thesis, it is crucial to know the physiology of a synapse, the site where the 
amphetamine-type drugs act. I will describe in the following sections the localization 
of amphetamines’ targets, the mechanism of uptake inhibition and the mechanism of 
drug-induced release. I will also discuss the relevance to discriminate uptake 
inhibition and release induction. 
 
90
Annual report 2012: the state of the drugs problem in Europe
As in 2010, about two thirds of the newly notified 
substances reported in 2011 were synthetic cannabinoids or 
synthetic cathinones; these two groups also represent two 
thirds of all new substances reported to the early warning 
system since 2005 (EMCDDA and Europol, 2011). Synthetic 
cannabinoids are the largest of the six different groups 
monitored (see Figure 20). Also monitored are a number 
of medicines (e.g. phenazepam and etizolam), metabolites 
or precursors of medicines (5-hydroxytryptophan) and 
substances based on medicines (e.g. camfetamine — 
a derivative of fencamfamine). An example of this is 
methoxetamine, a ketamine derivative reported in 2010 
and actively monitored by the early warning system, 
a substance with a potential for acute (Wood et al., 2012a) 
and chronic toxicity similar to that seen with ketamine.
Production and supply of new drugs
Most new psychoactive substances appearing on 
the European illicit drugs market are reported to be 
synthesised outside Europe, with China and, to a lesser 
extent, India being identified as the primary source 
countries. European law enforcement agencies have 
uncovered facilities associated with the importation, 
mixing and packaging of these substances. Reports 
indicate the involvement of organised crime in both the 
tableting and marketing of these substances, which are 
sold mainly as ‘legal highs’ on the Internet and in smart 
and head shops. In some cases, however, they are sold 
as illicit drugs such as ‘ecstasy’, using logos typically 
associated with this type of drug.
European law enforcement involvement in transnational 
cases related to the trafficking, mixing and packaging of 
new psychoactive substances are reported to have increased 
in recent years. Investigations focusing on mephedrone found 
that the drug was largely manufactured in China, often 
entering European countries in which it was controlled via 
a third country where it was not (Europol). Minor seizures, 
mainly of cathinones and synthetic cannabinoids, were 
reported by Germany, Estonia and Hungary, and from 
Denmark, concerning mCPP (133). Larger seizures, involving 
mainly unspecified new psychoactive substances, were 
reported by Latvia (about 5 kg) and Spain (seizure from 
a head shop totalling 96 kg) as well as a seizure of more 
than 20 kg of mephedrone originating from India in the 
Czech Republic. Other production-related facilities were 
dismantled or seized in Belgium, Ireland, Poland (5 kg of 
mephedrone) and the Netherlands, where 150 kg of white 
powders and approximately 20 000 packages containing 
several synthetic cannabinoids were seized at one facility.
(133) 1-(3-chlorophenyl)piperazine.
Figure 20: Main groups of new psychoactive substances identified through the early warning system since 2005
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Figure 3: Schematic overview on synaptic physiology of DA, NE, and 5-HT neurons as illustrated by Torres et al. 
[14]. Monoaminergic neurotransmitters are synthesized in the neuron, stored in vesicles and released for signal 
transmission via exocytotic fusion of the storage vesicles with the membrane. To end signal transmission, which 
occurs upon the stimulation of post-synaptic receptors, monoamines are cleared from the synaptic cleft by reuptake 
via monoamine transporters. Monoamine- and vesicular transporters are targets of psychoactive therapeutics 
and/or psychostimulant drugs of abuse. While pure uptake inhibitors (e.g., cocaine) act extracellularly, substrate-
type releasing drugs (e.g., MDMA) are transported into the presynapse and also act intracellularly. 
 
3.1. Localization of main sites of action, brain anatomy and synaptic physiology 
Brain regions containing DA neurons are the basal ganglia (includes striatum with 
nucleus accumbens), the ventral tegmental area, and the substantia nigra [13]. 
Noradrenergic neurons are mainly found in the locus coeruleus and are responsible 
for adrenergic neurotransmission [13]. Serotonergic neurons are located in raphe 
nuclei and are involved in the regulation of mood, anxiety, and perception [13]. From 
their origin, monoaminergic neurons expand widespread projections into different 
brain regions, representing the dopaminergic, noradrenergic, or serotonergic systems 
[16]. Dopaminergic neurons are important neurons in the brain’s mesolimbic system, 
which is essential for reward [13]. 
A monoaminergic neuron physiologically releases neurotransmitter exocytotically via 
vesicles, in which the monoamines are stored until release. Apart from the releasing 
function of vesicles, they protect the neurotransmitters during storage by their low pH 
conditions, and in the case of NE, vesicles are the location for the final step in its 
synthesis [16, 17]. After having been released into the synaptic cleft, monoamines 
reach the postsynapse and transmit the neurological signal by binding and thereby 
activating or deactivating postsynaptic receptors [16]. Finally, to end the signal 
transmission, monoamine reuptake transporters are responsible for clearing the 
neurotransmitters from the synaptic cleft back to the presynapse [15]. See Figure 3 for 
an illustrating summary of synaptic physiology. 
MICRODIALYSIS
Analytical technique that is used
to monitor extracellular levels of
neurotransmitters or other
molecules in vivo. A cannula is
inserted into the brain and test
solution is perfused through it.
Dialysis takes place between the
test and the extracellular
solutions,making it possible to
measure the transmitter levels at
the tissue surrounding the tip of
the cannula.
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R E V I EW S
ofmonoamine transporters, for substrates and inhibitors,
has been examined in brain preparations and in het-
erologous systems with recombinant transporters.
In general, there is good agreement between these 
two approaches. Although all three monoamines are
substrates of their cognate transporter, it has been
shown that either DAT or NET can transport both
dopamine and noradrenaline6. The heterologous
uptake of dopamine by NET has been shown in vivo by
MICRODIALYSIS7 and in synaptosomal preparations from
mouse cerebral cortex8.
made in the research on neurotransmitter trans-
porters for dopamine, noradrenaline, and 5-HT in the
central nervous system, emphasizing the most recent
developments.
Pharmacology of monoamine transporters
Transporters for dopamine, noradrenaline, and 5-HT
— DAT, NET and SERT, respectively — represent
established targets for many pharmacological agents
that affect brain function, including psychostimulants,
antidepressants and neurotoxins3–5 (FIG. 1). The sensitivity
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Figure 1 | Schematic representation of dopamine, noradrenaline and 5-HT synaptic terminals. Monoamine transporters are
localized to perisynaptic sites, where they are crucial for the termination of monoamine transmission and the maintenance of
presynaptic monoamine storage. Several selective pharmacological gents acting at each monoamine transporter are shown.
Amph., amphetamine; DA, dopamine; DAT, Dopamine transporter; L-DOPA, L-3,4-dihydroxyphenylalanine; 5-HT, 5-hydroxytryptamine;
MPP+, 1-methyl-4-phenylpyridinium; MDMA, (+)-3,4-methylenedioxymethamphetamine; NA, noradrenaline; NET, noradrenaline
transporter; SERT, 5-HT transporter.
Box 1 | Localization and distribution of monoamine transporters
In the brain,monoamine transporters are expressed almost exclusively in the neurons that contain their cognate
transmitter. In situ hybridization studies showed prominent dopamine transporter (DAT) expression in the cell bodies of
the substantia nigra and ventral tegmental area (VTA),noradrenaline transporter (NET) expression in the locus
coeruleus and other brainstem nuclei,and 5-HT transporter (SERT) expression in the median and dorsal raphe nuclei161.
In the mouse brain,DAT-like immunoreactivity was detected in the striatum,nucleus accumbens,olfactory tubercle,
nigrostriatal bu dl  and lateral habenula. In addition, cell bodies from neuro s of the substantia nigra an  VTA,as well as
neuronal processes in the substantia nigra, in layers I, II and III of the cingulate cortex and in the medial prefrontal cortex,
were DAT positive54,162,163.NET immunoreactivity in the brain was confined to noradrenergic somata,dendrites and
axons within the hippocampus and cortex164. SERT immunoreactive fibers were found widely distributed throughout the
brain, with the highest densities in regions that receive a dense serotonergic innervation, such as the cerebral cortex and
the CA1 and CA3 regions of the hippocampus. Immunopositive staining for SERT revealed that it was also present in the
cell bodies of the raphe nucleus165,166. In general, there is good agreement between the distribution ofmonoamine
transporters by immunocytochemical approaches and the use of radioactive uptake inhibitors to label transporter sites.
The specific localization ofmonoamine transporters within synaptic terminals has also been examined164,167–169.
Immunoelectron microscopy revealed that DAT,NET and SERT were localized at the plasma membrane,away from the
synaptic area (peri-synaptic area) indicating that transmitter release at the synapse diffuses out of the cleft to be transported
back into the terminal.These studies also found DAT,NET and SERT immunoreactivity that was associated with
intracellular organelles of tubulo-vesicular structure.
Monoamine transporters have also been found in peripheral locations170. In situ hybridization and immunohistochemical
studies indicate that DAT is expressed in the stomach,pancreas, and kidney170.NET is expressed in sympathetic
peripheral neurons, the adrenal medulla, the lung and the placenta170. The SERT protein has been detected in platelets171,
the intestinal tract172 and the adrenal gland173. In addition, SERT activity has been reported in astrocytes in culture174.
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3.2. Monoamine transport and uptake inhibition 
Monoamine transporters are secondary active transporters [4] since their driving force 
is an ion gradient, which is sustained by a Na+/Cl--ATPase [15]. The monoamine 
uptake transport follows Michaelis-Menten kinetics, giving the transport-specific 
constant KM. KM describes the affinity by which the transporter processes its substrate 
[15, 18].  
A wide range of therapeutics and abused substances target monoamine transporters to 
inhibit monoamine reuptake with different potencies and selectivities for the 
respective monoamines. Classical tricyclic antidepressants target all three monoamine 
transporters [17], whereas selective antidepressants like fluoxetine or nisoxetine are 
SERT or NET selective, respectively [17]. The amphetamine-like antidepressant and 
smoking cessation aid bupropion exhibits more potent DAT than NET inhibition [19, 
20]. The quantification of drugs’ transport inhibitions, giving the aforesaid 
characteristics of substances, follows enzyme kinetic rules and is expressed as 
potency (Ki or IC50 values) [21]. While Ki values are assay-independent constant 
values, IC50 values vary according to assays and condition modifications. For the 
present thesis we determined IC50 values only, since considerably less experiments 
need to be performed for this value compared to for Ki values [21]. Although Cheng 
and Prussoff describe ways to calculate a Ki value from a single IC50 value at specific 
assay conditions [22], we did not calculate Ki-values since we did not determine the 
mode of inhibition, namely competitive or non-competitive inhibition. 
 
3.3. Drug-induced monoamine release 
Increases in neurotransmitter concentrations in the synaptic cleft can occur via the 
physiological release of neurotransmitters by vesicles (exocytosis) and also by 
reuptake inhibition, since prevention of neurotransmitter recycling increases net 
neurotransmitter concentrations [17]. However, when amphetamines act in the 
synapses, there is a third way of neurotransmitter increase. Amphetamines induce 
non-exocytotic neurotransmitter release, not mediated by vesicles, but by the 
respective reuptake transporters [4]. The precise mechanism of amphetamine-induced 
monoamine efflux has not yet been determined. In the next sections, I summarize 
three different hypothetic mechanisms of drug-induced reverse transport. All models 
have their limitations and are contradicting either way. Thus, note that the mechanism 
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of release is controversially discussed and still remains to be completely resolved [4, 
23]. However, all models assume an uptake of the releasing drug into the cells. This 
fact is essential for the interpretation of the results in this thesis and in general for 
correct interpretation of in vitro data for biological or clinical relevance. It will be 
explained in paragraph 3.4. 
 
3.3.1. Amphetamines are substrates of the monoamine reuptake transporters 
Being substrates of the reuptake transporters like monoaminergic neurotransmitters, 
amphetamine-type drugs exhibit a distinct characteristic from non-releasing drugs 
such as cocaine or methylphenidate [4]. Several attempts have been made to quantify 
transport of amphetamine-like drugs through monoamine transporters. 
Amphetamine’s high lipophilicity and its preference to penetrate the cell membrane as 
unprotonated molecule challenge the quantification of the drug’s inward transport 
[23]. Sitte et al. show the Na+/K+-ATPase- and Na+-dependent uptake of the two 
amphetamine enantiomers and tyramine. They also demonstrated the inhibition of this 
uptake if experiments are performed on ice, which indicates active transport, or if the 
transporter inhibitor cocaine is present [24]. Verrico et al. showed the uptake of 
MDMA by DAT, SERT, and NET and it’s inhibition on ice [25].  
Taken together, the experiments assessing drug transport indicate similar or identical 
transport mechanisms for amphetamines and the physiological substrates, the 
monoamine neurotransmitters. This mechanistic key feature is essential to understand 
the mechanism of amphetamines-induced reverse transport of monoamines [4] and to 
understand the toxicological relevance of a substrate versus a non-transported 
non-releasing uptake inhibitor. 
 
3.3.2. Release model A: “facilitated exchange diffusion” – the revolving door 
model  
Sitte and Freissmuth explain in their comprehensive review one widely postulated 
model for monoamine release [23]. The “facilitated exchange diffusion” model 
considers the transporter as a protein in two main conformations, the outward-facing 
conformation and the inward-facing conformation (see Figure 4). If the binding site 
faces to the synaptic cleft, the substrate (e.g., a monoaminergic neurotransmitter or 
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the release-inducing amphetamine) binds to the transporter together with Na+, and the 
transporter changes its conformation to the binding site facing to the cytoplasma. 
Since Na+ concentration on the cytoplasmatic site is low, the cotransported Na+ 
molecule diffuses immediately from the binding site, resulting in a weak binding of 
the substrate, which then subsequently is released from its binding pocket to the 
cytoplasm. In the inward-facing state of the transporter, a substrate (e.g., the to be 
released neurotransmitter) located intracellularly can then bind to the transporter for a 
reverse transport from the inside to the outside. This transport occurs physiologically 
with a significantly lower probability since intracellular Na+ is diminished and thus 
substrate-transporter binding, for which Na+ is essential, occurs less frequently on the 
intracellular than on the extracellular site. However, the presence of a substrate, such 
as amphetamine, enhances the probability for inward-facing confirmation, and thus 
enhances the probability for reverse transport. Sulzer argues in his review that the 
facilitated exchange diffusion model follows a one to one exchange of releasing drug 
(substrate transported from extra- to intracellular space) with neurotransmitter 
(released by reverse transport from the cytosol to the synapse) [4]. Uptake transport of 
amphetamines or other releasing drug would be crucial to induce release and thus KM 
of the uptake of the releasing drug must theoretically correlate linearly with its 
potency to induce release. However, release can also be induced by disruption of the 
ion gradient over the plasma membrane [26, 27], or if amphetamine is injected 
directly into a neuron and thus circumvents its transporter mediated uptake [28]. 
Experiments with Zn2+ indicate that uptake and release do not necessarily need to 
occur via the same target. Zn2+ on one hand inhibits substrate uptake and on the other 
hand enhances amphetamine-stimulated DA efflux [29-31]. These observations led to 
seek for extended or other models.  
 
3.3.3. Release model B: “Channel-like transport modes” 
In the facilitated exchange diffusion model (described in details in 3.3.2.), we assume 
transport of a substrate to come along with the transport of an ion and thus with 
charge transfer. However, the observation of charge transfer not correlating with 
substrate transport through the transporters [32-34] led to the proposal of a “channel-
like transport mode” (Figure 4). It assumes the transporter’s confirmation to change to 
a structure that forms a pore or channel, allowing for autonomous diffusion of ions 
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and substrate [4]. This model is supported by a variety of observations. For example, 
patch-clamp measurements detect amphetamine-induced events that resemble 
classical ion-channels [28]. Sitte et al. support the channel-like transport theory in a 
study where they measured the uptake of the substrates D-amphetamine, 
L-amphetamine, tyramine, and DA [24]. Substrate uptake kinetics reveal a 
considerably lower KM-value for D-amphetamine (0.8 µM) than the KM-values of the 
other substrates, but Vmax of DA was about 20 times higher than D-amphetamine’s 
Vmax. They then found release-inducing properties of the substrates to correlate better 
with their current-inducing properties, measured by patch-clamp method, than with 
their uptake properties. However, release via the channel-like mode of a transporter is 
probably a rare event compared to facilitated exchange diffusion [35]. 
 
 
Figure 4: Schematic explanation of the channel-like transport mode and the facilitated exchange diffusion model 
as explained in the previous paragraphs, exemplary shown DAT (membrane protein) and action of amphetamine 
(chemical structure). Red indicates the binding site for amphetamine or DA. The yellow transporter visualizes 
DAT’s structural change to a channel-like pore. !
3.3.4. Release model C: “Oligomer-based counter-transport model” 
On the basis of lacking complete explanation of several observations with the 
fascilitated exchange diffusion and channel-like transport models as described in the 
previous sections, Sitte and Freissmuth describe in their review a model based on the 
observation that reuptake transporters are expressed in the plasmamembrane as 
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oligomers [23]. While, at maximal release, 50% of the transporters are in their 
outward-facing conformation and unphosphorylated, the remaining 50% are 
inward-facing and phosphorylated. Cytoplasmic neurotransmitters can then bind to 
the inward-facing transporter and are transported into the synaptic cleft. Bell-shaped 
release curves with a maximal release at lower concentrations than maximally 
applied, illustrate this oligomeric theory [36]. The “oligomer-based counter transport 
model” cannot yet explain if both or one of the two transporter confirmations is 
channel-like or needs one-to-one Na+ co-transport analogue to the facilitated diffusion 
model. Nevertheless, this model could unify the two controversially discussed models 
and explain phenomena, which were inexplicit before and is worth being further 
assessed. 
 
 
Figure 5: The oligomer-based counter-transport model explained and illustrated by Sitte and Freismuth [23]. The 
left oligomer (here drawn as dimer) of SERT shows maximal 5-HT release with one moiety of transporters 
occupied by para-chloroamphetamine (PCA), activating protein kinase C and allowing the other moiety of SERT 
to be phosphorylated. The phosphorylated transporters are able to release 5-HT from the intra- into the 
extracellular space. The right oligomer of SERT illustrates a situation with increased PCA concentrations, which 
prevents 5-HT release due to full occupation of SERT with PCA. 
 
3.3.5. Pathways and transporter modulation 
Regardless of the release models presented in the previous sections, drug-induced 
monoamine release through reuptake transporters occurs upon activation of signaling 
or modification mechanisms. DA release requires intracellular phosphorylation 
through protein kinase activity [37] and/or Ca2+/calmodulin-dependent 
phosphorylation [23]. Transporter internalization results in reduced transporter 
surface expression and thus in reduction of the amount of proteins available for 
release. This internalization, probably regulated via G-protein coupled receptors, is 
proposed to be a regulatory mechanism for drug-induced release [38]. 
congeners. However, it will be evident that in all instances
amphetamine triggers a substantial movement of excess
positive charges, i.e. Na+ influx. Na+ is a co-transported
substrate in all NSS family members. I the alternating
access model the concomitant translocation of substrates and
co-transported ions is strictly stoichiometric. While the
majority of the transporters of the NSS-family work in an
electrogenic manner, SERT is thought to be an exception
because it works in an electroneutral manner because of the
counter-transport of K+ (Rudnick 1999): in theory, charge-
flow must not necessarily be translated in measureable
steady-state current; for SERT, the prediction would be that
no net current can be measured. Theoretically, this movement
of ions may be assessed in electrophysiological experiments
by an increased noise upon transporter activity. Similar to the
unexpected observations of SERT-mediated currents (Bruns
et al. 1993; Mager et al. 1994), there was surprising
excessive current measured in DAT-expressing cells (Sonders
et al. 1997; Sitte et al. 1998). Hence, electrophysiological
investigations have shown that plasma membrane neuro-
transmitter transporters can function in a way similar to ion
channels (Sonders and Amara 1996). Still, the charge fluxes
carried by NSS-members are an enigmatic property of the
transporters, but they are cent al to understanding amph t-
amine-induced efflux.
Currents in transporters and their role in
amphetamine-induced efflux
Excess ion flux is observed during substrate influx in many
members of the NSS family; in addition, there is leak current,
which can be detected under basal conditions and blocked by
inhibitors (Mager et al. 1994, 1996; Galli et al. 1995, 1997,
1998). While the substrate-induced ion flow through neuro-
transmitter transporters is reminiscent of ligand-gated ion
channels, it is worth noting that the currents of the
transporters are smaller by orders magnitudes than those of
ion channels and their conductance is presumably also much
smaller.
It is a challenge to reconcile the view of the transporter as
a ‘pump with a channel’ with the alternating access model,
because the transport mechanism may be more complicated
than predicted from the scheme in Fig. 1. The issue is
succinctly summarized by Accardi and Miller (2004) who
concluded their description of secondary active transport
mediated by a prokaryotic homologue of ClC Cl) channels in
that ‘transporters and channels may be separated by an
exceedingly fine line’. Segments in the structure of LeuTAa
proteins can also be conceptually treated as gates that may
open simultaneously and thus convert the transporter into a
channel. How ver, there isn’t any evidence so far that
LeuTAa can also generate a transport-associated current (see
also below).
Small structural changes suffice to cross the ominous ‘line’
between a transporter and a channel, and this line is crossed
in nature: a good example for such subtl ties is the sodium-
glucose transporter SGLT-3: a mere glucose transporter in
pigs, but a glucose-activated Na+-channel in man and
functional as a glucose sensor (Diez-Sampedro et al.
2003). Conversely, both bacterial (Accardi and Miller
2004) and m mmalian chloride channels are actually H+/
Cl)-antiporters (Scheel et al. 2005). Similarly, the mamma-
lian SERT has significantly lower conducting properties than
its homolog from Drosophila melanogaster: in flies, the
Fig. 2 Schematic illustration of the oligomer-based counter-transport
model (described in more detail in Seidel et al. 2005). The left side
illustrates the effect of low concentrations of amphetamine (in
this figure, pCA stands for para-chloroamphetamine); only a fraction
of SERT moieties is occupied by pCA in the oligomeric complex
(shown here for the sake of simplicity as a dimer). Occupancy
by pCA precludes phosphorylation by PKC (Ramamoorthy and
Blakely 1999). The other SERT moieties in the oligomeric
complex that has not been occupied by pCA are subject to phos-
phorylation and thereby primed for outward transport of substrate.
Right, at high pCA concentrations, all transporter subunits are
occupied by pCA, which impairs the action of PKC and thus pre-
vents the accumulation of inward-facing conformations: efflux of
substrate is impaired.
344 | H. H. Sitte and M. Freissmuth
Journal Compilation ! 2009 International Society for Neurochemistry, J. Neurochem. (2010) 112, 340–355
! 2009 The Authors
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3.4. Toxicologically relevant distinction of non-releasing and releasing 
psychostimulants 
Compared to pure uptake inhibitors (e.g., fluoxetine) substrate-type releasers (e.g., 
fenfluramine) increase synaptic neurotransmitter concentration much more 
pronounced [39]. Also, psychotropic effects evoked by the 5-HT releaser MDMA are 
abolished due to SERT blockade with the pure uptake inhibitor citalopram [6]. Thus, 
it is obvious that a transporter-mediated release potentiates the effects of a releasing 
drug. However, pure monoamine uptake inhibitors like cocaine [40], methylphenidate 
[4], or MDPV [41] exert considerable psychostimulant effects through transporter 
blockade alone, suggesting that release, in particular of DA, is not essential for 
psychostimulation. One could argue that the information about the releasing 
properties of a drug is non-relevant if the net neurotransmitter concentration in the 
synaptic cleft is considerably increased due to drug action at monoamine transporters. 
However, substrate-type psychostimulants affect also synaptic physiology 
intracellularly, which makes an essential difference to non-releasing drugs. 
Physiologically, monoaminergic neurotransmitters are, after their uptake into the 
presynapse, removed from the cytosol by uptake into storage vesicles via the vesicular 
monoamine transporter 2 (VMAT2). If anyhow remaining in the cytosol, they are 
rapidly metabolized via mitochondrial monoamine oxidases (MAO) or intracellular 
catechol-O-methyltransferase (COMT) [16]. Amphetamines disturb vesicular 
accumulation of neurotransmitters into vesicles [42] and also inhibit MAO [4]. The 
resulting increased cytosolic availability of neurotransmitters is potentially toxic for 
the neuronal cell [7]. This fact should be considered for the interpretation of 
pharmacological in vitro data of abused drugs, but in particular also of therapeutic 
drugs. For example, amphetamine and methylphenidate are both approved for 
treatment of attention deficit hyperactivity disorder, but since amphetamine is a 
substrate of DAT while methylphenidate is a pure uptake inhibitor, methylphenidate 
might be the gentler therapeutic drug [4]. 
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4. Psychostimulant effects of amphetamines 
In the following two sections, the psychostimulant or subjective effects of MDMA 
and methamphetamine will be described and explained by their mechanism of action. 
The description of these two prototype drugs, MDMA being rated as a predominantly 
entactogenic and methamphetamine as stimulant drug, would serve as model to 
predict expected effects in humans from in vitro results. 
 
4.1. Subjective effects in humans induced by the entactogen MDMA 
MDMA acts on SERT, NET, and DAT by inhibiting the reuptake of 5-HT, NE, and 
DA, respectively, but also by inducing transporter-mediated release of the respective 
monoamines. It acts thereby more potently on SERT and NET than on DAT [25]. 
MDMA inhibits the monoamines metabolizing enzyme MAO [43]. It also inhibits 
VMAT2 [44], preventing it to transport monoamines into storage vesicles. Both 
MDMA’s effects on MAO and VMAT2 increase the cytosolic concentrations of 
monoamines. 
MDMA’s key psychostimulant effects are described as entactogenic, which means 
that the drug induces a subjective delightful psychotropic effect. This includes the 
feeling of closeness to others, relaxation, feeling of happiness and communicative 
openness [45]. MDMA lifts mood, increases empathy and confidence, promotes 
extroversion, increases self-esteem, and intensifies sensory perception. Psychomotor 
drive is only slightly increased [6].  
Human studies with drugs of abuse are difficult to perform but are the only definite 
way to associate drug’s subjective effects with the mode of action of a drug. 
Inhibition of SERT with the selective 5-HT reuptake inhibitor citalopram resulted in a 
reduction of most subjective MDMA effects. Euphoria, increased extroversion, and 
self-confidence were prominently reduced [6, 46]. This study documented that the 
psychological effects of MDMA are mostly due to 5-HT release [6]. In a similar 
study, pretreatment with the 5-HT2 receptor antagonist ketanserin abolished the mild 
perceptual changes and emotional excitation induced by MDMA [46]. Another study 
showed the attenuation of the euphoriant amphetamine-like aspects of MDMA by 
pretreatment with the DA D2-receptor antagonist haloperidol [46]. Liechti and 
Vollenweider concluded most subjective effects of MDMA to result from its effect at 
SERT (induction of 5-HT release and reuptake inhibition). Particular effects also 
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result from indirect action at specific monoamine postsynaptic receptors, since 
increased monoamine levels due to SERT and DAT modulation alter postsynaptic 
receptor stimulation [46]. Studies elucidating the role of NE in MDMA’s mode of 
action are part of this thesis project. 
 
4.2. Subjective effects of the stimulant methamphetamine 
In humans, methamphetamine (30 mg) produces mostly positive mood effects, 
euphoria, excitation, reduced tiredness, cardiostimulant effects (e.g., increased heart 
rate, elevated blood pressure, pupil dilatation, and hyperthermia), reduced appetite, 
and erratic behavior [7]. Lasting for a short time period, cognitive performance 
including attention is improved. Users describe the performance enhancing effects of 
methamphetamine as increased energy and increased desire for work and resulting 
higher work performance [47]. Anxiety is a common negative effect of 
methamphetamine. All previously described effects seem to increase dose-
dependently [7]. Doses higher than 30 mg could provoke psychotic symptoms. Also 
aggression, sustained talking, headaches, and hypertension are induced at high doses 
[48].  
Methamphetamine releases DA, NE, and 5-HT in a transporter-mediated way, 
inhibiting all monoamine transporters for monoamine reuptake [49]. Thereby it acts 
more potently at DAT and NET than at SERT [5, 49]. Methamphetamine also acts on 
VMAT2, releasing stored monoamines from the vesicles into the cytosol and 
preventing uptake into vesicles via VMAT2. Inhibiting MAO [50], methamphetamine 
prevents monoamines from metabolism. Taking these mechanisms together, they all 
lead to an increase of monoamines in the synaptic cleft and thus to an enhanced 
neurotransmission, which is the basic concept to explain methamphetamines diverse 
effects [4]. In detail, excitation or arousal, one of the most prominent effects of 
methamphetamine, results from α1- and β-adrenergic- and D1- and D2-receptor 
stimulation due to increased NE and DA concentrations in the synaptic cleft. Euphoria 
results from DA release in the nucleus accumbens. A generalized state of relaxation, 
in contrast, results from methamphetamines effects on serotonergic synapses. 
Improved cognitive performance mainly results from activation of the dopaminergic 
system, with α- and β-adrenergic receptors playing a role as well [7]. 
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5. Adverse effects and complications of stimulant drug use 
5.1. General overview on amphetamine-type drug-associated medical 
complications 
Amphetamine-type drugs like MDMA and methamphetamine activate the 
sympathetic nervous system, from which many acute negative effects derive [7, 51]. 
The cardiostimulant effects include high blood pressure, increased heart rates, and 
hyperthermia. MDMA and methamphetamine typically also increase muscle tensions, 
resulting e.g., in bruxism, and induce sleep disturbances [51]. Psychiatric acute 
complications might be uncontrolled agitation and psychosis. 
A typical methamphetamine-overdose includes agitation, pupil dilatation, tachycardia, 
hypertension and rapid respiration. Dangerous complications are hyperpyrexia and 
cardiac, hepatic, or renal failure [7]. Hyperthermia, probably resulting in 
hyperpyrexia, occurs frequently in hot environment like crowded clubs. Hyperthermia 
stimulates serious complications like rhabdomyolysis, myoglobinuria, acute renal 
failure, dissiminiated intravascular coagulation, cerebral hemorrhage, cardiac arrest, 
and liver failure [51, 52]. Apart of secondary effects of hyperthermia, hepatotoxicity 
and renal toxicity are important severe complications known to result from MDMA 
and methamphetamine ingestion, and hyponatremia as typical MDMA complication 
[7, 52].  
 
5.2. Hyponatremia – a potentially life-threatening complication of MDMA 
Hyponatremia derives from an inadequate secretion of antidiuretic hormone 
(syndrome of inappropriate antidiuretic hormone secretion (SIADH)) controlled by 
the hypothalamus, which results in increased renal water retention. SIADH is 
reflected by increased arginine vasopressin plasma levels [51] and results from the 
5-HT releasing property of MDMA [53, 54]. Massive sweating and excessive liquid 
intake also trigger hyponatremia [52]. Hyponatremia can cause life-threatening brain 
edema with seizures and respiration or circulation failures [52]. Affected cases 
display bizarre behavior accompanied with vomiting, drowsiness, reduced 
consciousness or coma and probably seizures [55]. Interestingly, hyponatremia is a 
phenomenon observed in MDMA-taking women but rarely in men [53].  
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5.3. Neurotoxicity – a short disquisition 
Speaking of adverse events and complications of MDMA and other amphetamine-
type drugs, the question of their neurotoxic potential comes up. MDMA is believed to 
be a classical neurotoxic drug. Indeed, animal experimentations with amphetamines, 
performed intensively for years, showed a persistent reduction in brain levels of 
neurotransmitters, e.g., for MDMA mainly a reduction in 5-HT and for 
methamphetamine a reduction in DA levels [56, 57]. The enzymes involved in 
monoamine synthesis, tryptophan hydroxylase in case of 5-HT and tyrosine 
hydroxylase in case of DA and NE, are reduced due to drug abuse. Binding studies 
using positron emission tomography in vivo detected reduced levels of monoamine 
reuptake transporters in animals, but also in humans [7, 56, 58]. Cytotoxicity of the 
neuron itself is controversially discussed, since species differences and dose scaling 
result in an unclear picture [56]. Also, several studies observed that MDMA 
administered intra-cerebrally did not induce neurotoxicity [51]. Since MDMA, if not 
administered systemically but directly injected into the brain, evades its hepatic 
metabolism, one or more of MDMA’s metabolites (see Figure 6) must be responsible 
for its toxicity [59].  
 
Figure 6: MDMA metabolism with the major pathway (blue) and the minor pathway (red). HHMA = 3,4-di-
hydroxymethamphetamine; HMMA = 3-hydroxy-4-methoxymethamphetamine; MDA = 3,4-methylenedioxy-
amphetamine; HHA = 3,4-dihydroxyamphetamine; HMA = 3-hydroxy-4-methoxyamphetamine. Pathway adapted 
from De La Torre et al. [60] as reviewed by Baumann et al. [56]. 
Concluding the findings of years of intense research on this topic, the term 
neurotoxicity should be reserved for compounds that damage nerve cells and be kept 
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apart from MDMA-associated neuronal changes including reduced neurotransmitter 
markers and down regulation mechanisms. There are hardly real structural damages 
with loss of neurons and resulting structural brain damage. How far neurotoxicity 
found in rodents is relevant for negative effects in humans is a matter of ongoing 
discussion. Assessment of neurotoxicity in humans is highly delicate since control 
groups usually do not perfectly match with the drug user group and there is 
confounding by life-style and other drugs used. Symptoms of depressed mood 
frequently observed in the days following MDMA use have also been linked to the 
sleep disruption associated with party drug use and clubbing rather than with the drug 
itself [61]. Often, people in the drug user group suffer from underlying psychological 
problems, take a variety of additional drugs, or they live a different daily routine than 
those in the control group [58]. One outstanding study matched the MDMA-taking 
group with the control group perfectly by nightlife habits (since sleep deprivation 
could bias MDMA related disorders, as the drug is mostly used at night-parties) and 
by the exclusion of other illicit drug use and massive alcohol consumption. 
Interestingly, this study failed to demonstrate cognitive impairment due to MDMA 
use [62]. 
 
5.4. Addiction – reward mechanisms 
Dependence, an adapted state of neuronal cells or brain systems due to excessive drug 
use, can lead to addiction, the compulsive drug use despite negative physical, social, 
or economic problems [63]. Studies on cues that induce drug craving in addicted 
persons associate mainly the prefrontal cortical regions and the amygdalae, in some 
cases also the nucleus accumbens, with drug addiction. The dopaminergic system 
plays a key role in reward (situations rated by the brain as positive experiences) and 
reinforcement (urge to repeat behaviors that are associated with the respective drugs) 
of addictive drugs [63]. It projects from the midbrain ventral tegmental area to the 
nucleus accumbens, the dorsal striatum and other forebrain sites. Being a major 
neurotransmitter in the dopaminergic system, DA is the crucial neurotransmitter 
involved in the development of addiction. Generally spoken, addictive drugs 
pharmacologically act by increasing DA in the synaptic cleft of neurons in the nucleus 
accumbens [63, 64]. Altered DA release causes synaptic plasticity, as well as changes 
in neurotransmitter receptors or receptor-mediated signaling. Synaptic plasticity, the 
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ability of synapses to regulate their strength of neuronal transmission according to the 
neuronal activity, is a mechanistic cause of addiction [63].  
Sulzer explains in his review in more details the crucial role of DA enhancement for 
the development of drug dependence [64]. DA enhancement in the synaptic cleft due 
to drug application can occur via four mechanisms:  
1. The enhancement of neuronal firing (e.g., nicotine, opiates),  
2. Inhibition of DA reuptake (cocaine as typical representative of this class),  
3. Alteration of release probability from the presynapse (e.g., nicotine, opiates), 
and  
4. DAT-mediated DA release (specialty of amphetamines).  
Amphetamine-type drugs cause both DA uptake inhibition (second mechanism) and 
DA release (forth mechanism) and are anticipated to be rather addictive drugs. 
Serotonergic system activation, on the other hand, is understood to be protective 
against addiction [65]. For example, serotonergic neurons can control DA neurons 
and thus DA neurotransmission, via 5-HT2C receptor activation [66, 67]. For a 
complete understanding of the addictive potential of a drug, it is necessary to assess 
both, effects on DA and 5-HT system activation [65, 68, 69].  
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Objectives 
Questions to be answered 
For this thesis, we investigated different aspects of the mechanism of action of 
amphetamine-type designer drugs. All aspects were related to the drugs’ 
pharmacology at monoamine transporters. We aimed to increase the understanding of 
the relation between in vitro pharmacology and human psychostimulant effects and 
drug-related complications such as acute or long-term medical problems. We focused 
our investigations on well-investigated substances like MDMA and 
methamphetamine as well as on hardly studied novel designer drugs. Taking MDMA 
as exemplary entactogenic drug, we aimed to assess which of the psychotropic and 
cardiostimulant effects in humans derive from transporter-mediated NE and 5-HT 
release. We also asked if cerebral NE/5-HT release blockade could prevent 
inappropriate secretion of antidiuretic hormone that frequently results in potentially 
life-threatening complications. With the stimulant and highly addictive 
methamphetamine, we chose an exemplary substance to work on pharmacological 
possibilities of addiction treatments. Thereby, we wanted to compare different 
therapeutics that target DAT. While these studies had a pronounced mechanistic 
focus, we also aimed to compile an extended set of descriptive in vitro experiments. 
We described novel but widely abused designer drugs and compared their 
pharmacological characteristics with well-investigated drugs, in particular with 
MDMA and methamphetamine. We aimed therewith to link descriptive in vitro 
pharmacology with a mechanistic understanding of positive or negative effects in 
humans. By improving the comprehension of the link between simple 
pharmacological in vitro tests and consequences of drug-use in humans, our research 
should provide a better understanding of designer drugs’ pharmacology and 
toxicology and support medical treatment of acute and long-term drug use. In 
particular, we aimed to throw light on the actual effects of designer drugs such as 
MDPV, about which media reports terrify both general public and medical personnel.  
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Story line 
Reading this thesis, the reader is first guided through the key pharmacological 
mechanism of amphetamine-type designer drugs in chapter 1 that contains two 
articles. One learns how drugs with similar chemical structures act differently on 
DAT, SERT, and NET in their potency and mechanism. One also learns to classify 
these designer drugs according to their pharmacological differences and which 
consequences on human effects can be drawn from in vitro pharmacological tests. In 
chapter 2, the reader will learn about the monoaminergic targets involved in the 
psychostimulant and cardiac effects of the entactogen MDMA, but also about the role 
of monoaminergic neurotransmitters in the development of hyponatremia, a 
potentially life-threatening complication of MDMA use. Finally, in chapter 3, the 
reader comes to know about key mechanisms in the development of stimulant 
addiction, which is a severe long-term complication for many drugs presented in 
chapter 1, and learns how these processes could pharmacologically be modulated. 
Presenting the research performed during my PhD studies in this composition, I aim 
to guide the reader through a comprehensive overview of amphetamine-type drugs’ 
pharmacology and to point to its consequences either of less-addictive empathogen 
drugs like MDMA, or on highly-addictive stimulants like methamphetamine. By 
focusing strongly on mechanistic background of these observations, I also present 
pharmacological opportunities to find solutions against these complications.  
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Contributions 
My main contribution to all publications and reports in this thesis was the 
establishment and in large part the accomplishment of all pharmacological in vitro 
assays. Exceptions were the in vitro blood-brain barrier tests and in vitro affinity 
assays, which were performed by collaborators. My contributions to the clinical 
studies were analytical measurements, namely the determination of plasma 
concentrations of MDMA, of metabolites, and of co-treatments. I also quantified  
copeptin and vasopressin in plasma samples. The analytical methods for the small 
molecules determinations were either developed and validated independently or in 
team-work. I am the first or co-equal first author on all papers and reports presented 
in this thesis, with the exception of paper 2a where I am the second author. This 
publication is included in my thesis since I made a significant effort for the analytical 
method development and for the measurement of analytes for pharmacokinetic 
assessments, and because the findings in paper 2a are valuable complementary 
information to paper 2b. !!
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Chapter 1: Pharmacological description and classification of 
amphetamine-type designer drugs in vitro 
This chapter contains two studies assessing the pharmacological profiles of 
amphetamine-type drugs and comparable stimulants in vitro. We tapped the full 
potential of classical pharmacological assays to determine potencies and the mode of 
action at a comprehensive set of monoaminergic pre- and postsynaptic targets. In 
paper 1a, we assessed the cathinones mephedrone, flephedrone, methylone, ethylone, 
butylone, cathinone, methcathinone, naphyrone, MDPV, pyrovalerone and compared 
their pharmacology with the non-β-keto amphetamines MDMA, 3,4-methylene-
dioxyphenyl-N-methyl-2-butanamine (MBDB), 3,4-methylenedioxy-N-ethylamphe-
tamine (MDEA), amphetamine, methamphetamine, and the non-amphetamine 
cocaine.  
Paper 1b is a complementary study on the pharmacology of second series of 
cathinone-derivatives and non-β-keto analogs. We assessed the monoaminergic 
actions of the cathinones methedrone, 4-methylethcathinone (4-MEC), 
N,N-dimethylcathinone, ethcathinone, 3-fluoromethcathinone (3-FMC), buphedrone, 
pentylone, and pentedrone. We compared these cathinones to the non-β-keto 
amphetamines para-methoxymethamphetamine (PMMA), para-methoxy-
amphetamine (PMA), 4-methylthioamphetamine (4-MTA), and N-ethylamphetamine.  
Having performed identical pharmacological assays in both papers 1a and 1b, we are 
able to directly compare the pharmacology of all 28 substances at 15 monoaminergic 
targets. The size and integrity of our extensive designer drugs characterization is to 
date unique and gives a comprehensive overview of the pharmacology of designer 
drugs with original data. 
 
Content of chapter 1: 
Paper 1a: Pharmacological characterization of designer cathinones in vitro 
Paper 1b: Monoamine transporter and receptor interaction profiles of a new 
series of designer cathinones 
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BACKGROUND AND PURPOSE
Designer b-keto amphetamines (e.g. cathinones, ‘bath salts’ and ‘research chemicals’) have become popular recreational
drugs, but their pharmacology is poorly characterized.
EXPERIMENTAL APPROACH
We determined the potencies of cathinones to inhibit DA, NA and 5-HT transport into transporter-transfected HEK 293 cells,
DA and 5-HT efflux from monoamine-preloaded cells, and monoamine receptor binding affinity.
KEY RESULTS
Mephedrone, methylone, ethylone, butylone and naphyrone acted as non-selective monoamine uptake inhibitors,
similar to cocaine. Mephedrone, methylone, ethylone and butylone also induced the release of 5-HT, similar to
3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and other entactogens. Cathinone, methcathinone and flephedrone,
similar to amphetamine and methamphetamine, acted as preferential DA and NA uptake inhibitors and induced the release
of DA. Pyrovalerone and 3,4-methylenedioxypyrovalerone (MDPV) were highly potent and selective DA and NA transporter
inhibitors but unlike amphetamines did not evoke the release of monoamines. The non-b-keto amphetamines are trace
amine-associated receptor 1 ligands, whereas the cathinones are not. All the cathinones showed high blood–brain barrier
permeability in an in vitro model; mephedrone and MDPV exhibited particularly high permeability.
CONCLUSIONS AND IMPLICATIONS
Cathinones have considerable pharmacological differences that form the basis of their suggested classification into three
groups. The predominant action of all cathinones on the DA transporter is probably associated with a considerable risk of
addiction.
Abbreviations
BBB, blood–brain barrier; DA, dopamine; DAT, dopamine transporter; MBDB, 3,4-methlyenedioxyphenyl-N-methyl-2-
butanamine; MDEA, 3,4-methylenedioxy-N-ethylamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MDPV,
3,4-methylenedioxypyrovalerone; NET, NA transporter; Pe, permeability coefficient; SERT, 5-HT transporter; TA receptor,
trace amine-associated receptor
Introduction
Stimulant drug abuse remains a major public health issue
worldwide. While ‘old stimulants’, including cocaine,
methamphetamine and amphetamine, and ‘entactogens’,
including 3,4-methylenedioxymethamphetamine (MDMA,
ecstasy), 3,4-methylenedioxy-N-ethylamphetamine (MDEA)
and 3,4-methlyenedioxyphenyl-N-methyl-2-butanamine
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(MBDB), continue to be used, novel designer cathinones are
emerging. Cathinones differ from amphetamines by the pres-
ence of a ketone oxygen group at the b-position (Figure 1).
The b-keto-amphetamines are distributed as ‘bath salts’,
‘research chemicals’ and ‘plant food’ via the Internet and
have been advertised as ‘legal highs’ with similar psycho-
tropic effects to MDMA or cocaine (Spiller et al., 2011).
As b-keto analogues of amphetamines, cathinones may be
expected to have amphetamine-like effects because of their
structural similarity. Cathinones enhance DA, NA and 5-HT
neurotransmission (Hadlock et al., 2011; Kehr et al., 2011;
Baumann et al., 2012; Lopez-Arnau et al., 2012; Martinez-
Clemente et al., 2012). However, the molecular pharmacol-
ogy of this novel class of stimulant drugs is poorly
documented. In particular, a systematic comparative charac-
terization of the effects of different cathinones on the human
DA, NA and 5-HT transporters and comparisons with classic
stimulants are lacking.
In the present study, we assessed the in vitro pharmacol-
ogy of cathinone, methcathinone, mephedrone (4-meth-
ylmethcathinone), flephedrone (4-flouromethcathinone),
methylone (3,4-methylenedioxymethcathinone, b -keto-
MDMA), ethylone (3,4-methylenedioxyethylcathinone,
b-keto-MDEA), butylone (b-keto-MBDB), pyrovalerone, 3,4-
methylenedioxypyrovalerone (MDPV) and naphyrone
(naphthylpyrovalerone). We determined the potencies of
these cathinones to inhibit DA, NA and 5-HT transport in
vitro. We also tested whether cathinones are releasers of DA or
5-HT and characterized the binding affinities of these drugs
for monoamine transporters, dopamine D1–3 receptors, a1 and
a2 adrenoceptors, 5-HT1A, 5-HT2A and 5-HT2C receptors, the
trace amine-associated receptor 1 (TA1 receptor) and the his-
tamine H1 receptor. Finally, blood-brain–barrier (BBB) perme-
ability was assessed using a human in vitro model. The
pharmacological profiles of the novel cathinones were
compared with their non-b-keto amphetamine analogues,
Figure 1
Chemical structures of cathinones, related amphetamines and cocaine.
BJPPharmacology of cathinones
British Journal of Pharmacology (2013) 168 458–470 459
including MDMA, MDEA, MBDB, amphetamine and meth-
amphetamine as well as with cocaine.
Methods
The drug target nomenclature conforms to BJP’s Guide to
Receptors and Channels (Alexander et al., 2011).
Drugs
The hydrochloride salts of the drugs (purity >98.5%) were
supplied by Lipomed (Arlesheim, Switzerland), with the
exception of naphyrone, which was synthesized according to
Meltzer et al. (2006). Racemic drugs were used except for
D-amphetamine and D-methamphetamine.
Radioligand binding
The radioligand binding assays were performed as described
previously (Revel et al., 2011; Hysek et al., 2012c). Briefly,
membrane preparations from HEK 293 cells (Invitrogen, Zug,
Switzerland) that overexpress the respective human trans-
porters (Tatsumi et al., 1997) or receptors (except for rat/
mouse TA1 receptor) (Revel et al., 2011) were incubated with
the radiolabelled selective ligands at concentrations equal to
Kd, and ligands displacement by the compounds was meas-
ured. Specific binding of the radioligand to the target receptor
was defined as the difference between the total binding and
nonspecific binding determined in the presence of selected
competitors in excess. The following radioligands and com-
petitors were used: N-methyl-[3H]-nisoxetine and indatraline
(NA transporter [NET]), [3H]-citalopram and indatraline (5-HT
transporter [SERT]) and [3H]-WIN35,428 and indatraline
(DA transporter [DAT]). [3H]-8-hydroxy-2-(di-n-propylamino)
tetralin (8-OH-DPAT) and indatraline (5-HT1A receptor),
[3H]-ketanserin and spiperone (5-HT2A receptor), [3H]-
mesulergine and mianserin (5-HT2C receptor), [3H]-prazosin
and risperidone (a1 adrenoceptor), [3H]-rauwolscine and
phentolamine (a2 adrenergic receptor), [3H]-SCH 23390 and
butaclamol (DA D1 receptor), [3H]-spiperone and spiperone
(DA D2 and D3 receptors), [3H]-pyrilamine and clozapine (his-
tamine H1 receptor) and [3H]-RO5166017 and RO5166017
(TA1 receptor). All radioligands were obtained from Perkin-
Elmer (Schwerzenbach, Switzerland), with the exception of
[3H]-RO5166017, which was synthesized at Roche (Basel,
Switzerland).
Monoamine uptake transporter inhibition
The potencies of the drugs to inhibit the SERT, NET and DAT
were evaluated in HEK 293 cells that stably expressed human
SERT, NET and DAT (Tatsumi et al., 1997) as previously
described (Hysek et al., 2012c). The DAT/SERT ratio was cal-
culated as 1/DAT IC50:1/SERT IC50.
Monoamine release
We assessed DAT- and SERT-mediated DA and 5-HT efflux in
HEK 293 cells that overexpressed human DAT or SERT respec-
tively. We cultured the cells in 24-well plates (XF24, Seahorse
Biosciences, North Billerica, MA) coated with poly-D-lysine to
70–100% confluency. After removing the culture medium, we
added 85 mL release buffer (Krebs–HEPES that contained
130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4,
1.2 mM KH2PO4, 10 mM HEPES, 10 mM D-glucose,
0.2 mg·mL-1 ascorbic acid and 10 mM pargyline) with 10 nM
[3H]-5-HT (SERT cells) or 10 nM [3H]-DA and 1 mM unlabelled
DA (DAT cells). We filled the cells with the respective radi-
olabelled monoamine for 20 min at 37°C. We then removed
the buffer and washed twice with warm buffer. We induced
[3H]-5-HT and [3H]-DA release by adding 1000 mL release
buffer that contained the drugs in different concentrations or
controls. We incubated the cells for 15 min at 37°C and
shaked at 300 r.p.m. on a rotary shaker. We then stopped the
release by removing the buffer and washing the cells twice
with ice-cold buffer. The release time was based on the dif-
ference between drug-stimulated and spontaneous release
(control) over time, which reached its maximum before
15 min. We then added 65 mL lysis buffer and lysed the cells
overnight in a refrigerator. We mixed 50 mL of the cell lysate
suspension with 2.5 mL UltimaGold and determined radio-
activity. The radioactive counts in the cells where no drug was
present in the release buffer (control) was defined as 100%,
and the percentages of radioactivity that remained in the cells
treated with drugs were calculated. Pure uptake transporter
inhibitors, including imipramine, citalopram, cocaine and
mazindol, have been shown to produce apparent substrate
efflux frommonoamine-preloaded HEK cells that is explained
by inhibition of transporter-mediated re-uptake of the sub-
strate that diffuses out of the cells (Scholze et al., 2000). The
DAT inhibitor mazindol and SERT inhibitor citalopram
reduced the amount of preloaded DA and 5-HT (mean ! SD)
by 15.6 ! 7 and 19.6 ! 8%, respectively, at the maximal
concentration of 100 mM (Emax) compared with controls. This
nonspecific release was subtracted from total release at the
maximal drug concentration of 100 mM to yield Emax values of
specific transporter-mediated release. We considered any drug
that produced significantly higher maximal DA efflux com-
pared with mazindol to be a DA releaser and a drug that
produced significantly higher maximal 5-HT efflux compared
with citalopram as a 5-HT releaser. EC50 values were calculated
using Prism (GraphPad, San Diego, CA). ANOVA followed by
Dunnett’s tests were used to compare drug effects with the
control condition. Efflux was studied in DAT- and SERT-
expressing cells because the action of a drug on the DA and
5-HT system was considered to be relevant for predicting its
stimulant-like properties and abuse potential (Rothman and
Baumann, 2006).
Cytotoxicity
Cell membrane integrity was verified using the ToxiLight
BioAssay Kit (Lonza, Basel, Switzerland) for all of the drugs
(10 and 100 mM) after 4 h of incubation at 37°C.
Transendothelial BBB transport
Transendothelial transport was assessed for a selection of
compounds using a human in vitro BBB permeability model
(Sano et al., 2010; 2012). Conditionally immortalized human
brain capillary endothelial cells (TY09) were obtained from
the Department of Neurology and Clinical Neuroscience,
Yamaguchi University, Japan. TY09 cells express the human
blood-to-brain influx and brain-to-blood efflux transporters,
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form tight cell monolayers and retain BBB-specific properties
independent of cell passage number (Sano et al., 2012). The
cells were grown in growth medium (EGM-MV BulletKit
CC-3125, Lonza, Verviers, Belgium) supplemented with
20% FBS (AMIMED, BioConcept, Allschwil, Switzerland),
100 U·mL-1 penicillin (Sigma, Buchs, Switzerland) and
100 mL·mL-1 streptomycin (Sigma). The cells were seeded on
Transwell polycarbonate membrane inserts (Corning, Baar,
Switzerland; 0.4 mm pore size, 12 mm insert diameter) pre-
coated with rat tail collagen type 1 solution (Becton Dickin-
son, Allschwil, Switzerland) at a density of 5 ¥ 104 cells·cm-2
and grown to confluence. Before the initiation of the trans-
port studies, the cell culture medium was replaced with pre-
warmed transport buffer (HBSS supplemented with 10 mM
HEPES and 1 mM Na-Pyruvate, pH 7.4), and 1.5 mM of the
test substance was added to the donor compartment of a
Transwell filter insert. The extracellular marker Lucifer yellow
CH dilithium salt (Sigma) was always combined with the test
compound in the same experiment to provide a control for
cellular tightness. The initial concentration of Lucifer yellow
applied was 10 mM. After 10, 20, 30, 45 and 60 min, 200 mL
samples were collected from the acceptor compartment and
replaced by buffer. Additionally, a sample of 200 mL was taken
from the stock solution and analysed. Lucifer yellow was
quantified by fluorescence spectroscopy using a Spectramax
M2 spectrophotometer (Molecular Devices, Sunnyvale, CA).
Drug concentrations were determined using HPLC
coupled to tandem MS. The analytes were extracted using
methanol that contained 0.1 mg·mL-1 MDMA-d5 (Lipomed,
Arlesheim, Switzerland). Chromatographic separation was
performed on a Shimadzu HPLC system (Shimadzu, Reinach,
Switzerland). A Reprosil Fluosil 100 PFP column (50 ¥ 2 mm,
2.2 mm, Dr Maisch, Ammerbuch-Entringen, Germany) was
used for the separation of the analytes. Eluent A (0.1% formic
acid in water) and eluent B (0.1% formic acid in methanol)
were used with the following gradient: 5% B for 0–0.4 min,
5–98% B for 0.4–1.9 min, 98% B for 1.9–2.7 min, and 5% B
for 2.7–3 min. The mobile phases were delivered at a constant
flow rate of 0.35 mL·min-1. The total run time was 3.0 min.
The column oven was set at 40°C. The injection volume was
10 mL. MS detection was performed using a triple quadrupole
MS (API3200, Applied Biosystems, Rotkreuz, Switzerland)
operated in electrospray ionization positive-ion mode. The
assays were linear in the concentration range of 1.2–
300 ng·mL-1 for all of the analytes. The selected mass-to-
charge (m/z) ratio transitions of the protonated MH+ analyte
ions used in selective reaction monitoring mode were the
following: MDMA 194→ 163, MDMA-d5 199→ 165, mephe-
drone 178→ 160, methylone 208→ 160, cocaine 304→ 182,
cathinone 150→ 132, methcathinone 164→ 146, ampheta-
mine 136→ 91, methamphetamine 150→ 91, MDPV
276→ 126. The dwell time was set at 20 ms for all of the
analytes.
Permeability coefficients were calculated according to
Equations 1–3 (Cecchelli et al., 1999):
Clearance mL Cl mL( ) ( )= =− X Cd (1)
where X is the cumulative amount of drug transported to the
acceptor compartment, and Cd is the concentration of the
substance in the donor compartment at each time point. Cd is
calculated by subtracting the accumulated transported
amount of drug from the initial amount in the donor com-
partment determined from the stock solution. Cl refers to the
total cleared volume at each time point. The permeability-
surface area product (PS) is determined by plotting Cl as a
function of time. The slope of the curve represents the PS
value. The PS values of the cell monolayer plus filter (PStotal)
and porous filter (PSfilter) were determined and used for the
calculation of the permeability coefficient (Pe) according to
the following equations:
1 1 1PS PS PSe total filter= − (2)
P PS Ae e= (3)
where A is the surface area of the filter. The Pe ratios were
obtained by normalizing the Pe values of the test compounds
(Pe test) with the corresponding Pe values of the extracellular
marker Lucifer yellow (Pe Lucifer yellow): Pe ratio = Pe test/Pe
Lucifer yellow. Pe! 1 indicates low trancellular permeability as
observed with highly hydrophilic compounds, such as
sucrose. Pe > 1 and <3 indicates intermediate permeability,
and Pe " 3 indicates high permeability (Sano et al., 2012).
Estimates of partition coefficient (CLogP) values (Ghose et al.,
1998) were calculated using ChemDraw Ultra 11 (Cambridg-
eSoft, Cambridge, MA).
Results
Receptor binding profiles
The monoamine transporter and receptor binding affinities
are shown in Table 1. Pyrovalerone and MDPV exhibited very
high affinity for the DAT and NET in the low nanomolar
range (<10 nM), consistent with their high potency as DAT
and NET inhibitors (Table 2). Cathinone and methcathinone
showed similar monoamine transporter binding profiles to
amphetamine and methamphetamine, with binding affini-
ties for the DAT and NET in the low micromolar range
(<10 mM) and no affinity for the SERT (>30 mM). Transporter
binding affinities for the DAT and SERT were generally lower
than the respective potencies as transporter inhibitors for
those compounds that also released DA or 5-HT respectively.
Mephedrone, flephedrone and methcathinone were the only
cathinones that exhibited relevant (<10 mM) 5-HT2A receptor
binding. These compounds and cathinone also bound to a1
adrenoceptors, which was not seen for the other drugs inves-
tigated. Cocaine and all of the cathinones showed lower
binding affinity for TA1 receptor compared with the non-b-
keto analogue amphetamines.
Inhibition of monoamine transporters
The effects of the cathinones and reference substances on
monoamine transporter function are shown in Figure 2. IC50
values for monoamine transport inhibition and DAT/SERT
inhibition ratios are shown in Table 2. Significant differences
were observed in the absolute and relative potencies of the
cathinones to inhibit monoamine transporter function.
Pyrovalerone and its derivative MDPV were the most potent
DAT inhibitors, significantly more potent than all of the
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other drugs. The rank order of potency for DAT inhibition
was MDPV and pyrovalerone >> naphyrone, cocaine, meth-
amphetamine, amphetamine and methcathinone > buty-
lone, mephedrone, methylone, ethylone, flephedrone and
MDEA > cathinone, MDMA and MBDB. The rank order of
potency for SERT inhibition was naphyrone, MDEA and
MDMA > MBDB, cocaine, ethylone, mephedrone and buty-
lone >> all of the others. The DAT/SERT inhibition ratios
ranged from >100 for pyrovalerone and MDPV (mostly DAT
inhibition) to 0.08 for MDMA (mostly SERT inhibition). The
entactogens MDMA, MBDB and MDEA were the only drugs
that blocked the SERT significantly more potently than the
DAT (DAT/SERT ratio << 1). Ethylone, mephedrone, naphy-
rone, butylone and methylone were similar to cocaine, with
DAT/SERT selectivity ratios in the range of 1–4. Cathinone
and methcathinone were similar to their non-b-keto ana-
logues amphetamine and methamphetamine, with DAT/
SERT inhibition ratios >10. The rank order of potency for NET
inhibition was pyrovalerone and MDPV > methampheta-
mine, methcathinone and amphetamine > cathinone, flephe-
drone, naphyrone and mephedrone > MDMA, cocaine and
methylone > MDEA, butylone, ethylone and MBDB. DAT and
NET but not SERT inhibition potency (IC50) values were cor-
related with psychotropic effective doses (Table 2) as reported
from experimental studies (Martin et al., 1971) or by recrea-
tional users (Derungs et al., 2011) http://www.erowid.org;
accessed June 20, 2012). The Spearman rank correlation coef-
ficients were rs = 0.73 and 0.79 respectively (both P < 0.01).
Monoamine release
Amphetamine, methamphetamine, cathinone, methcathi-
none, flephedrone, mephedrone and MDMA released DA
through the DAT (Figure 3 and Table 3). However, the
potency of MDMA to release DA was low (EC50 > 10 mM). The
entactogens MDMA, MDEA and MBDB, as well as the cathi-
nones methylone, ethylone, butylone and mephedrone
released 5-HT through the SERT. Amphetamine, metham-
phetamine, methcathinone and flephedrone also released
5-HT, however, only at very high concentrations (EC50 >
33 mM). The pyrovalerone derivatives, including pyrova-
lerone, naphyrone andMDPV, produced no DA or 5-HT efflux
similar to cocaine, indicating that these pyrovalerone deriva-
tives act as very potent transporter inhibitors but not sub-
strate releasers.
Cytotoxicity
None of the drugs showed apparent cytotoxicity at the con-
centrations used in the functional assays.
Transendothelial transport
All of the positively tested drugs exhibited Pe ratios !3, indi-
cating high permeability (Table 4). Pe ratios for mephedrone
and MDPV were >10, suggesting very high permeability.
Additionally, the apical to basolateral transport of MDPV was
significantly greater (P < 0.05) than basolateral to apical trans-
port, consistent with active transport by one of the blood-to-
brain influx carriers. Pe ratios could not be calculated for
cocaine and cathinone because of low recovery.Ta
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Discussion
All of the cathinones were inhibitors of the monoamine
transporters, but their selectivity for the SERT, NET and DAT
varied considerably. Further, most of the compounds were
substrate releasers. Thus, important pharmacological differ-
ences were found between different cathinones. We classified
the cathinones into three groups based on, firstly, their rela-
tive potency to act as SERT, NET and DAT inhibitors and,
secondly, their action as substrate releasers: (1) cocaine-
MDMA-mixed cathinones (including mephedrone, methyl-
one, ethylone, butylone and naphyrone, which act as
relatively nonselective monoamine uptake inhibitors similar
to cocaine and, with the exception of naphyrone, also as
MDMA-like 5-HT releasers); (2) methamphetamine-like cathi-
nones (including cathinone, methcathinone and flephe-
drone, which act as preferential catecholamine inhibitors and
DA releasers, similar to amphetamine and methampheta-
mine); and (3) pyrovalerone–cathinones (including pyrova-
lerone and MDPV, which act as very potent and selective
catecholamine uptake blockers but not substrate releasers).
The potency of drugs of abuse to inhibit the NET and DAT
or activate the NA and DA system is associated with their
psychostimulant effects and enhanced abuse liability
(Rothman et al., 2001). Consistently, we found that the doses
of the drugs abused by humans correlated with their potency
to inhibit catecholamine transport. In contrast, relatively
increased activation of the 5-HT system is linked to a reduc-
tion in abuse potential (Wee et al., 2005; Rothman and
Table 2
Monoamine transport inhibition
NET DAT SERT DAT/SERT ratio Recreational dose*
IC50 (mM) (95% CI) IC50 (mM) (95% CI) IC50 (mM) (95% CI) Ratio (95% CI) mg
MDMA 0.447 (0.33–0.60) 17 (12–24) 1.36 (1.0–2.0) 0.08 (0.04–0.16) 100
MBDB 2.80 (1.9–4.1) 22 (20–26) 2.04 (1.4–3.0) 0.09 (0.05–0.15) 200
MDEA 1.02 (0.78–1.3) 9.3 (8.0–11) 1.27 (0.93–1.7) 0.14 (0.01–0.21) 125
Ethylone 2.54 (2.0–3.2) 5.68 (4.9–6.5) 4.46 (3.8–5.2) 0.8 (0.6–1.1) 175
Mephedrone 0.254 (0.22–0.30) 3.31 (2.6–4.2) 4.64 (3.7–5.9) 1.4 (0.9–2.4) 150
Naphyrone 0.25 (0.20–0.32) 0.47 (0.40–0.55) 0.96 (0.85–1.09) 2.0 (1.5–2.7) 25
Butylone 2.02 (1.5–2.7) 2.90 (2.5–3.4) 6.22 (4.3–9.0) 2.1 (1.3–3.6) 150
Cocaine 0.451 (0.38–0.59) 0.768 (0.6–1.0) 2.37 (2.0–2.9) 3.1 (2–4.8) 75
Methylone 0.542 (0.39–0.75) 4.82 (3.8–6.1) 15.5 (10–26) 3.3 (1.5–6.8) 150
Flephedrone 0.246 (0.16–0.37) 6.35 (4.2–9.5) >10 5.8 (0.8–41) 200
Cathinone 0.199 (0.15–0.26) 14.0 (10–20) >100 >10 50
Methcathinone 0.085 (0.06–0.17) 1.12 (0.83–1.5) >10 >10 59
Amphetamine 0.094 (0.06–0.14) 1.30 (0.83–2.0) >10 >10 30
Methamphetamine 0.064 (0.04–0.09) 1.05 (0.74–1.5) >10 >10 30
Pyrovalerone 0.043 (0.03–0.06) 0.035 (0.03–0.04) 13.0 (10.8–15.8) >100 20
MDPV 0.044 (0.03–0.07) 0.031 (0.03–0.04) 9.30 (6.8–12.8) >100 5
Values are means of three to four independent experiments and 95% confidence intervals (CI).
Drugs are ranked according to the DAT/SERT ratio = 1/DAT IC50 : 1/SERT IC50.
*Estimated average.
Table 3
Monoamine release from monoamine-preloaded cells
DAT SERT
EC50 (mM)
(95% CI)
EC50 (mM)
(95% CI)
MDMA 22 (8.9–53) 5.63 (3.5–9.2)
MBDB >100 2.49 (1.0–6.9)
MDEA >100 2.88 (1.6–5.0)
Ethylone >100 9.90 (2.4–40)
Mephedrone 3.75 (1.7–8.4) 5.98 (3.2–11)
Naphyrone >100 >100
Butylone >100 5.5 (1.8–17)
Cocaine >100 >100
Methylone >100 >10
Flephedrone 12.5 (5.7–28) >33
Cathinone 5.64 (3.0–10) >100
Methcathinone 2.36 (1.7–3.3) >33
Amphetamine 1.76 (1.1–2.9) >33
Methamphetamine 1.56 (0.9–2.8) >33
Pyrovalerone >100 >100
MDPV >100 >100
Values are means.
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Baumann, 2006; Baumann et al., 2011) and more ‘entac-
togenic’ MDMA-like subjective drug effects (Liechti et al.,
2000a). Thus, the relative in vitro effect on the DAT versus
SERT is useful to predict drug characteristics in vivo and
compare novel cathinones with known psychostimulants.
MDMA is selective for the SERT, with a DAT/SERT inhibition
ratio of 0.08 (present study) and DA/5-HT release potency
ratio <1 (Baumann et al., 2012), and produces positive mood
effects in humans with little psychostimulation (Liechti et al.,
2001). Cocaine has a DAT/SERT ratio close to unity, and
methamphetamine is more selective for the DAT, with a DAT/
SERT inhibition ratio >10 and DA/5-HT release ratio >100
(Baumann et al., 2012) and has mostly psychostimulant
effects in humans.
Cocaine-MDMA-mixed cathinones
Mephedrone, methylone, ethylone, butylone and naphyrone
exhibited relative DAT versus SERT inhibition potencies in
the range of 1–5, similar to cocaine. Uptake inhibition studies
using rat synaptosomes found that mephedrone was equally
potent at the DAT and SERT (Hadlock et al., 2011). Methylone
and butylone were slightly more potent DAT than SERT
inhibitors at the human transporter as previously shown for
methylone (Cozzi et al., 1999). Equal uptake inhibition
Figure 3
Dopamine and 5-HT release. HEK 293 cells that stably express the DA or 5-HT transporter were preloaded with [3H]-DA or [3H]-5-HT, respectively,
washed and incubated with drugs. Transporter-mediated release is expressed as % reduction in monoamine cell content at the maximal drug
concentration (100 mM) compared with controls. **P < 0.01, ***P < 0.001, significant effects compared with controls. The EC50 values are shown
in Table 3. The data are expressed as the mean ! SEM of three independent experiments.
Table 4
Blood-brain barrier permeability
Pe ratio
Apical to basolateral Basolateral to apical Permeability aActive transport bCLogP
MDMA 6.0 ! 0.56 7.4 ! 2.4 + No 1.85
Mephedrone 14.0 ! 10.4 12.2 ! 6.1 ++ No 1.67
Methylone 6.1 ! 2.8 5.3 ! 1.3 + No 1.39
Methcathinone 5.9 ! 2.8 8.5 ! 3.2 + No 1.19
Amphetamine 6.3 ! 3.7 5.2 ! 1.3 + No 1.74
Methamphetamine 5.4 ! 1.1 6.4 ! 3.0 + No 1.74
MDPV 37.2 ! 11.3 12.0 ! 11.2 ++ Yes 3.80
Data are expressed as mean ! SD (n = 3–9).
Pe ratios indicate the blood–brain barrier permeability of the drug in relation to the extracellular marker lucifer yellow (Pe = 1).
+, high permeability (Pe ratio >3). ++, very high permeability (Pe ratio >10).
aP <0.05 significant difference between apical to basolateral compared with basolateral to apical transport indicating active transport.
bCLogP, prediction of partition coefficient (lipophilicity).
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potencies for the DAT and SERT were shown for methylone
and butylone using rat brain synaptosomes (Nagai et al.,
2007; Lopez-Arnau et al., 2012). Ethylone was an equipotent
inhibitor of all three transporters, and we are not aware of
other published data. Compared with methylone, ethylone
and butylone, the respective non-b-keto analogue entac-
togens MDMA, MDEA and MBDB were 10-fold more selective
for the SERT versus DAT, consistent with previous data on
methylone and MDMA (Cozzi et al., 1999; Nagai et al., 2007).
Together the data indicate that the cocaine–MDMA–mixed
cathinones are more dopaminergic with regard to monoam-
ine transporter inhibition than their entactogen analogs.
In terms of monoamine release, the cocaine–MDMA–
mixed cathinones were comparable with MDMA. Ethylone
and butylone released 5-HT, comparable with their non-b-
keto entactogen analogues MBDB and MDEA, but with lower
potency. Previous studies found that the monoamine release
profiles of mephedrone and methylone resembled those of
MDMA, with DAT/SERT and NET/DAT ratios close to unity
(Nagai et al., 2007; Baumann et al., 2012). However, mephe-
drone was a more potent releaser of DA than MDMA in the
present study and from striatal suspensions preloaded with
DA (Hadlock et al., 2011). An in vivo microdialysis study in
rats showed that mephedrone also produced a rapid and
pronounced increase in nucleus accumbens DA levels, com-
parable with amphetamine and unlike MDMA, which only
moderately elevates DA levels (Kehr et al., 2011). Both
mephedrone and MDMA also produced strong increases in
extracellular 5-HT, whereas amphetamine had only a moder-
ate effect on 5-HT levels (Kehr et al., 2011). Other microdi-
alysis studies showed that mephedrone and methylone
elevated extracellular DA and 5-HT levels in the rat nucleus
accumbens, with relatively higher effects on 5-HT levels
(Aarde et al., 2011; Baumann et al., 2012), similar to MDMA
and unlike methamphetamine, which preferentially increases
DA (Baumann et al., 2012). Thus, mephedrone shares some of
the DA-releasing properties of amphetamine and metham-
phetamine and 5-HT-releasing property of MDMA. Mephe-
drone also produced relatively weak motor stimulation
similar to MDMA, unlike amphetamine that strongly
increases locomotor activity in rats (Kehr et al., 2011), and a
preference to move along the walls of the test box (Motbey
et al., 2012) as previously described for MDMA. Like MDMA,
mephedrone also reduced voluntary wheel running in rats,
while running was increased by methamphetamine or MDPV
(Huang et al., 2012). Similar to mephedrone, methylone was
also reported to be a weak motor stimulant compared with
methamphetamine (Baumann et al., 2012). Drug discrimina-
tion studies in rats also showed that methylone generalized
well to MDMA and at lower potency also to amphetamine
(Dal Cason et al., 1997). Mephedrone is self-administered by
rats (Aarde et al., 2011; Hadlock et al., 2011), has been
reported to produce strong craving in humans (Brunt et al.,
2011) and when administered intranasally is rated by users to
be more addictive than cocaine (Winstock et al., 2011). Fur-
thermore, mephedrone showed very high BBB permeability
in our in vitro model, confirming that mephedrone readily
enters the brain (Hadlock et al., 2011). Overall, the pharma-
cological effects of mephedrone and methylone appear to be
relatively similar to those of MDMA but share more of the DA
system-stimulating properties of amphetamine and metham-
phetamine and the DAT versus SERT inhibition profile of
cocaine. The subjective effects of mephedrone have been
reported to be similar to those of cocaine (Winstock et al.,
2011) but also MDMA (Carhart-Harris et al., 2011). Impor-
tantly, MDMA is mostly used orally, whereas intranasal
administration is the most common route of use for mephe-
drone (Winstock et al., 2011) and cocaine. Users noted that
the high obtained with the intranasal use of mephedrone was
similar to or better than the high produced by cocaine (Win-
stock et al., 2011). These observations indicate that the oral
use of mephedrone produces overall similar effects to MDMA,
whereas intranasal use results in more cocaine-like psycho-
tropic effects. Similar to mephedrone and methylone, ethyl-
one and butylone may be associated with an increased risk of
addiction compared to their non-b-keto analogues because of
the stronger relative activation of the DA system.
The pyrovalerone derivative naphyrone exhibited a
monoamine uptake transporter inhibition profile that was
very close to that of cocaine, with equal relative potency at all
three transporters. Similar to cocaine, naphyrone was not a
monoamine releaser. Naphyrone is distinct from pyrova-
lerone and its derivative MDPV because of its higher absolute
and relative SERT-inhibiting potency. Although the structure
would suggest similar pharmacological effects to the other
pyrovalerone derivatives, the additional SERT inhibition may
indicate more similar effects to cocaine in humans (Derungs
et al., 2011).
Methamphetamine-like cathinones
Cathinone and methcathinone exhibited a relative monoam-
ine transporter inhibition profile that was very similar to that
of the non-b-keto analogues amphetamine and metham-
phetamine, with high inhibitory potencies at the DAT and
low potencies at the SERT, consistent with previous findings
(Cozzi et al., 1999; Fleckenstein et al., 1999). Cathinone and
methcathinone were also potent releasers of DA but not 5-HT,
similar to amphetamine and methamphetamine. Cathinone
and methcathinone have previously been shown to release
radiolabelled DA and 5-HT from rat brain preparations with
similar DA versus 5-HT selectivity to amphetamine (Kalix,
1990) and methamphetamine (Glennon et al., 1987), but
with two- to three-fold lower potency. Methcathinone has
been shown to be a substrate for the transporter (Cozzi and
Foley, 2003), similar to the classic amphetamines and MDMA
(Rothman et al., 2001; Verrico et al., 2007). Cathinone and
methcathinone produce amphetamine-like locomotor stimu-
lation in animals (Glennon et al., 1987; Kelly, 2011), and
cathinone is self-administered by rats (Gosnell et al., 1996) or
rhesus monkeys (Johanson and Schuster, 1981; Woolverton
and Johanson, 1984) with reinforcing efficacies comparable
to amphetamine and cocaine. Clinically, cathinone and
methcathinone have been reported to produce similar toxic-
ity to amphetamine, including hypertension, hyperthermia,
euphoria, locomotor activation and hallucinations following
higher or repeated doses (Kalix, 1990; Widler et al., 1994).
Thus, the pharmacology of cathinone and methcathinone
is qualitatively very close to that of amphetamine and
methamphetamine.
Flephedrone was a DAT but not a SERT inhibitor, similar
to its analogue 4-fluoroamphetamine (Nagai et al., 2007).
Flephedrone released DA but not 5-HT (IC50 >33 mM). The
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DAT/SERT selectivity profile of flephedrone is therefore equal
to the methamphetamine-like cathinones. In contrast,
flephedrone had higher 5-HT2A receptor binding that was
similar to mephedrone and MDMA. We are not aware of any
other in vitro or in vivo data on flephedrone. Agitation and
psychosis were reported in a patient who insufflated flephe-
drone and MDPV powder (Thornton et al., 2012).
Pyrovalerone cathinones
Pyrovalerone and its derivative MDPV were very potent DAT
inhibitors as previously shown (Meltzer et al., 2006) and at
least 10-fold more potent than cocaine and methampheta-
mine. In contrast to the pyrovalerone derivative naphyrone,
MDPV and pyrovalerone are weak inhibitors of the SERT,
resulting in high DAT selectivity, with DAT/SERT inhibition
ratios >100. MDPV and pyrovalerone were also the most
potent NET inhibitors. Despite the high potency to block the
DAT, pyrovalerone and MDPV did not produce DA efflux.
Thus, pyrovalerone derivative cathinones are pure trans-
porter uptake inhibitors. Consistent with the potent effect on
catecholamine carriers, MDPV, compared with mephedrone,
produced behavioural effects in animals at lower doses (Aarde
et al., 2011) and has been reported to produce mostly sym-
pathomimetic toxicity and psychotic reactions in humans
(Spiller et al., 2011). Similar to methamphetamine, MDPV
and pyrovalerone did not exhibit affinity for the 5-HT2A
receptor and exhibited low affinity for TA1 receptors, consist-
ent with the other cathinones.
Pyrovalerone derivatives have been suggested to easily
cross the BBB because of their high lipophilicity (Meltzer
et al., 2006; Coppola and Mondola, 2012). All of the cathi-
nones and non-b-keto amphetamine analogues showed good
membrane permeation in our in vitro BBB model, but we
indeed documented very high transmembrane permeability
of MDPV and a potential active transport. Although the high
brain uptake may contribute to the higher potency of MDPV
compared with the non-pyrovalerone cathinones, the high
potency at the NET and DAT is more likely to be responsible
for the psychotropic effects at low doses in humans. In fact,
we found that the potencies to inhibit the NET and DAT were
significantly correlated with the doses reported to produce
psychotropic effects in recreational users. Consistently,
pyrovalerone and MDPV are at least 10-fold more potent
inhibitors of the NET or DAT compared with mephedrone;
this was demonstrated in the present study and previously
(Meltzer et al., 2006), and are used recreationally at approxi-
mately 10-fold lower doses than mephedrone (Derungs et al.,
2011), whereas both MDPV and mephedrone exhibited very
high BBB penetrance in our study. The potency of the pyrova-
lerone derivatives at the DAT and NET and high brain pen-
etrance could result in high sympathomimetic toxicity and
risk of addiction in humans. MDPV has also been shown to
be a potent reinforcer in rats, similar to methamphetamine
(Watteron et al., 2011).
Structure–activity relationship and binding to
monoamine receptors
b-Keto-amphetamines appear to have similar effects on
plasma membrane monoamine transporters compared with
their non-b-keto analogues, with slightly higher selectivity
for the DAT over the SERT. b-Keto-analogue cathinones also
exhibited approximately 10-fold lower affinity for the TA1
receptor compared with their respective non-b-keto ampheta-
mines. TA1 receptors play an important role in the modula-
tion of dopaminergic and 5-hydroxytryptaminergic activity
(Lindemann et al., 2008; Revel et al., 2011). Activation of TA1
receptors negatively modulates dopaminergic neurotransmis-
sion. Importantly, methamphetamine decreased DAT surface
expression via a TA1 receptor-mediated mechanism and
thereby reduced the presence of its own pharmacological
target (Xie and Miller, 2009). MDMA and amphetamine have
been shown to produce enhanced DA and 5-HT release and
locomotor activity in TA1 receptor knockout mice compared
with wild-type mice (Lindemann et al., 2008; Di Cara et al.,
2011). Because methamphetamine and MDMA auto-inhibit
their neurochemical and functional effects via TA1 receptors,
low affinity for these receptors may result in stronger effects
on monoamine systems by cathinones compared with the
classic amphetamines. The higher selectivity of the cathi-
nones for the DAT and lack of TA1 receptor binding may
result in an increased risk of dependence compared with
classic non-b-keto analogue stimulants (Rothman and
Baumann, 2006). Because 5-HT release dampens the stimu-
lant effects of amphetamine-type drugs, the lower activity of
the cathinones at the SERT would be expected to result in
more stimulant-like effects (Baumann et al., 2011) compared
with the non-b-keto analogues. The a-ethyl-substituted com-
pounds MBDB and butylone exhibited fivefold lower absolute
and relative NET inhibition potencies than their a-methyl-
analogues MDMA and methylone, in line with previous
studies (Montgomery et al., 2007). The lower affinity for NET
has been associated with the low stimulant and euphorigenic
properties of MBDB (Montgomery et al., 2007).
Several of the drugs evaluated in the present study exhib-
ited moderate direct affinity for 5-HT receptors and adreno-
ceptors, with Ki values in the 1–10 mM range. Direct
interactions between MDMA and 5-HT2 receptors rather
than indirect agonist effects via 5-HT release have been sug-
gested to contribute to MDMA-induced excitation and
hallucinogen-like perceptual alterations at higher doses
(Liechti et al., 2000b; 2001). MDMA, MBDB, mephedrone,
flephedrone and methcathinone bound to 5-HT2A receptors,
consistent with previous data on mephedrone, methylone
and MDMA (Lopez-Arnau et al., 2012; Martinez-Clemente
et al., 2012). Stimulation of 5-HT2A receptors has also been
shown to enhance DA release (Gudelsky et al., 1994), poten-
tially increasing abuse liability. Although flephedrone and
methcathinone show low potency at the SERT, these drugs
may have direct effects on the 5-HT system via 5-HT2A recep-
tor activation at higher doses. Amphetamine and metham-
phetamine bound to 5-HT1A receptors, potentially resulting
in behavioural effects that are opposite to those induced
by 5-HT2A receptor stimulation (Nichols, 2004; Gatch et al.,
2011). Mephedrone, flephedrone, cathinone and methcathi-
none exhibited affinity for a1A adrenoceptors, which have
been implicated in stimulant-induced vasoconstriction,
hyperthermia (Hysek et al., 2012b) and euphoria (Newton
et al., 2012). Finally, amphetamine and methamphetamine
bound to a2A receptors, which modulate NA release and sym-
pathomimetic toxicity (Hysek et al., 2012a).
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It is important to note that we assessed the effects of
racemic cathinones, whereas stereoselective and drug-specific
interactions have been demonstrated for amphetamines
(Lyon et al., 1986; Steele et al., 1987; Acquas et al., 2007).
Furthermore, we did not investigate drug interactions with
intracellular targets such as monoamine oxidase or the
vesicular monoamine transporter.
In summary, considerable differences were found in the
pharmacology of the different cathinones. Mephedrone,
methylone, ethylone, butylone and naphyrone acted as non-
selective monoamine uptake inhibitors, similar to cocaine
and, with the exception of naphyrone, also induced the
release of 5-HT, similar to MDMA. Cathinone and methcathi-
none were found to be selective catecholamine uptake inhibi-
tors and releasers, similar to their non-b-keto analogues
amphetamine and methamphetamine. Pyrovalerone and
MDPV were shown to be highly potent and selective catecho-
lamine transporter inhibitors but not substrate releasers.
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Summary 
Background and purpose: Psychoactive β-keto amphetamines (cathinones) are sold 
as “bath salts” or “legal highs” and recreationally abused. We characterized the 
pharmacology of a new series of cathinones including methedrone, 4-
methylethcathinone (4-MEC), 3-fluoromethcathinone (3-FMC), pentylone, 
ethcathinone, buphedrone, pentedrone, and N,N-dimethylcathinone.  
Experimental approach: We determined noradrenaline (NA), dopamine (DA), and 
serotonin (5-HT) uptake inhibition using HEK 293 cells that express the respective 
human monoamine transporter. We investigated drugs-induce efflux of NE, DA, or 5-
HT from monoamine-preloaded cells and determined the binding affinities to 
monoamine transporters and receptors.    
Key results: All cathinones were potent NA uptake inhibitors, but differed in their 
DA versus 5-HT transporter inhibition profiles and in their effects to release 
monoamines. Methedrone was a more potent 5-HT than DA transporter inhibitor and 
released NA and 5-HT similar to para-methoxymethamphetamine (PMMA), para-
methoxyamphetamine (PMA), 4-methylthioamphetamine (4-MTA), or 3,4-
methylenedioxymethamphetamine (MDMA). 4-MEC and pentylone equipotently 
inhibited all monoamine transporters and released 5-HT. Ethcathinone and 3-FMC 
inhibited NA and DA uptake and released NA and 3-FMC also DA similar to N-
ethylamphetamine and methamphetamine. Pentedrone and N,N-dimethylcathinone 
were non-releasing NA and DA uptake inhibitors as previously shown for 
pyrovalerone cathinones. Buphedrone preferentially inhibited NA and DA uptake and 
also released NA. None of the cathinones bound to rodent trace amine-associated 
receptor 1 in contrast to the non-β-keto-amphetamines. None of the cathinones 
exhibited relevant binding to other monoamine receptors.  
Conclusions and implications: We described considerable differences in the 
monoamine transporter interaction profiles among different cathinones and compared 
with related amphetamines.   
 
 
Keywords: cathinone, amphetamine, legal high, research chemical, serotonin, 
dopamine, noradrenaline transporter 
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Abbreviations  
DA, dopamine; DAT, dopamine transporter; HEK, human embryonic kidney; 5-HT, 
serotonin; MDMA, 3,4-methylenedioxymethamphetamine; MDPV, 3,4-
methylenedioxypyrovalerone; 4-MTA, 4-methylthioamphetamine; NA, 
noradrenaline; NET, noradrenaline transporter; PMA, para-methoxyamphetamine 
(PMA), PMMA, para-methoxymethamphetamine; SERT, serotonin transporter; TA, 
trace amine-associated receptor 
 
 
 
Introduction 
The market of illicit stimulants has become complex. From 2005 to 2011, 34 
novel cathinone-type designer drugs have been detected in the European Union 
(EMCDDA, 2012). These drugs are typically available online as “legal highs”, “bath 
salts”, or “research chemicals” (EMCDDA, 2012) and added to the users’ club drug 
repertoires (Moore et al., 2013) resulting in unknown health risks. Intoxications with 
different cathinone derivatives have been reported worldwide (Borek & Holstege, 
2012; James et al., 2011; Prosser & Nelson, 2012; Zuba et al., 2013). Structurally, the 
novel designer cathinones are all substituted amphetamines, but their pharmacology 
and toxicology show considerable variability (Dal Cason et al., 1997; Simmler et al., 
2013) and are not known in many cases. Recent studies characterized the in vitro 
pharmacological profiles of cathinones including ethylone, mephedrone, naphyrone, 
butylone, methylone, flephedrone, cathinone, methcathinone, pyrovalerone, and 3,4-
methylenedioxypyrovalerone (MDPV) (Baumann et al., 2013; Eshleman et al., 2013; 
Iversen et al., 2013; Lopez-Arnau et al., 2012; Simmler et al., 2013). These 
preclinical studies allow to compare the pharmacological mechanism of action of the 
novel designer drugs with well-known amphetamines including methamphetamine 
and 3,4-methylenedioxymethamphetamine (MDMA).  
In the present study, we characterized the in vitro pharmacology of a second 
series of cathinones including methedrone, 4-methylethcathinone (4-MEC), 3-
fluoromethcathinone (3-FMC), pentylone, ethcathinone, buphedrone, pentedrone, and 
N,N-dimethylcathinone, as well as profiles of the non-β-keto amphetamine analog 
comparator drugs 4-methylthioamphetamine (4-MTA), para-methoxyamphetamine 
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(PMA), para-methoxymethamphetamine (PMMA), MDMA, N-ethylamphetamine, 
and methamphetamine, complementing our previous characterization of this class of 
designer drugs (Simmler et al., 2013). Being amphetamine derivatives, these drugs 
were expected to interact predominantly with monoamine transporters and receptors. 
We determined the potencies of the drugs to inhibit the human noradrenaline (NA), 
dopamine (DA), and serotonin (5-HT) uptake transporters (NET, DAT, and SERT, 
respectively). We tested whether the drugs induce transporter-mediated release of 
NA, DA or 5-HT and characterized the biniding affinities of the drugs for monoamine 
transporters, α1 and α2 adrenergic receptors, dopamine D1-3 receptors, 5-HT1A, 5-
HT2A, 5-HT2C receptors, the histamine H1 receptor, and the trace amine-associated 
receptor 1 (TA1).  
Methedrone is the β-keto-substituted analog of PMMA. PMMA and PMA are 
para-ring-substituted amphetamine-derivatives sold as Ecstasy, alone or in 
combination with MDMA (Brunt et al., 2012). PMA and PMMA epidemics have 
been described for many years worldwide (Johansen et al., 2003; Lurie et al., 2012; 
Vevelstad et al., 2012). PMA and PMMA use has been associated with particularly 
high morbidity and mortality in particular due to hyperthermia (Brunt et al., 2012; 
Lurie et al., 2012; Refstad, 2003). Methedrone is found in bath salts products 
(Marinetti & Antonides, 2013) and it may exhibit a high risk for mortality (Wikstrom 
et al., 2010) similar to PMA. PMA inhibits the SERT and induces 5-HT release 
(Callaghan et al., 2005) like MDMA. In animals, PMMA and PMA produce effects 
similar to MDMA, but more potent, and lack amphetamine-like stimulant effects in 
rodent drug discrimination-studies (Dukat et al., 2002; Glennon et al., 2007). 
Pharmacological data on methedrone are not available. 4-MTA is the methylthio-
analog of PMA and also a SERT inhibitor (Huang et al., 1992) and 5-HT releaser 
(Gobbi et al., 2008; Huang et al., 1992). 4-MTA produces MDMA-like effects in 
animals and humans (Winstock et al., 2002) and is typically used by Ecstasy users 
(Winstock et al., 2002). Fatalities possibly linked to 5-HT syndrome have been 
described (De Letter et al., 2001).  
4-Methylethcathinone (4-MEC) is reported to be available over the Internet as 
“NRG-2” (Brandt et al., 2010) and is a substitute for mephedrone (Zuba & Byrska, 
2012). 4-MEC inhibits the DAT, NET, and SERT (Iversen et al., 2013). Whether 4-
MEC is also a monoamine releaser is not known.  
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3-FMC has been detected in legal highs (Archer, 2009). 3-FMC was shown to 
have pronounced locomotor stimulant and ataxic effects in mice (Marusich et al., 
2012) but its pharmacological profile is unknown. The pharmacology of its structural 
isomer 4-fluoromethcathinone (flephedrone) has recently been described (Eshleman 
et al., 2013; Simmler et al., 2013).  
Ethcathinone was detected in a patient presenting with severe hyponatremia and 
seizures (Boulanger-Gobeil et al., 2012). Ethcathinone is the β-keto-analog of N-
ethylamphetamine, which is similar to methamphetamine but contains an N-ethyl-
group. Ethcathinone is a rat NET, DAT, and SERT inhibitor and also releases NA and 
5-HT, but not DA from rat synaptosomes (Yu et al., 2000). N-Ethylamphetamine 
releases NA and with lower potency also 5-HT and DA from rat synaptosomes 
(Tessel & Rutledge, 1976). We found no data on effects of ethcathinone on the human 
monoamine transporters.  
Pentedrone, buphedrone, and pentylone are recently identified novel designer 
cathinones (Maheux & Copeland, 2012; Westphal et al., 2012; Zuba & Byrska, 2012). 
Buphedrone was detected in “Vanilla Sky” and other “legal high” pills as a frequent 
substitute for mephedrone in Eastern Europe (Zuba et al., 2013). Intoxications with 
buphedrone and its recreational use have recently been described (Zuba et al., 2013). 
Pentylone has been detected in “legal high” samples from the Internet (Brandt et al., 
2011) and headshops (Westphal et al., 2012) or fatalities associated with “bath salts” 
in the US (Marinetti & Antonides, 2013). Buphedrone and pentedrone are the α-ethyl 
and α-pentyl β-keto analogs of methamphetamine, respectively. Pentedrone is 
structurally identical to pentylone, but without the MDMA-like 3,4-methylenedioxy-
group (Figure 1). Pentylone is a β-keto-analog of MDMA, similar to methylone and 
butylone (Simmler et al., 2013), containing an α-pentyl-group. N,N-
dimethylcathinone is the N-methylated β-keto-analog of methamphetamine and it has 
similar but less potent stimulant effects (Dal Cason et al., 1997). We found no data on 
the molecular pharmacology of pentylone, pentedrone, buphedrone, or N,N-
dimethylcathinone. 
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Methods 
 
Drugs 
Drugs were supplied by Lipomed (Arlesheim, Switzerland) as hydrochloride 
salts (purity >98.5%). Racemic drugs were used except for d-methamphetamine. All 
radioligands were obtained from Perkin Elmer (Schwerzenbach, Switzerland) or 
Anawa (Wangen, Switzerland) with the exception of [3H]RO5166017, which was 
synthesized at Roche (Basel, Switzerland). 
 
Monoamine uptake transporter inhibition 
Inhibition of NET, SERT, and DAT was assessed in HEK 293 cells that stably 
expressed human NET, SERT or DAT (Tatsumi et al., 1997) as previously described 
(Hysek et al., 2012). DAT/SERT ratio was calculated as 1/DAT IC50 : 1/SERT IC50.  
 
 Transporter-mediated monoamine release 
We studied transporter-mediated NA, 5-HT, and DA efflux in HEK 293 cells that 
overexpressed the respective human monoamine transporter as previously reported in 
detail (Simmler et al., 2013). In brief, we preloaded the cells by incubating HEK-
SERT cells with 10 nM [3H]5-HT, HEK-DAT cells with 10 nM [3H]DA and 1 µM 
unlabeled DA, and HEK-NET cells with 10 nM [3H]NA and 10 µM unlabeled NA for 
20 min. Then, we washed twice, and induced release by adding 1000 µM of release 
buffer containing the test drugs at concentrations of 10 µM and 100 µM. We 
incubated the HEK-SERT and HEK-DAT cells for 15 min and the HEK-NET cells 
for 45 min at 37 °C by shaking at 300 r.p.m on a rotary shaker. We then stopped the 
release by removing the buffer and gently washing the cells twice with cold buffer. 
We quantified the radioactivity remaining in the cells (HEK-SERT and HEK-DAT) or 
in the removed buffer (HEK-NET). Nonspecific “pseudoefflux”, which arises from 
substrate diffusing out of the cells and inhibition of reuptake (Rosenauer et al., 2013; 
Scholze et al., 2000), was assessed using the transporter inhibitors nisoxetine (HEK-
NET cells), citalopram (HEK-SERT cells), or mazindol (HEK-DAT cells) at 10 µM. 
Nonspecific release was subtracted from Emax of total release to yield Emax values of 
specific transporter-mediated release. Methamphetamine and MDMA were used as 
comparator compounds known to induce monoamine release in this assay (Simmler et 
al., 2013). We used analysis of variance followed by Dunnett’s tests to compare drug 
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effects with the control condition. Drugs that induced significantly higher maximal 
monoamine efflux compared to the respective transporter inhibitors (nonspecific 
release) were considered monoamine releasers.  
 
Radioligand binding assays 
The radioligand binding assays were performed as described previously (Hysek et al., 
2012; Revel et al., 2011; Simmler et al., 2013). Briefly, membrane preparations of 
HEK 293 cells (Invitrogen, Zug, Switzerland) that overexpress the respective 
transporters (Tatsumi et al., 1997) or receptors (human genes except for TA1 
receptors that were rat/mouse) (Revel et al., 2011) were incubated with the 
radiolabelled selective ligands at concentrations equal to Kd and ligands displacement 
by the compounds measured. The following radioligands and competitors were used: 
N-methyl-[3H]-nisoxetine and indatraline (NET), [3H]citalopram and indatraline 
(SERT), and [3H]WIN35,428 and indatraline (DAT). [3H]8-Hydroxy-2-(di-n-
propylamino)tetralin (8-OH-DPAT) and indatraline (5-HT1A receptor), [3H]ketanserin 
and spiperone (5-HT2A receptor), [3H]mesulergine and mianserin (5-HT2C receptor), 
[3H]prazosin and risperidone (α1 adrenergic receptor), [3H]rauwolscine and 
phentolamine (α2 adrenergic receptor), [3H]SCH 23390 and butaclamol (DA D1 
receptor), [3H]spiperone and spiperone (DA D2 and D3 receptors), [3H]pyrilamine and 
clozapine (histaminergic H1 receptor), and [3H]RO5166017 and RO5166017 (TA1). 
To evaluation the relationship between binding affinity to the transporter and 
functional inhibition potencies, we calculated Pearson correlations for the pure 
transporter inhibitor and substrate releaser subgroups. 
 
 
Results 
 
Monoamine uptake transporter inhibition 
The effects of the cathinones and comparator drugs on monoamine transporter 
function are shown in Figure 1. The IC50 values for monoamine transport inhibition 
and the DAT/SERT inhibition ratios are shown in Table 1. With the exception of 
N,N-dimethylcathinone, which was a weak NET and DAT inhibitor, all compounds 
shared potent effects as NET inhibitors while their DAT and SERT inhibition 
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potencies varied considerably as evidenced by the wide range of their DAT/SERT 
inhibition ratios. 4-MTA, PMA, PMMA, and methedrone were potent SERT and NET 
inhibitors but weak inhibitors of DAT similar to MDMA. The DAT/SERT ratio was 
below 0.5 for all these MDMA-like drugs. Methedrone was the only cathinone in the 
present series of drugs with an MDMA-like profile and DAT/SERT ratio below 1. 
With the exception of methedrone, all cathinones examined in this series 
preferentially inhibited NET and DAT over SERT. In particular 3-FMC, pentedrone, 
buphedrone, and N,N,-dimethylcathinone exhibited very low potency at SERT and 
DAT/SERT inhibition ratios >10. Ethylamphetamine was equipotent at DAT and 
SERT, while its β-keto analog ethcathinone was 10-fold less potent at SERT versus 
DAT. In contrast, 4-MEC, the 4-ring-methylated analog of ethcathinone, was 6-fold 
more potent at SERT than ethcathinone. Similarly, the 3,4-ring methoxylated analog 
of pentedrone, pentylone was at least 10-fold more potent at SERT than pentedrone. 
NET, but not DAT or SERT inhibition potency values (IC50) were correlated with 
estimated reported mean doses taken by recreational users (http://www.erowid.org 
and other user home pages) (R=0.60; P<0.05, N=13; Table 1). N,N-
dimethylcathinone was not included due to a lack of data on effective doses used in 
humans.   
 
Transporter-mediated monoamine release 
Maximal monoamine releasing effects are shown in Figure 2. All compounds induced 
release of at least one monoamine with the exception of pentedrone and N,N-
dimethylcathinone, which were non-releasers. Methedrone and 3-FMC released all 
three monoamines similar to all the non-β-keto amphetamines methamphetamine, 
MDMA, PMMA, PMA, and N-ethylamphetamine. Ethcathinone and 4-MTA released 
NA and 5-HT. 4-MEC and pentylone weakly released 5-HT. Buphedrone released 
NA.  
 
Binding affinities 
Monoamine transporter and receptor binding affinities are shown in Table 2. None of 
the drugs exhibited very high binding (<100 nM) to any of the monoamine 
transporters or human receptors. There were submicromolar (<1 µM) affinity DAT 
interactions with the cathinones 4-MEC, pentylone, ethcathinone, and pentedrone but 
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not with the non-β-keto amphetamines. Conversely, the non-β-keto amphetamines but 
not the cathinones showed affinity to rat and mouse TA.  
Ethcathinone and the non-β-keto amphetamines N-ethylamphetamine and 
methamphetamine showed relevant (<10 µM) 5-HT1A receptor binding. The 
cathinones 4-MEC and N,N-dimethylcathinone and the non-β-keto amphetamines 4-
MTA and MDMA showed relevant (<10 µM) 5-HT2A receptor binding. The 
cathinones 4-MEC, 3-FMC, and N,N-dimethylcathinone and the non-β-keto 
amphetamines 4-MTA and N-ethylamphetamine showed relevant (<10 µM) 5-HT2C 
receptor binding. 4-MTA, N-ethylamphetamine, and methamphetamine showed 
relevant (<10 µM) adrenergic α2 receptor binding. None of the drugs tested bound to 
DA D1-3 or histamine H1 receptors.  
There were differences in the associations between transporter affinities and 
functional transporter inhibition potencies between the pure uptake inhibitors and the 
monoamine releasers depending on transporter type. For the NET, Ki and IC50 values 
were significantly correlated for the pure transporter inhibitors (R=0.97, P<0.05, N=4) 
but not for the releasers (R=0.08, NS, N=8). For the DAT, Ki and IC50 values were 
significantly correlated for both the pure transporter inhibitors (R=0.93, P<0.001, 
N=8) and releasers (R=0.87, P<0.05, N=7). For the SERT, Ki and IC50 values were 
not correlated for the pure transporter inhibitors nor the releasers (R=0.53, NS, N=3 
and R=0.6, NS, N=10; respectively). Additionally, the pure uptake inhibitors and 
releasers typically differed by their ratio of Ki value to IC50 value. Most releasers 
showed higher functional potency values compared to binding potency values 
resulting in ratios > 6 for NET and >1 for DAT and SERT with some exceptions for 
drugs that released monoamines only at high drug concentrations (>10 µM).  
 
 
Discussion 
 
We characterized the monoamine receptor binding profiles and interactions with the 
monoamine transporters of a series of seven novel designer cathinones, components 
of “bath salts” or “legal highs”. The pharmacological profiles of the seven cathinone 
derivatives were compared with their non-β-keto analogs or related non-β-keto 
substituted amphetamines. All cathinones inhibited monoamine transport as expected 
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based on their amphetamine structure. However, there are considerable differences 
among these cathinones as well as in comparison with the non-β-keto amphetamines. 
We have previously characterized a first series of ten cathinone derivatives together 
with five non-β-keto amphetamine analogs and cocaine using identical methods as in 
the present study (Simmler et al., 2013). The profiles of the second series of 
compounds described here can therefore directly be compared with those of our 
previous study (Simmler et al., 2013), which have been confirmed and extended by 
others (Baumann et al., 2013; Eshleman et al., 2013; Iversen et al., 2013; Rosenauer 
et al., 2013). First, the compounds markedly differed with regard to their 
serotoninergic versus dopaminergic properties as expressed by the DAT/SERT ratio, 
possibly an in vitro marker of the abuse potential of a drug (Rothman & Baumann, 
2006; Simmler et al., 2013). Second, some cathinones were pure uptake inhibitors 
while others were substrate releasers. Third, cathinones typically did not bind to 
rodent TA1 in contrast to the non-β-keto-amphetamines. 
 
Methedrone is a serotonergic cathinone similar to other para-(4)-substituted 
amphetamines and MDMA 
Methedrone was 7-fold more potent as a SERT versus DAT inhibitor and was the 
cathinone with the highest selectivity for SERT in both the present and previously 
studied series of compounds (Simmler et al., 2013), exhibiting a profile identical to 
MDMA. Methedrone also produced monoamine efflux similar to MDMA. 
Methedrone is therefore the most MDMA-like cathinone presently described in terms 
of monoamine transporter interaction profile. Interestingly, methylone, which is the 
exact β-keto analog of MDMA, was less selective for the SERT versus DAT 
compared to methedrone (Simmler et al., 2013). Methedrone is the β-keto analog of 
PMMA. Both methedrone and PMMA are para-methoxy- or methylthio-
amphetamines similar to PMA and 4-MTA, which have been included as comparator 
compounds into the present series. PMA is the demethylated analog of PMMA and 
also a metabolite of PMMA in vivo (Staack & Maurer, 2005). Compared to other 
amphetamines, PMA, PMMA, and 4-MTA have long been associated with 
particularly high clinical toxicity and many fatalities mostly due to 5-HT syndrome, 
hyperthermia and associated multi-organ failure (De Letter et al., 2001; Johansen et 
al., 2003; Lurie et al., 2012; Vevelstad et al., 2012). Similar fatal intoxications have 
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recently been described with methedrone (Wikstrom et al., 2010). Our study provides 
first molecular pharmacological data on methedrone and PMMA and confirms the 
previously characterized profiles of PMA and 4-MTA (Gobbi et al., 2008; Gough et 
al., 2002; Huang et al., 1992; Quinn et al., 2006). The present study showed that all 
these para-substituted amphetamines are potent NET and SERT inhibitors with low 
potency at DAT confirming data on 4-MTA (Huang et al., 1992). The compounds 
have similar or even higher preference for SERT over DAT compared with MDMA.  
They all released NA and 5-HT and at high concentrations (>10 µM) also DA as 
previously shown for 4-MTA and PMA in vitro and in vivo (Gobbi et al., 2008; 
Gough et al., 2002; Huang et al., 1992; Quinn et al., 2006; Sotomayor-Zarate et al., 
2012). The in vivo hyperthermic properties of the para-substituted amphetamines are 
stronger than those of MDMA (Daws et al., 2000) and have been associated with 
serotonergic and adrenergic receptor activation (Carmo et al., 2003), as well as 
monoamine oxidase A (MAO) inhibition (Carmo et al., 2003). In fact, PMA is a 
much stronger MAO inhibitor than other amphetamines (Green & El Hait, 1980). 
 
4-MEC and pentylone are cocaine-MDMA-mixed cathinones 
All cathinones with the exception of methedrone were more potent at the 
catecholamine transporters compared to the SERT. 4-MEC and pentylone inhibited all 
monoamine transporters with approximately equal potency similar to cocaine. 4-MEC 
and pentylone released 5-HT similar to MDMA. Thus, 4-MEC and pentylone are 
cocaine-MDMA-mixed cathinones with very similar profiles to ethylone, butylone, 
and methylone (Simmler et al., 2013). 4-MEC, pentylone, and butylone (Simmler et 
al., 2013) release only 5-HT but not DA differentiating them from the popular 
cathinone derivative mephedrone, which releases both 5-HT and DA (Hadlock et al., 
2011; Kehr et al., 2011; Simmler et al., 2013). Release of 5-HT by 4-MEC and 
pentylone may reduce the stimulant-like and addictive properties compared to 
mephedrone (Bauer et al., 2013). The monoamine uptake transporter inhibition profile 
of 4-MEC described in the present study is consistent with that recently reported 
(Iversen et al., 2013). No data are available on pentylone.  
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Ethcathinone and 3-FMC are methamphetamine-like cathinones 
Ethcathinone was a weaker SERT inhibitor than its non-β-keto analog N-
ethylamphetamine confirming that cathinones are more potent inhibitors of NET and 
DAT than SERT compared with their non-β-keto amphetamine analogs (Iversen et 
al., 2013; Simmler et al., 2013). Ethcathinone and 3-FMC exhibited similar 
monoamine uptake transporter inhibition profiles to methamphetamine and 
flephedrone (Simmler et al., 2013). In addition, ethcathinone released NA and 5-HT 
but not DA as shown previously in studies using rat synaptosomes (Yu et al., 2000) 
and 3-FMC released all monoamines. Similar release of DA and 5-HT has also been 
documented for flephedrone, the positional isomer of 3-FMC (Simmler et al., 2013).  
Ethcatinone and 3-FMC can be classified as a methamphetamine-like cathinones 
(Simmler et al., 2013) although ethcathinone did not release DA.  
 
Pentedrone and N,N-dimethylcathinone are pure monoamine uptake inhibitors 
similar to the pyrovalerone cathinones 
Pentedrone and N,N-dimethylcathinone are uptake inhibitors only similar to cocaine 
and as previously shown for the pyrovalerone cathinones pyrovalerone, MDPV, and 
naphyrone (Baumann et al., 2013; Cameron et al., 2013; Eshleman et al., 2013; 
Simmler et al., 2013). These pure uptake inhibitors likely do not enter the intracellular 
space of the synapse via the transporter, which may be associated with less 
intracellular pharmacological effects and toxicity compared with the substrate-type 
releasers (Eshleman et al., 2013). All non-releaser compounds including pentedrone 
and N,N-dimethylcathinon and the pyrovalerones pyrovalerone, MDPV, and 
naphyrone (Simmler et al., 2013) are tertiary amines or contain an α-propyl group or 
share both structural characteristics suggesting that these structures may prevent 
uptake by the transporters. Pentedrone and N,N-dimethylcathinone preferentially 
inhibited the catecholamine transporter NET and DAT versus SERT, although with 
lower potency and catecholamine transporter selectivity compared with pyrovalerone 
and MDPV, which are very potent and selective catecholamine inhibitors (Simmler et 
al., 2013). 4- or 3,4-Substitutions at the phenyl ring result in serotonergic selectivity 
as documented by the low DAT/SERT inhibition ratio of MDMA, 4-MTA, PMA, 
PMMA, and methedrone. Similarly, the 4- or 3,4-phenylringsubstituted compounds 
methylethcathinone, pentylone, and naphyrone (Simmler et al., 2013) have some 
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activity at the SERT. None of the cathinone derivatives characterized in the present 
study exhibited the very high potency at the DAT and the high DAT/SERT inhibition 
ratio > 100 previously shown for MDPV (Baumann et al., 2013; Simmler et al., 2013) 
and associated with compulsive use (Watterson et al., 2012). Nevertheless, the 
DAT/SERT inhibition ratios of buphedrone, pentedrone, and N,N-dimethylcathinone 
were all > 10, similar to methamphetamine (Simmler et al., 2013), and possibly 
indicating high abuse potential (Bauer et al., 2013). NET inhibition potency was 
inversely associated with the reported doses of the drugs abused by humans, 
consistent with our previous findings (Simmler et al., 2013). This correlation was not 
found for DAT or SERT inhibition potencies. N,N-dimethylcathinone was not added 
to the correlation because of its low transporter inhibition potency values and the lack 
of data on dosing in humans. The monoamine transporter inhibition potencies of N,N-
dimethylcathinone were at east 10-fold lower than the ones of d-amphetamine or d-
methamphetamine in the present study. We are not aware of other in vitro data. In 
animal tests of stimulus generalization, racemic N,N-dimethylcathinone was 1.5 fold 
less potent than d-amphetamine or d-methamphetamine (Dal Cason et al., 1997). The 
reason for this discrepancy is not clear.   
Buphedrone is a catecholamine selective transporter inhibitor similar to 
pentedrone. Buphedrone did not release DA or 5-HT similar to pentedrone but it 
released NA. Buphedrone therefore has characteristics of both the pyrovalerone-and 
methamphetamine-like cathinones (Simmler et al., 2013).  
 
Binding profiles to monoamine receptors and transporters 
In the present study, we also evaluated binding to the monoamine transporters and to 
a series of other monoaminergic receptors. For the cathinones, submicromolar affinity 
interactions were observed with the monoamine transporters but not with other 
receptors indicating that interactions with monoamine receptors likely do not 
contribute much to the clinical effects of these drugs. We have previously shown that 
cathinones exhibit approximately 10-fold lower affinity for TA1 receptors compared 
to their non-β-keto analogs (Simmler et al., 2013). We have now extended this 
observation by showing that a series of additional cathinones consistently did not 
show relevant TA1 binding affinity in contrast to a series of additional non-β-keto 
amphetamines. Animal studies indicate that non-β-keto amphetamines such as 
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MDMA or methamphetamine inhibit their own neurochemical and locomotor 
stimulant effects via TA1 activation (Di Cara et al., 2011). The lack of this TA1-
mediated “auto-inhibition” in the cathinones may contribute to more stimulant-like 
and addictive properties in this new class of designer drugs compared with the 
traditional amphetamines (Simmler et al., 2013). 
Hallucinogens interact with 5-HT1, 5-HT2A and 5-HT2C receptors (Nichols, 
2004) and several of the drugs tested here showed low-affinity binding to these 
receptors. N-Ethylamphetamine, ethcathinone, and methamphetamine bound to 5-
HT1A receptors as observed for some other compounds from our previous series 
(Simmler et al., 2013). The cathinones 4-MEC and N,N-dimethylcathinone exhibited 
affinity to 5-HT2A receptors similar to the non-β-keto amphetamines MDMA and 4-
MTA, and as previously shown for the cathinones mephedrone, flephedrone, 
naphyrone, and methcathinone (Eshleman et al., 2013; Simmler et al., 2013). The 
cathinones 4-MEC, 3-FMC, and N,N-dimethylcathinone as well as the non-β-keto 
amphetamines 4-MTA and N-ethylamphetamine bound to 5-HT2C receptors. In line 
with our previous study (Simmler et al., 2013) and the work by others (Eshleman et 
al., 2013), no submicromolar binding was observed at the 5-HT1A, 5-HT2A, or 5-HT2C 
receptors for any of the drugs. Further, others showed that several cathinones did not 
act as functional agonists or antagonists at these 5-HT receptors or that their 
functional potencies were very low (Eshleman et al., 2013). Actions at 5-HT receptors 
are therefore more likely to result from drug-induced release of endogenous 5-HT 
rather than from direct interactions of the drugs with these 5-HT receptors as is the 
case with substituted phenethylamine hallucinogens (Nichols, 2004). In contrast, 
submicromolar affinity to the 5-HT2B receptor has been reported for naphyrone and 
mephedrone (Iversen et al., 2013). We did not assess 5-HT2B receptor binding in the 
present study. 5-HT2B receptors have been implicated in drug-associated cardiac valve 
fibroses (Roth, 2007) as well as in the behavioral effects of MDMA (Doly et al., 
2008). Some previously described cathinones but none of the present ones exhibited 
low micromolar affinity for adrenergic α1 receptors. Low-affinity α2 receptors 
binding was observed for most non-β-keto amphetamines and some of the cathinones 
in the present and in our previous study (Simmler et al., 2013). There were no 
relevant interactions with DA D1-3 or histamine H1 receptors.  
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Substrate releasers show higher transporter inhibition potency values compared 
to binding affinity values, resulting in ratios of binding Ki to uptake inhibition IC50 >1 
(Eshleman et al., 2013; Rudnick & Wall, 1992; Simmler et al., 2013). This 
phenomenon was also observed for most but not all monoamine releasers in the 
present study. Additionally, it has previously been noted that binding potencies 
correlate poorly with the inhibition potencies of substrate uptake (Iversen et al., 
2013). We found significant correlations between DAT binding and DAT inhibition 
potencies for both the pure transporter inhibitors and the substrate releasers across the 
14 drugs studied here or across 27 drugs including also the previously characterized 
drugs (Simmler et al., 2013). In contrast, we found no associations between SERT 
binding and SERT inhibition potencies. For the NET, binding and inhibition potencies 
were correlated only for the pure uptake inhibitors, but not for the releasers. These 
findings may indicate that radioligands used in the SERT binding assay and SERT 
inhibitors likely bind to different sites on the SERT (Iversen et al., 2013). In contrast, 
radioligands and pure transporter inhibitors, but not amphetamine-type catecholamine 
releasers, may bind to the same sites at the DAT and the NET.  
The present study has limitations. First, stereoselective effects have been 
described for amphetamines including substituted cathinones (Dal Cason et al., 1997), 
but we used only racemic drugs similar to those recreationally used. Second, we did 
not investigate drug effects on intracellular targets such as the vesicular monoamine 
transporter or monoamine oxidase, which are typically affected by amphetamines 
(Eshleman et al., 2013; Green & El Hait, 1980). Of note, no relevant interactions with 
the vesicular monoamine transporter were observed for a series of first-generation 
cathinones (Eshleman et al., 2013).  
In summary, we described the pharmacology of a series of novel designer 
cathinones. These drugs were all potent inhibitors of NET, but there were marked 
differences in their DAT and SERT inhibition profiles and in their properties to also 
release monoamines.  
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Table 1 Monoamine transporter inhibition
NET DAT SERT DAT/SERT ratio Recreational dose**
IC50 [µM] (95% CI) IC50 [µM] (95% CI) IC50 [µM] (95% CI) Ratio (95% CI) mg
4-MTA* 1.52 (1.3-1.9) 22 (15-32) 0.54 (0.37-0.80) 0.02 (0.01-0.05) 120
PMA* 0.80 (0.50-1.0) 71 (60-83) 2.37 (2.0-2.9) 0.03 (0.02-0.05) 70
PMMA* 1.20 (0.75-1.8) 49 (18-135) 1.77 (1.1-2.9) 0.04 (0.01-0.16) 50
MDMA*, # 0.45 (0.33-0.60) 17 (12-24) 1.36 (1.0-2.0) 0.08 (0.04-0.16) 100
Methedrone 2.24 (1.4-3.5) 35 (15-79) 4.73 (3.2-6.9) 0.14 (0.04-0.46) 200
N-Ethylamphetamine* 0.20 (0.15-0.27) 5.86 (4.8-7.1) 8.77 (6-13) 1.5 (0.9-2.7) 100
4-MEC 2.23 (1.6-3.2) 4.28 (3.4-5.4) 7.93 (3.5-18) 1.85 (0.6-5.3) 100
Pentylone 0.99 (0.72-1.4) 1.34 (1.0-1.7) 8.37 (5.4-13) 6.2 (3.2-13) 125
Ethcathinone 0.44 (0.34-0.56) 5.00 (3.7-6.8) 48 (4-529) 9.6 (0.6-142) 60
Methamphetamine*, # 0.064 (0.04-0.09) 1.05 (0.74-1.5) 23 (14-40) > 10 30
3-FMC 0.19 (0.13-0.29) 1.7 (1.0-3.0) 56 (7-472) >10 100
Buphedrone 0.65 (0.51-0.81) 4.24 (3.3-5.5) 70 (2-2700) > 10 80
Pentedrone 0.61 (0.52-0.72) 2.50 (2.0-3.2) 135 (5-3700) > 10 100
N,N-Dimethylcathinone 7.71 (5-12) 27 (21-36) > 500 > 10 NA
Values are means of three to four independent experiments and 95% confidence intervals (CI). 
Drugs are ranked according to the DAT/SERT ratio = 1/DAT IC50 : 1/SERT IC50.
*non-beta-keto-amphetamine comparator compounds.
**estimated average. 
# values from Simmler et al. 
NA, not available
Table 2. Monoamine transporter and receptor binding affinities 
NET DAT SERT 5-HT1A 5-HT2A 5-HT2C a1A a2A D1 D2 D3 H1 TAAR1rat TAAR1mouse
4-MTA* 1.2±0.6 6.8±1.3 28.0±15 >18 1.5±0.4 1.8±1.0 >6 7.4±1.0 >12.5 >10 >16 >13 0.28±0.04 0.04±0.01
PMA* 15.6±2.1 18.5±3.9 7.1±0.8 >20 11.2±2.1 >13 >6 >25 >12.5 6.4±4.0 >16 >13 0.66±0.01 0.14±0.1
PMMA* 13.7±6.0 24.5±3.9 11.7±1.4 >20 13.6±3.0 >13 >6 >25 >12.5 10.1±1.0 14.0±3.4 >13 1.25±0.2 0.26±0.1
MDMA*, # 30.5±8.0 6.5±2.5 13.3±0.6 12.2±0.8 7.8±2.4 >13 >6 15.0±10 >12.5 25.2±12 >16 >13 0.37±0.12 2.4±1.1
Methedrone 15.6±4.6 20.7±3.4 25.7±14 >20 >13 >13 >6 >25 >12.5 >10 >16 >13 >10 >10
N-Ethylamphetamine* >30 1.0±0.02 26.4±6.1 3.4±0.5 >13 6.0±5.2 >6 2.9±0.3 >12.5 >10 >16 >13 2.5±1.6 >10
4-MEC 6.8±0.5 0.89±0.01 7.7±0.4 >20 3.8±1.6 5.2±0.3 >6 >18 >12.5 >10 >16 >13 >10 >10
Pentylone 9.0±2.4 0.24±0.02 2.0±0.5 >18 >13 >13 >6 >25 >12.5 >10 >16 >13 >10 >10
Ethcathinone 0.22±0.1 0.88±0.1 37.6±9.0 8.5±1.1 >13 >13 >6 15.5±1.9 >12.5 >10 >16 >13 >10 >10
Methamphetamine*, # 4.3±2.1 1.9±0.9 26.7±11 8.1±0.8 >13 >13 >6 6.1±1.6 >12.5 >10 >16 >13 0.35±0.1 0.55±0.2
3-FMC >30 1.9±0.2 36.1±1.4 >18 >13 6.1±2.2 >6 10±2.2 >12.5 >10 >16 >13 >10 5.8±4.0
Buphedrone 4.7±3.6 1.2±0.2 29.2±18.5 >18 >13 >13 >6 23.9±4.2 >12.5 >10 >16 >13 >10 >10
Pentedrone 4.5±1.3 0.34±0.03 17.3±6.1 >18 >13 >13 >6 35.4±16 >12.5 >10 >16 >13 >10 >10
N,N-Dimethylcathinone 23.8±13 4.7±1.1 >30 >18 6.5±0.8 6.5±0.8 >6 25.4±11 >12.5 >10 >16 >13 >10 >10
NA, not assessed
Values are Ki  given as µM (mean ±SD) 
*non-beta-keto-amphetamine comparator compounds.
#values for MDMA are from Simmler et al. 2013
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Figure 1 Monoamine uptake inhibition. Dose-response curves for the inhibition of 
[3H]NA, [3H]DA, and [3H]5-HT into NET-, DAT-, and SERT-transfected HEK 293 
cells, respectively. The data are expressed as means ± SEM of three independent 
experiments. The lines show the data fit by nonlinear regression. IC50 values are 
shown in Table 2.   
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Figure 2 Monoamine release. HEK 293 cells expressing NET, DAT, or SERT were 
loaded with [3H]NA, [3H]DA, or [3H]5-HT, respectively, washed and incubated with 
drugs. Monoamine release is expressed as the maximal release in % of controls at 
high drug concentrations (10 µM or 100 µM). The data are expressed as the mean ± 
SEM of at least three independent experiments. *P<0.05, **P<0.01, and ***P<0.001, 
significant effects compared with controls.  
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Chapter 2: Acute effects of MDMA in humans – mechanistic 
studies 
Chapter 2 focuses on the acute psychostimulant effects in humans, taking the 
empathogen amphetamine-derivative MDMA as model substance. We investigated 
the role of transporter-mediated NE and 5-HT release in the cardio- and 
psychostimulant effects of MDMA in paper 2a and paper 2b. We addressed this 
objective in two randomized placebo-controlled studies with healthy volunteers by 
assessing the interaction between a pure transporter blocker and MDMA. Paper 2b 
also contains in vitro data that describe and confirm the interaction of MDMA with 
the transporter blocker at the isolated targets. Paper 2a, assessing the role of NE 
release alone, and paper 2b, describing the role of the NET/SERT double-blockade, 
are presented here as synergistic pieces of work.  
Paper 2c has its focus on MDMA-induced increases in antidiuretic hormone that 
could result in hyponatremia and ensuing life-threatening complications. This study 
also investigates the role of NE-/5-HT release in MDMA-induced increased 
antidiuretic hormone plasma levels and points toward differences in men and women. 
 
Content of chapter 2: 
Paper 2a: The norepinephrine transporter inhibitor reboxetine reduces 
stimulant effects of MDMA (“Ecstasy”) in humans 
Paper 2b: Duloxetine inhibits effects of MDMA (“Ecstasy”) in vitro and in 
humans in a randomized placebo-controlled laboratory study 
Paper 2c: Sex differences in the effects of MDMA (“Ecstasy”) on plasma 
copeptin in healthy subjects 
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The Norepinephrine Transporter Inhibitor Reboxetine Reduces 
Stimulant Effects of MDMA (“Ecstasy”) in Humans 
 
CM Hysek1, LD Simmler1, M Ineichen1, E Grouzmann2, MC Hoener3, 
R Brenneisen4, J Huwyler5, and ME Liechti1 
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3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) is 
widely used as a recreational drug, but it is also being investi-
gated as an adjunct to psychotherapy in patients with post-trau-
matic stress disorder.1 In humans, MDMA produces euphoria, 
happiness, and cardiovascular activation.2–4 In vitro, MDMA 
induces carrier-mediated release of dopamine (DA), serotonin 
(5-HT), and norepinephrine (NE) through DA (DAT), 5-HT 
(SERT), and NE transporter (NET), respectively.5–9 However, 
it is not clear how these monoamines contribute to the acute 
psychostimulant e!ects of MDMA in humans.8,10
"e role of DA in the reinforcing e!ects of psychostimu-
lants is well established in animal models. However, deletions 
of dopamine D1, D2, and D3 receptor genes in mice had mini-
mal e!ects on MDMA-induced acute changes in locomotor 
behavior,11 and DAT inhibition did not a!ect acute responses 
to MDMA in rhesus monkeys.12 In humans, DA D2 recep-
tor antagonists reduced amphetamine-induced and MDMA-
induced euphoria only at doses that produced dysphoria.13–15 
"erefore, non-DA systems may be principally responsible for 
the acute e!ects of MDMA.
SERT inhibitors (SSRIs) decrease MDMA-induced 5-HT 
release in vitro7 and in animals16 and also attenuate behavioral 
e!ects of MDMA in animals.17 Consistent with this preclinical 
evidence for a role of SERT, SSRIs reduced the subjective and 
cardiovascular response to MDMA in humans,18–21 indicating 
that MDMA-induced, SERT-mediated 5-HT release critically 
contributes to the psychotropic and physical e!ects of MDMA 
in humans. However, the blood pressure response to MDMA 
is only partly attenuated by blockade of 5-HT release18 and is 
largely una!ected by postsynaptic 5-HT1 or 5-HT2 receptor 
antagonist pretreatment.22,23
"e role of the NET in the mechanism of action of MDMA 
in humans has not yet been explored. As compared to SERT 
and DAT, MDMA exhibits higher a#nity for human NET.5,6 
MDMA releases NE more potently than 5-HT or DA from 
monoamine-preloaded human embryonic kidney (HEK) cells 
transfected with the corresponding human monoamine trans-
porter.6 "e NET inhibitor desipramine and the SERT inhibitor 
citalopram, but not the DAT/NET inhibitor methylphenidate, 
reversed the acute cognitive e!ects of MDMA in rhesus mon-
keys.12 NE also plays a role in mediating the peripheral e!ects 
of MDMA. MDMA increases the levels of circulating NE in 
rats.24 "e adrenergic A1 receptor antagonist prazosin reversed 
MDMA-associated locomotor stimulation25 and vascular 
e!ects26 in rats. "e NET inhibitor nisoxetine abolished contrac-
tion of the rat aorta produced by 4-methylthioampethamine,27 
a compound with a pharmacology similar to that of MDMA. 
Clinically, MDMA increases plasma NE levels4 and stimulates 
1Psychopharmacology Research Group, Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Internal Medicine, 
University Hospital and University of Basel, Basel, Switzerland; 2Division of Clinical Pharmacology and Toxicology, University Hospital, Lausanne, Switzerland; 
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Switzerland; 5Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. Correspondence: ME Liechti (mliechti@uhbs.ch)
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The Norepinephrine Transporter Inhibitor 
Reboxetine Reduces Stimulant Effects of MDMA 
(“Ecstasy”) in Humans
CM Hysek1, LD Simmler1, M Ineichen1, E Grouzmann2, MC Hoener3, R Brenneisen4, J Huwyler5  
and ME Liechti1
This study assessed the pharmacodynamic and pharmacokinetic effects of the interaction between the selective 
norepinephrine (NE) transporter inhibitor reboxetine and 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) in 
16 healthy subjects. The study used a double-blind, placebo-controlled crossover design. Reboxetine reduced the effects 
of MDMA including elevations in plasma levels of NE, increases in blood pressure and heart rate, subjective drug high, 
stimulation, and emotional excitation. These effects were evident despite an increase in the concentrations of MDMA 
and its active metabolite 3,4-methylenedioxyamphetamine (MDA) in plasma. The results demonstrate that transporter-
mediated NE release has a critical role in the cardiovascular and stimulant-like effects of MDMA in humans.
See COMMENTARY page 215
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the sympathetic nervous system, as evidenced by increases in 
heart rate, blood pressure, pupil size, and body temperature.18 
Serious adverse e!ects of uncontrolled ecstasy use also include 
hypertensive and hyperthermic reactions that are likely to be 
mediated by an activation of the adrenergic system by MDMA.28 
"e importance of NE in the mechanism of action of amphet-
amine-type stimulants in general is further supported by the 
observation that the subjective e!ects of these stimulants in 
humans correlate with their potency to release NE and not with 
their e!ect on DA.8 Further support for a role of the NET in the 
e!ects of psychostimulants derives from the clinical #ndings 
that the NET inhibitor atomoxetine attenuated cocaine-induced 
systolic blood pressure increases29 and cardiovascular and sub-
jective responses to d-amphetamine in humans.30 Together, the 
preclinical and clinical #ndings suggest that NE may contribute 
critically to the psychotropic and, even more importantly, the 
Table 1 Mean ± SEM values and statistics of drug effects
Placebo–placebo 
(mean p SEM)
Reboxetine–
placebo  
(mean p SEM)
Placebo–MDMA 
(mean p SEM)
Reboxetine–
MDMA  
(mean p SEM) F(3,45) = P <
Circulating catecholamines
 Epinephrine (nmol/l) At 1 h 0.11 p 0.02 0.08 p 0.02 0.35 p 0.08* 0.21 p 0.03 6.70 0.001
 Norepinephrine (nmol/l) At 1 h 1.29 p 0.16 1.18 p 0.15 2.05 p 0.20** 1.31 p 0.13†† 12.40 0.001
Physiologic effects
 SBP (mm Hg) Emax 11.1 p 2.1 8.5 p 1.5 38.7 p 2.6*** 20.7 p 2.6*,††† 33.50 0.001
 DBP (mm Hg) Emax 8.6 p 1.5 5.2 p 1.0 20.8 p 1.7*** 15.8 p 1.9* 17.40 0.001
 MAP (mm Hg) Emax 8.0 p 1.4 5.1 p 1.0 25.8 p 1.9*** 16.2 p 1.9**,†† 30.80 0.001
 Heart rate (beats/min) Emax 11.3 p 1.9 12.3 p 2.4 31.7 p 3.1*** 23.4 p 3.0**,† 17.90 0.001
 Body temperature (°C) Emax 0.41 p 0.06 0.46 p 0.07 0.74 p 0.10* 0.51 p 0.09 3.40 0.05
Visual analog scales (VAS, %max)
 Any drug effect Emax 1.9 p 1.3 8.0 p 3.4 85.4 p 4.8*** 67.7 p 6.2***,†† 120.40 0.001
 Drug high Emax 4.9 p 3.7 9.3 p 4.6 86.31 p 4.0*** 65.3 p 8.1***,† 61.10 0.001
 Stimulated Emax 2.6 p 2.6 3.4 p 2.5 71.9 p 8.0*** 51.1 p 9.4***,† 34.00 0.001
 Closeness Emax 0.25 p 0.19 0.00 p 0.00 33.9 p 5.9*** 20.8 p 4.5***,† 22.70 0.001
 Good drug effect Emax 0.06 p 0.06 6.3 p 3.4 85.6 p 4.1*** 72.6 p 7.2*** 114.60 0.001
 Liking Emax 3.1 p 3.1 15.6 p 7.0 86.6 p 4.7*** 77.9 p 5.1** 75.60 0.001
Adjective Mood Rating Scale (AMRS score)
 Activity Emax 1.56 p 0.52 1.38 p 0.45 3.81 p 0.98* 4.19 p 1.02** 4.80 0.05
 Inactivation Emax 1.88 p 0.82 3.56 p 1.03 8.19 p 2.06 6.50 p 1.73 4.80 0.05
 Extroversion Emax 1.06 p 0.31 1.25 p 0.57 4.00 p 078* 4.13 p 0.83** 10.10 0.001
 Introversion Emin −0.44 p 0.20 −1.06 p 0.35 −3.00 p 0.82*** −1.19 p 0.39†† 6.20 0.001
 Well-being Emax 1.75 p 0.37 2.56 p 0.83 6.50 p 1.28** 6.25 p 1.46* 16.60 0.001
 Emotional excitation Emax 0.44 p 0.27 1.53 p 0.69 7.50 p 1.20*** 3.94 p 1.14*,† 14.20 0.001
 Anxiety-depression Emax 0.31 p 0.18 1.25 p 0.50 2.25 p 0.71 1.38 p 0.62 2.90 0.05
 Dreaminess Emax 0.69 p 0.25 1.63 p 0.46 4.00 p 0.74*** 3.19 p 0.68** 7.30 0.001
State-Trait Anxiety Inventory Emax 1.44 p 0.58 2.19 p 0.98 10.19 p 2.36** 3.81 p 1.06† 9.40 0.001
List of complaints (total score)
 Acute adverse effects At 3 h −1.00 p 0.53 −0.19 p 1.30 10.13 p 1.90*** 1.94 p 2.80† 7.73 0.001
 Subacute adverse effects At 24 h −1.19 p 0.63 0.06 p 0.92 5.38 p 1.47** 0.44 p 1.33† 5.95 0.01
Ex vivo binding (Ki,%)
 NET 24.00 p 1.28 9.09 p 1.66*** 22.17 p 1.66 7.16 p 0.83***,††† 48.02 0.001
 SERT >25 >25 >25 >25
 DAT >25 >25 >25 >25
Values are mean p SEM of changes from baseline of 16 subjects.
DAT, dopamine transporter; DBP, diastolic blood pressure; Emax, peak effects; Emin, minimum effects; Ki, inhibition constant calculated as % of plasma sample dilution with 
undiluted plasma set as 100%; MAP, mean arterial pressure; MDMA, 3,4-methylenedioxymethamphetamine; NET, norepinephrine transporter; SBP, systolic blood pressure; SERT, 
serotonin transporter.
*P < 0.05, **P < 0.01, ***P < 0.001 compared to placebo–placebo. †P < 0.05, ††P < 0.01, †††P < 0.001 compared to placebo–MDMA.
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cardiovascular e!ects of MDMA in humans. "is study evalu-
ated pharmacokinetic and pharmacodynamic e!ects of the 
interaction between the selective NET inhibitor reboxetine and 
MDMA in healthy subjects. We hypothesized that pretreatment 
with reboxetine would attenuate the subjective, neuroendocrine, 
cardiovascular, and adverse e!ects of MDMA to the extent that 
they depend on NET-mediated release of NE.
Pharmacokinetic interactions were evaluated to con#rm that 
the e!ects of reboxetine on the MDMA response could not be 
explained by the exposure to MDMA or its active metabolites 
being too low. MDMA is n-demethylated to the active, but minor, 
metabolite 3,4-methylenedioxyamphetamine (MDA) by cyto-
chrome P450 (CYP) 2B6 and 3A4. "e major pathway of MDMA 
degradation includes CYP2D6-mediated O-demethylation to 
3,4-dyhydroxymethamphetamine (HHMA), followed by cate-
chol-O-methyltransferase-catalyzed methylation to 4-hydroxy-
3-methoxymethamphetamine (HMMA).31
RESULTS
Pharmacodynamics
MDMA increased the levels of both circulating NE and epine-
phrine relative to placebo. Reboxetine prevented the MDMA-
induced increase in NE, an endocrine correlate of sympathetic 
activation (Table 1). It also reduced the cardiovascular and psy-
chostimulant e!ects of MDMA. Reboxetine decreased MDMA-
induced elevations in blood pressure and heart rate (Figure 1 and 
Table 1) and attenuated MDMA-induced visual analog scale (VAS) 
score increases in “any drug e!ect,” “drug high,” “stimulated,” and 
“closeness to others” (Figure 2 and Table 1). In contrast, reboxetine 
did not a!ect MDMA-induced VAS score changes with regard to 
“good drug e!ect” and “drug liking” (Figure 2 and Table 1). On 
the 5-Dimensions of Altered States of Consciousness (5D-ASC) 
Rating Scale, analysis of variance showed signi#cant main e!ects 
of the drug in the sum score and in all the dimensions of the scale 
(F(3,45) = 32.8, 32.9, 8.5, and 17.8 for ASC, oceanic boundlessness 
(OB), anxious ego dissolution (AED), and visionary restructurali-
zation (VR), respectively; all P < 0.001). MDMA robustly increased 
scores in the OB, AED, and VR dimensions relative to placebo (all 
P < 0.001) (Figure 3). Reboxetine reduced MDMA’s e!ect on the 
total ASC score (P < 0.01) in the OB dimension (P < 0.01) and in 
the VR dimension (P < 0.05), including signi#cant reductions in 
OB item clusters for “experience of unity” (P < 0.01) and “blissful 
state” (P < 0.1). With respect to the Adjective Mood Rating Scale 
(AMRS) scale, reboxetine prevented MDMA-induced increase in 
emotional excitation and decrease in introversion (Figure 4 and 
Table 1). MDMA increased a sense of well-being, extroversion, 
and dreaminess and produced inactivation at 1.25 h and activation 
at 2 h, which resulted in peak increases in both activity and inacti-
vation relative to placebo. Reboxetine had no e!ect on these sub-
jective e!ects associated with MDMA. Finally, reboxetine reduced 
MDMA-induced elevations in State-Trait Anxiety Inventory 
(STAI) anxiety scores (Figure 4 and Table 1).
Adverse effects
MDMA increased the total list of complaints adverse e!ects 
score at 3 h and again at 24 h a$er administration, relative to 
placebo (Table 1). "e most frequently reported adverse e!ects 
of placebo–MDMA and reboxetine–MDMA included lack of 
appetite (n = 12 and n = 8, respectively), di%culty in concentrat-
ing (n = 12 and n = 12, respectively), tremor (n = 9 and n = 3, 
respectively), restlessness (n = 8 and n = 4, respectively), and 
dizziness (n = 6 and n = 4, respectively). Reboxetine decreased 
the number of MDMA-induced adverse e!ects (Table 1).
Pharmacokinetics
"e decrease in the pharmacodynamic response to MDMA 
a$er reboxetine pretreatment is not attributable to a phar-
macokinetic interaction between reboxetine and MDMA 
because reboxetine was shown to increase exposure to 
MDMA. Reboxetine increased the maximum concentration 
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Figure 1 Physiologic effects. Values are mean ± SEM of changes from 
baseline in 16 subjects. Reboxetine was administered at t = −12 h and at 
t = −1 h. 3,4-Methylenedioxymethamphetamine (MDMA) was administered at 
t = 0 h. Reboxetine pretreatment reduced MDMA-induced elevations in blood 
pressure and heart rate.
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(Cmax) of MDMA by 19 p 6% (F(1,15) = 9.23; P < 0.01) and the 
area under the plasma concentration–time curve (AUC)0–24 h 
by 9 p 4% (F(1,15) = 5.53; P < 0.05) (Figure 5a and Table 2). 
Reboxetine also increased AUC0–24 h and AUC0–∞ values 
of MDA by 50 p 13% (F(1,15) = 15.98; P < 0.001) and 66 p 
16% (F(1,15) = 19.03; P < 0.001), respectively (Figure 5b and 
Table 2). Conversely, MDMA increased the Cmax of reboxetine 
by 16 p 6% (F(1,15) = 5.97; P < 0.05) (Figure 5c and Table 2). 
!e pharmacokinetic parameters of MDMA were not depen-
dent on CYP2D6 phenotype.
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Pharmacokinetic–pharmacodynamic relationship
Figure 5d,e shows MDMA’s e!ects in terms of the plasma con-
centration. MDMA-induced changes in (Figure 5d) mean arte-
rial pressure (MAP) and (Figures 5e) “any drug e!ect” returned 
to baseline within 8 h and 6 h, respectively, when MDMA con-
centrations were still high (clockwise hysteresis). Reboxetine 
pretreatment attenuated both physical and subjective responses 
to MDMA (Figure 5d,e).
Ex vivo binding studies
Plasma from subjects treated with reboxetine–placebo or rebox-
etine–MDMA inhibited ex vivo radioligand binding to NET but 
not to SERT or DAT (Table 1).
DISCUSSION
In this study, pretreatment with the selective NET inhibitor 
reboxetine prevented MDMA-induced increase in circulating 
levels of NE, which is a marker of sympathetic system activa-
tion, and signi"cantly reduced the cardiovascular response to 
MDMA. Reboxetine also attenuated some, but not all, of the 
psychotropic e!ects of MDMA and reduced MDMA-induced 
drug high, stimulation, emotional excitation, and anxiety, as 
well as the blissful state and experience of unity elicited by 
MDMA. Reboxetine also ameliorated some of the adverse 
e!ects of MDMA such as tremor and restlessness. Overall, 
blockade of NET resulted in a pronounced decrease in the car-
diovascular stimulant e!ects of MDMA and a moderate attenu-
ation of its psychostimulant properties. In contrast, good drug 
e!ects and the sense of well-being associated with MDMA 
were not signi"cantly altered by reboxetine pretreatment. #e 
"ndings are consistent with a role for NET in the mediation 
of the sympathomimetic stimulant-like aspects of the MDMA 
e!ect.
#e pharmacodynamic interaction observed in this study can-
not be explained on the basis of a pharmacokinetic interaction 
between reboxetine and MDMA because reboxetine decreased 
the pharmacodynamic e!ects of MDMA even while it increased 
the Cmax of MDMA by 20% and the AUC0–24 h of MDMA and 
its active metabolite MDA by 10% and 50%, respectively. #e 
potent CYP2D6 inhibitor paroxetine has previously been shown 
to increase the Cmax and AUC0–27 h of MDMA by 20% and 30%, 
respectively, and of MDA by 20% and 20%, respectively31 (simi-
lar to the e!ect of reboxetine in our study), whereas it decreased 
MDMA metabolism to HHMA and HMMA.31 #e e!ects of 
paroxetine and reboxetine on MDMA metabolism can there-
fore be explained by CYP2D6 inhibition32 and a shi$ of the 
metabolism from the major pathway (by reducing HHMA and 
HMMA formation) to a minor pathway (including an increase 
in MDA formation). However, we did not measure HHMA 
and HMMA levels in plasma, and this may be a limitation with 
respect to the conclusion regarding pathways. Furthermore, 
MDMA is itself a mechanism-based inhibitor of CYP2D6, and 
its pharmacokinetics is nonlinear.33,34 In this study, we used an 
ex vivo binding assay to investigate whether the plasma sam-
ples taken from the subjects exhibited NET-binding properties. 
We con"rmed that plasma from reboxetine-treated subjects 
displaced 3H-nisoxetine from NET and that there was a trend 
toward this e!ect with regard to plasma from MDMA-treated 
subjects. Although both reboxetine and MDMA bind to NET in 
vitro and inhibit NE uptake,6,35 MDMA is also a NET substrate 
and releases NE.6 #e pharmacodynamic interaction between 
reboxetine and MDMA observed in this study is consistent with 
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inhibition of the MDMA-induced NET-mediated NE release by 
reboxetine.
!e role for NET in the mechanism of action of MDMA, as 
suggested by the results of this study, is in line with both pre-
clinical and clinical data from other studies, as outlined in the 
introduction. As compared to SERT and DAT, MDMA shows 
higher a"nity to NET in vitro5,6 and releases NE more potently 
than 5-HT or DA.6,8 In humans, NET inhibition reduced 
cardiostimulant responses to cocaine29 and both cardiostimulant 
and psychostimulant responses to d-amphetamine,30 similar to 
the $ndings in our study with MDMA.
!e SERT inhibitor citalopram has been shown to reduce the 
cardiovascular and subjective e%ects of MDMA in humans.18,19 
Citalopram reduced MDMA-induced increases in systolic blood 
pressure and emotional excitation by <50% and positive mood 
effects by >50%. In contrast, reboxetine reduced MDMA-
Table 2 Pharmacokinetic parameters of MDMA, MDA, and reboxetine
Cmax (ng/ml) Tmax (h) T1/2 (h) AUC0–24 h (ng/ml·h) AUC0–d (ng/ml·h)
MDMA
 Placebo–MDMA 298.0 p 12.3 2.6 p 0.2 9.6 p 0.8 3,357.1 p 159.0 4,127.2 p 229.2
 Reboxetine–MDMA 351.0 p 19.0** 2.8 p 0.4 7.0 p 0.3 3,629.1 p 167.5* 4,106.2 p 215.8
MDA
 Placebo–MDA 19.0 p 2.1 4.7 p 0.6 16.1 p 1.8 227.4 p 19.0 358.6 p 25.0
 Reboxetine–MDA 23.0 p 2.7 7.0 p 0.6 17.3 p 1.9 327.7 p 24.0** 572.2 p 48.9***
Reboxetine
 Reboxetine–placebo 371.7 p 33.9 3.3 p 0.4 13.7 p 0.7 5,704.4p599.6 8,292.5 p 1,042.2
 Reboxetine–MDMA 416.9 p 31.1† 3.6 p 0.5 13.2 p 0.9 6,176.2 p 553.2 9,103.4 p 1,099.9
Values are mean p SEM of 16 healthy subjects.
AUC, area under the plasma concentration–time curve; Cmax, maximum plasma concentration; MDA, 3,4-methylenedioxyamphetamine; MDMA, 
3,4-methylenedioxymethamphetamine; T1/2, terminal elimination half-life; Tmax, time to maximum plasma concentration.
*P < 0.05, **P < 0.01, ***P < 0.001 compared to placebo–MDMA. †P < 0.05 compared to reboxetine–placebo.
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induced increases in systolic blood pressure and emotional 
excitation by >50% and positive mood e!ects by <50%. "e 
two studies indicate that SERT-mediated 5-HT release is more 
important than NET-mediated NE release for MDMA-typical 
positive mood e!ects, whereas NET-mediated NE release pri-
marily mediates the more stimulant-typical emotional excitation 
and cardiovascular response to MDMA. "e e!ect of reboxetine 
on subjective responses to MDMA is similar to changes in the 
subjective e!ects of d-amphetamine a$er pretreatment with the 
NET inhibitor atomoxetine.30 As in our study, NET inhibition 
reduced amphetamine-induced increases in subjective ratings 
of “stimulated” and “high” but not in “drug liking,”30 thereby 
reinforcing the view that NET contributes mainly to the psy-
chostimulant aspect of amphetamines.36
DA is commonly thought to mediate the reinforcing and 
rewarding e!ects of drugs of abuse. For example, the DAT/NET 
inhibitor methylphenidate has been shown to reduce intrave-
nous amphetamine use in amphetamine-dependent patients.37 
"e role of DA in the mediation of the acute subjective e!ects of 
amphetamine-type stimulants in humans is less clear. "e DAT/
NET inhibitor bupropion was shown to attenuate subjective 
responses to methamphetamine.38 However, the e!ect of DAT 
inhibition on the acute response to MDMA has not been studied 
in humans. We have previously shown that the DA D2 antago-
nist haloperidol reduces the positive mood elicited by MDMA 
and that haloperidol depresses mood also when given alone, as 
compared to the e!ect of placebo.15 Similarly, DA D2 receptor 
blockade did not a!ect subjective responses to d-amphetamine, 
according to the results of most studies.13,14 Accordingly, DA may 
primarily mediate the reinforcing properties of psychostimulants 
but might not be the primary mediator of their acute e!ects.8
"e exact mechanism by which monoamine transport inhibi-
tors interact with MDMA-induced monoamine release is not 
known. "e SERT, DAT, and NET inhibitor indatraline blocks 
MDMA-induced transmitter release according to simple com-
petitive models.7 Other inhibitors alter the e%ciency of the 
MDMA-induced transmitter release in a noncompetitive man-
ner, possibly by inducing conformational changes in the trans-
porter protein.7 A channel-like conformation of DAT, resulting 
in rapid DA e&ux, has also been described for amphetamine-
induced DA release.39
The present study adds to a better understanding of the 
mechanism of action of MDMA. Our 'nding that reboxetine 
reduces the subjective e!ects of MDMA (stimulant and drug 
high) is similar to the 'nding from another study that atom-
oxetine attenuates the subjective e!ects of d-amphetamine.30 
Taken together, these 'ndings indicate that NET inhibitors may 
potentially be useful as treatments for stimulant addiction.36,40 
However, further clinical studies are needed to explore the thera-
peutic potential of NET inhibitors in stimulant dependence.
In summary, we showed that NE plays a critical role in the 
acute physiologic and subjective e!ects of MDMA in humans.
METHODS
Study design. We used a double-blind, placebo-controlled, randomized, 
crossover design with four experimental conditions (placebo–placebo, 
reboxetine–placebo, placebo–MDMA, and reboxetine–MDMA). The 
order of the four test sessions was counterbalanced. Washout periods 
between sessions were 10–14 days long. The study was conducted in 
accordance with the Declaration of Helsinki and the International 
Conference on Harmonisation Guidelines on Good Clinical Practice 
and was approved by the Ethics Committee of the Canton of Basel, 
Switzerland. The use of MDMA in healthy subjects was authorized by 
the Swiss Federal Office of Public Health, Bern, Switzerland. The study 
was registered at ClinicalTrials.gov (NCT00886886).
Study outline. Subjects completed a screening session, four test sessions 
with a next-day follow-up, and an end-of-study visit. Test sessions took 
place in a quiet hospital research ward with no more than two research 
subjects present per session. Prior to admission to the test sessions, the 
subjects were asked about potential health problems; drug tests and urine 
tests for pregnancy were also performed. An indwelling intravenous cath-
eter was placed in the antecubital vein for blood sampling. Reboxetine 
(8 mg orally) or placebo was administered at 20:00 h the day before the 
test session and again at 7:00 h a$er a light meal on the day of the test. 
MDMA (125 mg orally) or placebo was administered at 8:00 h, 1 and 
12 h a$er reboxetine. A standardized lunch was served at 12:00 h, and 
subjects were sent home at 18:00 h. On the day following each test session, 
the subjects returned to the research ward at 8:00 h for the assessment of 
adverse e!ects and blood sampling. During the test sessions, the subjects 
did not drink beverages containing ca!eine or alcohol. "ey were read-
ing, listening to music, or walking around in the research ward. For most 
of the time, they were sitting or lying comfortably. Outcome measures 
were assessed repeatedly before and a$er drug administration.
Subjects. Sixteen healthy subjects (eight men and eight women), 20–44 
years of age (mean p SD: 25.7 p 5.5 years), were recruited on the uni-
versity campus by word of mouth. Exclusion criteria included: age <18 
or >45 years, pregnancy (urine pregnancy test before each test session), 
abnormal body mass index (<18.5 or >25 kg/m2), personal or family 
('rst-degree relative) history of psychiatric disorder (as assessed by the 
structured clinical interview for axis I and II disorders according to the 
Diagnostic and Statistical Manual of Mental Disorders, fourth edition 
(DSM-IV),41 supplemented by psychometric instruments),42 regular use 
of medications, chronic or acute physical illness (as assessed by physical 
examination, electrocardiogram, standard hematological, and chemical 
blood analyses), smoking (more than 10 cigarettes/day), lifetime history 
of illicit drug use more than 've times (except for tetrahydrocannabi-
nol), illicit drug use within the past 2 months, and illicit drug use during 
the study (urine tests for drug use before test sessions using TRIAGE 8, 
Biosite, San Diego, CA). "e subjects were asked to abstain from exces-
sive alcohol consumption between test sessions and, in particular, to limit 
alcohol use to one glass on the day before each test session. "ree subjects 
were light smokers (fewer than 10 cigarettes/day). "ey maintained their 
usual smoking habit but were not allowed to smoke for 6 h a$er MDMA/
placebo administration. Eleven subjects had previously used cannabis. 
Six subjects had illicit drug experiences (one to four times): one subject 
had tried cocaine, one had tried ecstasy, two had tried psilocybin, one 
had tried psilocybin and ecstasy, and one had tried ecstasy, psilocybin, 
and cocaine. "e three subjects with ecstasy experience had all used the 
drug only once. All the subjects were phenotyped for CYP2D6 activity, 
using dextrometorphan as the probe drug. "ere were 10 extensive, 4 
intermediate, and 2 poor CYP2D6 metabolizers in the study. All subjects 
gave their written informed consent before participating in the study, and 
they were paid for their participation.
Study drugs. (p) MDMA hydrochloride (Lipomed AG, Arlesheim, 
Switzerland) was obtained from the Swiss Federal Office of Public 
Health and prepared as gelatin capsules (100 mg and 25 mg) by Bichsel 
Laboratories AG, Interlaken, Switzerland, in accordance with good 
manufacturing practice. Identical placebo (lactose) capsules were pre-
pared. MDMA was administered in a single absolute dose of 125 mg, 
corresponding to a dose of 1.85 p 0.24 mg/kg body weight. "is dose 
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of MDMA corresponds to a typical recreational dose of ecstasy, and 
comparable doses of MDMA have previously been used in controlled 
settings.2–4,43 Reboxetine is a potent, selective, and speci!c NE uptake 
inhibitor.35 Reboxetine (8 mg, Edronax; P!zer, Zurich, Switzerland) and 
identical-looking placebo (lactose) capsules were similarly prepared by 
Bichsel Laboratories. Reboxetine (8 mg) or placebo was administered 
twice, 12 h and 1 h before MDMA (125 mg) or placebo. Similar dosing 
regimens have previously been used to manipulate the NE system func-
tion in healthy subjects.44
Pharmacodynamics
Psychometric scales: Subjective measures included VAS,21 the AMRS,45 
the 5D-ASC,46 and the STAI.42
VAS: VASs included “any drug e"ect,” “drug high,” “stimulated,” “close-
ness to others,” “good drug e"ect,” and “liking.”3,20,21 VASs were pre-
sented as 100-mm horizontal lines marked “not at all” on the le# and 
“extremely” on the right. $e VAS for “closeness to others” was bidirec-
tional (p 50 mm). VAS tests were administered 1 h before and at 0, 0.33, 
1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 h a#er MDMA/placebo administration.
5D-ASC: $e 5D-ASC rating scale measures alterations in mood, 
perception, experience of self in relation to environment, and thought 
disorder. $e instrument comprises !ve subscales (dimensions)46 and 
eleven lower-order scales47: $e 5D-ASC dimension OB (27 items) 
measures derealization and depersonalization associated with positive 
emotional states ranging from heightened mood to euphoric exaltation. 
$e corresponding lower-order scales are “experience of unity,” “spiritual 
experience,” “blissful state,” and “insightfulness.” $e dimension AED 
(21 items) summarizes ego disintegration and loss of self-control, phe-
nomena associated with anxiety. $e corresponding lower-order scales 
are “disembodiment,” “impaired control of cognition,” and “anxiety.” $e 
dimension “VR (18 items) consists of the lower-order scales “complex 
imagery,” “elementary imagery,” “audiovisual synesthesia,” and “changed 
meaning of percepts.” Two other dimensions of the scale were not used in 
our study. $e global ASC score was constructed by adding the OB, AED, 
and VR scores. $e 5D-ASC scale was administered 4 h a#er administra-
tion of MDMA or placebo.
AMRS: $e 60-item Likert-scale short version of the AMRS45 was 
administered 1 h before and at 1.25, 2, 3, and 24 h a#er MDMA or pla-
cebo. $e AMRS contains subscales for activity, inactivation, extroversion 
and introversion, well-being, emotional excitation, anxiety–depression, 
and dreaminess.
STAI: $e STAI state-anxiety scale42 test was administered 1 h before 
and at 1.25, 2, and 3 h a#er MDMA or placebo.
Physiologic measures. Physiologic measures were assessed repeatedly, at 
−1, 0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, and 10 h a#er administration 
of MDMA or placebo. Heart rate, systolic blood pressure, and diastolic 
blood pressure were measured using an OMRON M7 blood pressure 
monitor (OMRON Healthcare Europe, Hoofddorp, $e Netherlands) in 
the dominant arm a#er a resting time of 5–10 min, with the volunteer sit-
ting in bed with the back supported. Measures were taken twice per time 
point with an interval of 1 min, and the average was used for analysis. 
Between measurements, subjects were allowed to engage in nonstrenuous 
activities. Core (tympanic) temperature was assessed using a GENIUS 
2 ear thermometer (Tyco Healthcare Group, Watertown, NY). $e tem-
perature of the room was maintained at 22.5 p 0.5 °C.
Adverse effects. Adverse e"ects were assessed at 0, 3, and 24 h a#er 
administration of MDMA or placebo by using the List of Complaints.2,48 
$e scale consists of 66 items, yielding a total adverse e"ects score (non-
weighted sum of the item answers), reliably measuring physical and gen-
eral discomfort. $e scale has previously been shown to be sensitive to 
the adverse e"ects of MDMA.2,22
Blood collection for endocrine and pharmacokinetic measurements. 
Samples of whole blood for the determination of MDMA, MDA, and 
reboxetine levels were collected into lithium heparin monovettes at −1, 
0, 0.33, 0.66, 1, 1.5, 2,3.5, 3, 3.5, 4, 6, 8, 10, and 24 h a#er administration 
of MDMA or placebo. Blood samples to determine concentrations of NE 
and epinephrine were taken 60 min a#er administration of MDMA or 
placebo. All blood samples were collected on ice and centrifuged within 
10 min at 4 ºC. Plasma was then stored at −70 ºC until analysis.
Laboratory analyses
Catecholamines: $e levels of free catecholamines (NE and epinephrine) 
were determined using a modi!ed method of the RECIPE kit (ClinRep; 
RECIPE Chemicals and Instruments, Munich, Germany) (see Sup-
plementary Methods online). $e lower limit of quanti!cation was 
20 pmol/l, and interassay precisions (coe&cient of variation (CV)) were 
<15%.
MDMA and MDA: Plasma concentrations of MDMA and its active 
metabolite, 3,4-methylenedioxyamphetamine (MDA), were determined 
using high-performance liquid chromatography with diode-array detec-
tion49 (see Supplementary Methods online). $e limit of quanti!cation 
was 5 ng/ml for MDMA and 2 ng/ml for MDA. Interday precision values 
(CV) were 7 and 4%, and interday accuracy values were 96–106% and 
100–103% for MDMA and MDA, respectively.
Reboxetine: Plasma reboxetine concentrations were analyzed using liq-
uid chromatography–mass spectrometry (see Supplementary Methods 
online). $e limit of quanti!cation was 34.5 ng/ml. Interday precision 
(CV) values were 5.7 and 3.2%, and interday accuracy values were 98.5 
and 101.8%, at 92 ng/ml and at 344 ng/ml, respectively.
Ex vivo binding: Plasma samples for investigating ex vivo binding were 
collected 60 min a#er administration of MDMA or placebo. We deter-
mined the potencies of plasma to inhibit 3H-nisoxetine, 3H-citalopram, 
and 3H-WIN35, 428 binding to NET, SERT, and DAT, respectively (see 
Supplementary Methods online). Ki values were calculated as percent-
ages of plasma sample dilutions required for obtaining 50% of maximum 
e"ect (10 µmol/l indatraline in human plasma was used to achieve 100% 
inhibition). Undiluted plasma samples were set as 100%. $erefore, a Ki 
of 10% indicates that a plasma sample diluted 10-fold displaced 50% of 
the radioligand.
Pharmacokinetics. Data for plasma concentrations of MDMA, MDA, 
and reboxetine were analyzed using noncompartmental methods 
(WinNonlin; Pharsight, Mountain View, CA). Cmax and time to maxi-
mum concentration (Tmax) were obtained directly from the concen-
tration–time curves of observed values. $e terminal elimination rate 
constant (Lz) was estimated by log-linear regression a#er semilogarithmic 
transformation of the data, using at least three data points of the termi-
nal linear phase of the concentration–time curve. Terminal elimination 
half-life (t1/2) was calculated using Lz and the equation t1/2 = ln2/Lz. $e 
AUC0–24 h was calculated using the linear trapezoidal rule. $e AUC0–d 
was determined by extrapolation of the AUC0–24 h, using Lz.
Statistical analysis. Values were transformed to di"erences from base-
line. Peak e"ects (Emax) were determined for repeated measures. Emax 
values were compared by one-way General Linear Models repeated meas-
ures analysis of variance with drug as a factor, using STATISTICA 6.0 
(StatSo#, Tulsa, OK). Tukey post hoc comparisons were performed based 
on signi!cant main e"ects of treatment. Additional analyses of variance 
were performed with drug order as an additional factor so as to exclude 
carryover e"ects. $e criterion for signi!cance was P < 0.05. MAP was 
calculated from diastolic blood pressure and systolic blood pressure using 
the formula MAP = DBP + (SBP−DBP)/3.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at 
http://www.nature.com/cpt
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Abstract
This study assessed the effects of the serotonin (5-HT) and norepinephrine (NE) transporter inhibitor duloxetine on the
effects of 3,4–methylenedioxy-methamphetamine (MDMA, ecstasy) in vitro and in 16 healthy subjects. The clinical study
used a double-blind, randomized, placebo-controlled, four-session, crossover design. In vitro, duloxetine blocked the release
of both 5-HT and NE by MDMA or by its metabolite 3,4-methylenedioxyamphetamine from transmitter-loaded human cells
expressing the 5-HT or NE transporter. In humans, duloxetine inhibited the effects of MDMA including elevations in
circulating NE, increases in blood pressure and heart rate, and the subjective drug effects. Duloxetine inhibited the
pharmacodynamic response to MDMA despite an increase in duloxetine-associated elevations in plasma MDMA levels. The
findings confirm the important role of MDMA-induced 5-HT and NE release in the psychotropic effects of MDMA. Duloxetine
may be useful in the treatment of psychostimulant dependence.
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Introduction
Amphetamine derivatives, including 3,4-methylenedioxy-
methamphetamine (MDMA, ‘‘ecstasy’’) bind to monoamine
transporters and potently release serotonin (5-hydroxytryptamine
[5-HT]), norepinephrine (NE), and dopamine (DA) through the 5-
HT (SERT), NE (NET), and DA (DAT) transporters, respectively
[1,2,3,4]. The pharmacological effect of MDMA can be blocked
by monoamine transporter inhibitors. In vitro, the MDMA-induced
release of NE, DA, or 5-HT from rat brain synaptosomes
preloaded with monoamines is competitively inhibited by the
monoamine transporter inhibitor indatraline [5,6]. In humans,
SERT inhibition reduced the psychotropic response to MDMA
[7,8,9]. NET inhibition also attenuated the acute effects of
MDMA [10] and amphetamine [11] in humans. In contrast,
clonidine, which inhibits the vesicular release of NE, did not
inhibit the effects of MDMA in humans [12]. Thus, the available
evidence indicates that the MDMA-induced transporter-mediated
release of 5-HT and NE appears to be involved in aspects of the
acute subjective and cardiovascular responses to psychostimulants
[2,7,10,11]. However, the response to MDMA in humans was
only moderately affected when either the SERT or NET was
pharmacologically blocked [7,10]. Therefore, we evaluated the
effects of dual SERT and NET inhibition with duloxetine on the
pharmacokinetics (PK) and pharmacodynamics (PD) of MDMA in
humans. Duloxetine was used because it is the most potent and
selective dual SERT and NET inhibitor, although it also inhibits
the DAT with 10- to 100-fold lower potency compared with the
SERT and NET [13,14]. MDMA is mainly metabolized to 3,4-
dihydroxymethamphetamine (HHMA) by cytochrome P450
(CYP) 2D6-mediated O-demethylation, followed by catechol-O-
methyltransferase-catalyzed methylation to 4-hydroxy-3-methox-
ymethamphetamine (HMMA) [15]. Because duloxetine inhibits
CYP 2D6 [16], we expected an increase in plasma MDMA
concentrations after duloxetine pretreatment. MDMA is also N-
demethylated to the active metabolite 3,4-mehthylenedioxyam-
phetamine (MDA). Whether the effects of MDA on 5-HT and NE
release are inhibited by transporter inhibitors is unknown.
Additionally, the inhibition of MDMA’s effect on 5-HT and NE
release by duloxetine has not been studied. Therefore, we also
assessed the effects of duloxetine on 5-HT and NE release induced
by MDMA or MDA in vitro using cells that express the respective
human transporters. We also sought to link the in vitro and in vivo
data to provide additional insights into the differential modulatory
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role of 5-HT and NE in the effects of MDMA in humans. Because
the data on monoamine transporter affinity and inhibition have
mostly been derived from studies that used rat transporters [17],
we investigated the binding and inhibition characteristics of the
human monoamine transporters for MDMA, MDA, and dulox-
etine and the transporter inhibitors used in previous clinical studies
[7,8,9,10] and in vitro studies [5,6]. Finally, we used an ex vivo
binding assay to assess whether plasma samples taken from the
drug-treated participants in the clinical study exhibit SERT, NET,
and DAT-binding properties ex vivo.
The overall hypothesis of the present study was that duloxetine
would potently bind to SERT and NET and block theMDMA- and
MDA-induced transporter-mediated release of 5-HT and NE in vitro
and markedly reduce the acute effects of MDMA in vivo in humans.
Methods
Clinical Study
The protocol for the clinical trial, the CONSORT checklist,
and the CONSORT flowchart are available as supporting
information; see Protocol S1, Checklist S1, and Figure 1. There
were no changes to the protocol during the study.
Ethics
The study was conducted in accordance with the Declaration of
Helsinki and approved by the Ethics Committee of the Canton of
Basel, Switzerland. All of the subjects provided written informed
consent before participating in the study, and they were paid for
their participation.
Design
We used a double-blind, placebo-controlled, randomized,
crossover design with four experiential conditions (placebo-placebo,
duloxetine-placebo, placebo-MDMA, and duloxetine-MDMA) in a
balanced order. The washout periods between the sessions were at
least 10 days long.
Participants
Sixteen healthy subjects (eight men, eight women) with a
mean6SD age of 26.166.0 years participated in the study. The
allocation to treatment order was performed by drawing from
blocks of eight different balanced drug treatment sequences by a
pharmacist not involved in the study. Each code was stored in a
sealed envelope until the termination of the study. Data from all 16
subjects were available for the final analysis (Figure 1). The
sample-size estimation showed that 13 subjects would be needed to
detect a meaningful reduction of 20% of the MDMA drug effect
by duloxetine with more than 80% power using a within-subjects
study design. The exclusion criteria included the following; (i) age
,18 or.45 years, (ii) pregnancy determined by a urine test before
each session, (iii) body mass index ,18.5 kg/m2 or .25 kg/m2,
(iv) personal or family (first-degree relative) history of psychiatric
disorder (determined by the structured clinical interview of Axis I
and Axis II disorders according the Diagnostic and Statistical Manual
of Mental Disorders, 4th edition [18] supplemented by the SCL-90-R
Symptom Checklist [19,20] (v) regular use of medications, (vi)
chronic or acute physical illness assessed by physical examination,
electrocardiogram, standard hematological, and chemical blood
analyses, (vii) smoking more than 10 cigarettes per day, (viii) a
lifetime history of using illicit drugs more than five times with the
exception of cannabis, (ix) illicit drug use within the last 2 months,
and (x) illicit drug use during the study determined by urine tests
conducted before the test sessions. None of the 16 subjects had
used ecstasy previously. The subjects were asked to abstain from
excessive alcohol consumption between the test sessions and limit
their alcohol use to one glass on the day before the test session. All
of the subjects were phenotyped for cytochrome P450 (CYP) 2D6
Figure 1. CONSORT flowchart.
doi:10.1371/journal.pone.0036476.g001
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activity using dextromethorphan. Thirteen extensive, two inter-
mediate, and one poor CYP 2D6 metabolizer were identified in
the study. The female subjects were investigated during the
follicular phase (day 2–14) of their menstrual cycle.
Drugs
(6 )MDMA hydrochloride (C11H15NO2, Lipomed, Arlesheim,
Switzerland) was obtained from the Swiss Federal Office of Public
Health and prepared as gelatin capsules (100 mg and 25 mg).
Identical placebo (lactose) capsules were prepared. MDMA was
administered in a single absolute dose of 125 mg that
corresponded to an average dose of 1.8760.36 mg/kg body
weight. This dose of MDMA corresponds to a typical recreational
dose of ecstasy, and comparable doses of MDMA have previously
been used in controlled settings. Duloxetine (Cymbalta, Eli Lilly,
Vernier, Switzerland) was prepared as 60 mg gelatine capsules,
and identically looking placebo (lactose) capsules were similarly
prepared. Duloxetine (120 mg) or placebo was administered twice
16 and 4 h before MDMA or placebo administration, respectively.
The dose of the two administrations of duloxetine (120 mg/day on
two separate days) was in the upper range of the chronic doses
used clinically (60–120 mg/day). This dosing schedule was used to
obtain high plasma concentrations of duloxetine similar to those
reached with chronic administration of 60 mg/day. Drugs were
administered without food.
Assessments
Psychometric measures. The psychometric measures in-
cluded Visual Analog Scales (VAS) [8,10], the Adjective Mood
Rating Scale (AMRS) [21], and 5-Dimensions of Altered States of
Consciousness (5D-ASC) [22,23]. The VASs included ‘‘any drug
effect,’’ ‘‘good drug effect,’’ ‘‘bad drug effect,’’ ‘‘drug liking,’’
‘‘drug high,’’ ‘‘stimulated,’’ ‘‘fear,’’ ‘‘closeness to others,’’ ‘‘talka-
tive,’’ and ‘‘open’’ [8,10,12,24,25]. The VASs were pre-
sented as 100 mm horizontal lines marked ‘‘not at all’’ on the
left and ‘‘extremely’’ on the right. The VASs for ‘‘closeness to
others,’’ ‘‘open,’’ and ‘‘talkative’’ were bidirectional (650 mm).
The VASs were administered 4 h before and 0, 0.33, 1, 1.5, 2, 2.5,
3, 3.5, 4, and 5 h after MDMA or placebo administration. The 60-
item Likert-type scale of the short version of the AMRS [21] was
administered 4 h before and 1.25, 2, and 5 h after MDMA or
placebo administration. The AMRS contains subscales for activity,
extroversion and introversion, well-being, emotional excitation,
anxiety-depression, and dreaminess. The 5D-ASC rating scale
measures alterations in mood, perception, experience of self in
relation to the environment, and thought disorder. The 5D-ASC
rating scale comprises five subscales or dimensions [22] and 11
lower-order scales [23]. The 5D-ASC dimension ‘‘oceanic
boundlessness’’ (OB, 27 items) measures derealization and
depersonalization associated with positive emotional states, rang-
ing from heightened mood to euphoric exaltation. The corre-
sponding lower-order scales include ‘‘experience of unity,’’
‘‘spiritual experience,’’ ‘‘blissful state,’’ and ‘‘insightfulness.’’ The
5D-ASC dimension ‘‘anxious ego dissolution’’ (AED, 21 items)
summarizes ego disintegration and loss of self-control phenomena,
two phenomena associated with anxiety. The corresponding
lower-order scales include ‘‘disembodiment,’’ ‘‘impaired control
of cognition,’’ and ‘‘anxiety.’’ The dimension ‘‘visionary restruc-
turalization’’ (VR, 18 items) consists of the lower-order scales
‘‘complex imagery,’’ ‘‘elementary imagery,’’ ‘‘audiovisual synes-
thesia,’’ and ‘‘changed meaning of percepts.’’ Two other
dimensions of the scale were not used in our study. The global
ASC score was determined by adding the OB, AED, and VR
scores. The 5D-ASC scale was administered 4 h after MDMA or
placebo administration.
Physiologic measures. Physiologic measures were assessed
repeatedly 4, 3, 2, and 1 h before and 0, 0.33, 0.66, 1, 1.5, 2, 2.5,
3, 4, 5, and 6 h after MDMA or placebo administration. Heart
rate, systolic blood pressure, and diastolic blood pressure were
measured using an OMRON M7 blood pressure monitor
(OMRON Healthcare Europe, Hoofddorp, The Netherlands).
Measures were taken twice per time point with an interval of
1 min, and the average was used for the analysis. Core (tympanic)
temperature was assessed using a GENIUS 2 ear thermometer
(Tyco Healthcare Group, Watertown, NY). The temperature of
the room was maintained at 23.260.5uC. Adverse effects were
assessed using the List of Complaints (LC) [26], which consists of
66 items that yield a total adverse effects score and reliably
measure physical and general discomfort.
Plasma catecholamines and Pharmacokinetics (PK).
Blood samples to determine the concentrations of NE and
epinephrine were collected 4 h before and 1 and 2 h after
MDMA or placebo administration. The levels of free cate-
cholamines (NE and epinephrine) were determined using high-
performance liquid chromatography (HPLC) with an elec-
trochemical detector as described previously [10]. Plasma
concentrations of copeptin were also determined in this study as
reported elsewhere [27]. Samples of whole blood for the
determination of MDMA, MDA, HMMA, and duloxetine were
collected into lithium heparin monovettes -4, 0, 0.33, 0.66, 1, 1.5,
2, 2.5, 3, 4, and 6 h after administration of MDMA or placebo.
Plasma concentrations of MDMA, MDA, HMMA, and duloxetine
were analyzed by HPLC coupled to a tandem mass spectrometer
as described previously [12]. The assays were linear in the
concentration ranges of 1–1000 ng/ml for MDMA and MDA, 1–
500 ng/ml for HMMA, and 2.5–1000 ng/ml for duloxetine. The
performance of the method was monitored using quality control
(QC) samples at the lower limit of quantification (LLOQ) and at
two or three QC concentrations. The interassay accuracy values
for the QC samples ranged from 97.5% to 100% for MDMA,
from 95.3% to 103% for MDA, from 91.1% to 106% for HMMA,
and from 93.2% to 96.4% for duloxetine. The interassay precision
values ranged from 2.8% to 8.0% for MDMA, from 3.8% to
10.5% for MDA, from 3.1% to 8.8% for HMMA, and from 4.7%
to 9.3% for duloxetine. No hydrolysis was performed. Thus, the
values for HMMA represent the drug concentrations of the non-
conjugated metabolite. All blood samples were collected on ice
and centrifuged within 10 min at 4uC. The plasma was then stored
at –20uC until the analysis.
In vitro Studies
Binding to monoamine transporters in vitro. Human
embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland)
stably transfected with the human NET, SERT, or DAT as
previously described [28] were cultured. The cells were collected
and washed three times with phosphate-buffered saline (PBS). The
pellets were frozen at –80uC. The pellets were then resuspended in
400 ml of 20 mMHEPES-NaOH, pH 7.4, that contained 10 mM
EDTA at 4uC. After homogenization with a Polytron (Kinematica,
Lucerne, Switzerland) at 10000 rotations per minute (rpm) for
15 s, the homogenates were centrifuged at 480006g for 30 min at
4uC. Aliquots of the membrane stocks were frozen at –80uC. All
assays were performed at least three times. The test compounds
were diluted in 20 ml of binding buffer (252 mM NaCl, 5.4 mM
KCl, 20 mM Na2HPO4, 3.52 mM KH2PO4, pH 7.4) and 10
point dilution curves were made and transferred to 96-well white
polystyrene assay plates (Sigma-Aldrich, Buchs, Switzerland). N-
Duloxetine and MDMA
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methyl-3H-nisoxetine (,87 Ci/mmol, Perkin-Elmer) was the
radioligand for the NET assay and had a dissociation constant
(Kd) of 9 nM. Fifty microliters of 12 nM [
3H]-nisoxetine was
added to each well of the assay plates, targeting a final [3H]-
nisoxetine concentration of 3 nM. [3H]-citalopram (,72 Ci/
mmol; Perkin-Elmer) was the radioligand for the SERT assay
and had a Kd of 2.2 nM. Fifty microliters of 8 nM [
3H]-
citalopram was added to each well of the SERT assay plates,
targeting a final [3H]-citalopram concentration of 2 nM. [3H]-
WIN35,428 (,86 Ci/mmol; Perkin-Elmer) was the radioligand
for the DAT assay and had a Kd of 12 nM. Fifty microliters of
[3H]-WIN35,428 (,40 nM concentration) was added to each well
of the hDAT assay plates, targeting a final [3H]-WIN35428
concentration of 10 nM. Twenty microliters of binding buffer
alone in the assay plate defined the total binding, whereas binding
in the presence of 10 mM indatraline defined nonspecific binding.
Frozen NET, SERT, or DAT membrane stocks were thawed and
resuspended to a concentration of approximately 0.04 mg
protein/ml binding buffer (1:1 diluted in H2O) using a polytron
tissue homogenizer. The membrane homogenates (40 mg/ml)
were then lightly mixed for 5–30 min with polyvinyl toluene (PCT)
wheat germ agglutinin-coated scintillation proximity assay (WGA-
SPA; Amersham Biosciences) beads at 7.7 mg beads/ml homog-
enate. One hundred thirty microliters of the membrane/bead
mixture were added to each well of the assay plate that contained
radioligand and test compounds (final volume in each well, 200 ml)
to start the assay, which was incubated for approximately 2 h at
room temperature with agitation. The assay plates were then
counted in the PVT SPA counting mode of a Packard Topcount.
Fifty microliters of the [3H]-nisoxetine, [3H]-citalopram, or [3H]-
WIN35428 stocks were counted in 5 ml of ReadySafe scintillation
cocktail (Beckman Industries) on a Packard 1900CA liquid
scintillation counter to determine the total counts added to the
respective assays. Non-linear regression was used to fit the data to
sigmoid curves and determine IC50 values for binding and uptake.
Ki values for binding and uptake were calculated using the
following Cheng-Prusoff equation: Ki = IC50/(1+ [S]/Km).[29].
Monoamine uptake in vitro. Two different methodological
approaches were used to assess the effects of the drug on
monoamine uptake. Method A used centrifugation through silicon
oil, and method B used buffer to stop the reaction and wash the
cells. Method A: The SERT, NET, and DAT functions were
evaluated in human HEK 293 cells that stably expressed human
SERT, NET, and DAT. The cells were grown in Dulbecco’s
modified Eagle’s medium (Invitrogen, Zug, Switzerland) with 10%
fetal bovine serum and 250 mg/ml geneticine. The cells (100 ml,
46106 cells/ml) were incubated for 10 min with 25 ml uptake
buffer (9.99 mM L-glucose, 0.492 mM MgCl2, 4.56 mM KCl,
119.7 mM NaCl, 0.7 mM NaH2PO4, 1.295 mM NaH2PO4,
0.015 mM sodium bicarbonate, and 1 mg/ml ascorbic acid for
[3H]-DA uptake) that contained various concentrations of
inhibitor at 25uC. Fifty microliters of 5 nM (final concentration)
[3H]-5-HT (80 Ci/mmol; Anawa), [
3H]-NE (14.8 Ci/mmol;
Perkin-Elmer), or [3H]-DA (13.8 Ci/mmol; Perkin-Elmer) was
added to start uptake. Uptake was stopped after 10 min, and
radioactivity was measured as described below for 5-HT and NE
release. Cell integrity after MDMA treatment was confirmed by
the Toxilight toxicity assay (Lonza, Basel, Switzerland). The data
were fit by non-linear regression, and Km, EC50, and Emax values
were calculated using Prism (GraphPad, San Diego, CA).
Preliminary experiments showed that the accumulation of 5-HT
and NE by the cells was time-dependent and complete after 5 min
for both 5-HT and NE, respectively. The 5-HT and NE transport
velocity was concentration-dependent and could be described by
Michaelis-Menten kinetics. The Km values were 4896147 nM,
4506125 nM, and 17076297 nM for 5-HT, NE, and DA,
respectively. Nonspecific uptake was determined for each exper-
iment in the presence of 10 mM fluoxetine for SERT cells, 10 mM
nisoxetine for NET cells, and 10 mM mazindol for DAT cells and
subtracted from the total counts to yield specific uptake.
Nonspecific uptake was ,10% of total uptake. Method B: Ligand
potencies to inhibit [3H]-DA, [3H]-5-HT, and [3H]-NE uptake via
the human DAT, SERT and NET recombinantly expressed in
HEK 293 cells were determined. The cells were grown in
Dulbecco’s modified Eagle’s medium (Invitrogen, Zug, Switzer-
land) with 10% fetal bovine serum and 250 mg/ml geneticine in
cell culture flasks. One day before the experiment, the cells were
seeded in a volume of 110 ml at a density of 0.3 million cells/ml in
96-well plates (Packard) and incubated at 37uC and 5% CO2
overnight. On the day of the uptake experiment, the 96-well plates
that contained the cells were washed with Krebs Ringer
bicarbonate buffer (Sigma-Aldrich, Buchs, Switzerland). Test
compounds (100 ml, diluted in Krebs Ringer bicarbonate buffer)
were added to the microtiter plates and incubated at 37uC for
30 min. Afterward, 50 ml [3H]-DA (35–54 Ci/mmol; Perkin-
Elmer; final concentration, 100 nM), [3H]-5-HT (28–100 Ci/
mmol; Perkin-Elmer; final concentration, 10 nM), or [3H]-NE
(5.3–14 Ci/mmol; Perkin-Elmer; final concentration, 100 nM)
were added to DAT-, SERT-, and NET-containing cells,
respectively, and incubated for 10 min at 37uC. Extracellular
[3H]-DA, [3H]-5-HT, and [3H]-NE were removed, and the plates
were washed twice with Krebs Ringer bicarbonate buffer.
Nonspecific uptake was determined in the presence of 10 mM
indatraline. Scintillant (Microscint 40, 250 ml) was dispensed to
every well, and radioactivity was determined at least 1 h later on
the Packard Topcount plate reader. The data were fit by non-
linear regression, and the IC50 was calculated using Excel
(Microsoft, Redmont, CA, USA). The compounds were tested at
least three times. The Km values were 1082 nM for [
3H]-5-HT
and .10000 nM for [3H]-DA and [3H]-NE.
5-HT and NE release in vitro. Transporter-mediated
MDMA- and MDA-induced 5-HT and NE release was evaluated
using [3H]-5-HT- and [3H]-NE-preloaded HEK 293 cells that
stably expressed human SERT and NET, respectively. The
procedures were adapted from previous studies [2,3]. SERT- or
NET-expressing cells (100 ml, 46106 cells/ml) were incubated at
25uC for 10 min with 50 ml of 5 nM (final concentration) [3H]-5-
HT or 10 nM [3H]-NE solutions, respectively. Steady-state load
with radiolabeled substrate was reached within 5 min and
remained stable for 60 min for both cell lines. Duloxetine or
other transporter inhibitors (5 ml) were added after 10 min, and
the release of [3H]-5-HT and [3H]-NE was then initiated after
another 2 min by the addition of MDMA, MDA, or buffer (25 ml).
The release reaction was stopped after 10 and 30 min for [3H]-5-
HT and [3H]-NE, respectively. The release times were based on
the evaluation of the release-over-time curves for MDMA and
MDA. The release of [3H]-5-HT and [3H]-NE was complete
within 5 and 25 min, respectively, when a new steady state was
reached and maintained for 30 min. To stop the release reaction
and wash the cells, 100 ml of the cell suspension was transferred to
0.5 ml microcentrifuge tubes that contained 50 ml of 3 M KOH
and 200 ml silicon oil (1:1 mixture of silicon oil types Ar20 and
Ar200; Wacker Chemie, Munich, Germany) and centrifuged in a
tabletop microfuge (Eppendorf, Basel, Switzerland) for 3 min at
13,200 rpm. This transports the cells through the silicon oil layer
to the KOH layer, thereby separating the cells from the buffer,
which remains on top of the silicon oil layer [30]. The centrifuge
tubes were then transferred to liquid nitrogen. The amount of
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tracer that remained in the cells was quantified by cutting the
frozen centrifuge tube above the KOH/oil interface and putting
the tip of the tube with the cell pellet in a scintillation vial that
contained 500 ml lysis buffer (0.05 M TRIS-HCl, 50 mM NaCl,
5 mM EDTA, and 1% Nonidet P-40 substitute in water). The
samples were then shaken for 1 h on a rotary shaker, and 7 ml of
scintillation fluid (Ultimagold, Perkin Elmer, Schwerzenbach,
Switzerland) was added. Cell-associated radioactivity was then
counted. The silicon oil assay allowed for the precise termination
of the transport/release process and an effective cell wash. The
experimental control condition (100% retained) was defined as the
[3H]-5HT or [3H]-NE that remained in the cells when buffer and
duloxetine were added without MDMA or MDA. A second
control condition (100% release) was defined as the [3H]-5-HT or
[3H]-NE released by 100 mM tyramine [6]. Data analysis using
either of the two control conditions yielded similar results, and the
data are presented as release expressed as the percentage of
monoamine retained. Dose-response curves were generated using
9–11 concentrations of MDMA/MDA. Nonspecific binding/
uptake was determined using preincubation with 10 mM fluoxetine
for SERT cells and 10 mM nisoxetine for NET cells before
incubation with radioligands and was ,3% of total activity. All
data points were derived from at least three independent
experiments, each assayed in triplicate. The data were fit by
non-linear regression, and EC50 and Emax values were calculated
using Prism (GraphPad, San Diego, CA).
Ex vivo Binding to Monoamine Transporters
Plasma samples for assessing ex vivo binding to monoamine
transporters were collected 120 min after MDMA/placebo
administration. We determined the potencies of the plasma to
inhibit [3H]-nisoxetine, [3H]-citalopram, and [3H]-WIN35,428
binding to NET, SERT, and DAT, respectively, according to the
method described previously [10]. IC50 values were calculated as a
percentage of the plasma sample dilutions required to obtain 50%
of the maximum effect. Indatraline (10 mM) in human plasma was
used to achieve 100% inhibition. Undiluted plasma samples were
set at 100%. Thus, an IC50 of 10% indicates that a 10-fold diluted
plasma sample displaced 50% of the radioligand.
Statistical Analyses
Pharmacodynamics. Clinical data values were transformed
to differences from baseline. Peak effects (Emax) were determined
for repeated measures. Emax values were compared using General
Linear Models repeated-measures analysis of variance, with drug
as within-subject factor, using Statistica 6.0 software (StatSoft,
Tulsa, OK). Tukey post hoc comparisons were performed based on
significant main effects of treatment. Additional analyses of
variance were performed, with period as factor to exclude period
effects. Correlation analyses were performed using Pearson’s
correlations. The criterion for significance was p,0.05. Mean
arterial pressure (MAP) was calculated from diastolic blood
pressure and systolic blood pressure using the following formula:
MAP=DBP+(SBP - DBP)/3.
Pharmacokinetics. The plasma concentration data for
MDMA, MDA, HMMA, and duloxetine were analyzed using
non-compartmental methods. Cmax and tmax were obtained
directly from the observed concentration-time curves. The
terminal elimination rate constant (lz) was estimated by log-linear
regression after semilogarithmic transformation of the data, using
the last two to three data points of the terminal linear phase of the
concentration-time curve of MDMA or duloxetine. Terminal
elimination half-life (t1/2) was calculated using lz and the equation
t1/2 = ln2/lz. The area under the plasma concentration-time curve
up to 6 h (AUC0-6h) was calculated using the linear trapezoidal
rule. The AUC0–‘ was determined by extrapolation of AUC0–6h
using lz. The PK parameters were determined using the PK
functions for Excel (Microsoft, Redmont, CA, USA). Plasma
concentrations were only determined up to 6 h after MDMA
administration because the aim of the study was to assess potential
changes in MDMA plasma levels while relevant pharmacody-
namic effects or MDMA were present. It was therefore not
possible to determine t1/2 for HMMA and MDA because of their
long t1/2, which would require sampling for an extended time.
PK-PD modeling: First, a soft-link PK-PD model was used to
evaluate the in vivo relationship between the concentration of
MDMA and subjective effect of the drug. The change in the VAS
for any drug effect was used as the pharmacodynamic measure in
each individual. Because we observed clockwise hysteresis in the
effect-concentration relationship over time, we used PK-PD data
pairs within the ascending part of the individual curves up to Emax
or Cmax. Our estimate of Emax, which should represent the
maximal response portion of the dose-response curve, may already
have been affected by tolerance. However, Emax values of 100%
(scale maximum) or stable high values were reached by most
subjects, indicating that tolerance was not an issue early in the
effect-time curve. Based on the good brain penetration of MDMA
and absence of a time lag, we assumed rapid equilibration between
plasma and the central compartment (brain). A sigmoid Emax
model was then fitted to the pooled data of all individuals: E=Emax
6Cp
h/(EC50
h+Cph), in which E is the observed effect, Cp indicates
the MDMA plasma concentration, EC50 indicates the plasma
concentration at which 50% of the maximal effect is reached, Emax
is the maximal effect, and h is the Hill slope. The sigmoid Emax
model provided a better fit than a simple Emax or linear model.
Data pooling was used because only few data pairs were available
per subject. Non-linear regression was used to obtain parameter
estimates. Second, we also used a hard-link PK-PD model to
predict in vivo PD effects based on the in vitro concentration-
response data linked to the observed individual in vivo PK. The in
vitro concentration-response relationship was described by a
sigmoidal dose-response variable slope model fitted to the effects
of MDMA on 5-HT or NE release using non-linear regression
(Prism, GraphPad, San Diego, CA). The equation was the
following: E=Emax/(1+10(LogEC50-C)6h), in which C denotes the
concentration of MDMA in the assay, and h denotes the Hill slope.
The in vitro effect-concentration relationship was determined for
MDMA-induced 5-HT and NE release separately, and separate
PD predictions were derived for each model. Similar to the soft-
link PK-PD model, a single compartment PK model (plasma=
brain concentration) was used, and only ascending PK or PD
values were included. The in vivo data were linked to the PK of
each individual, and a mean predicted effect-time curve was
established.
Results
Pharmacodynamics (PD)
Duloxetine markedly reduced the psychotropic and cardiosti-
mulant responses to MDMA in humans. Duloxetine decreased all
aspects of MDMA’s subjective effects in the VASs [8,10],
including psychostimulant effects such as feelings of ‘‘good drug
effects,’’ ‘‘drug liking,’’ ‘‘drug high,’’ and ‘‘stimulation’’ (Table 1;
Fig. 2b-d) but also so-called ‘‘entactogenic’’ or ‘‘empathogenic’’
MDMA-typical effects [31,32] such as feelings of being ‘‘open,’’
‘‘closer to others,’’ and more ‘‘talkative’’ (Table 1; Fig. 2e and f). In
the AMRS [21], duloxetine prevented MDMA-induced increases
in ‘‘well-being,’’ ‘‘emotional excitation,’’ and ‘‘extroversion’’
Duloxetine and MDMA
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(Fig. 3). In the 5D-ASC [22,23], duloxetine robustly reduced
MDMA’s effects on the total ASC score (p,0.001) and in all three
main dimensions of the scale (main effect of drug: F3,45 = 26.2,
32.6, 5.67, and 26.6 for ASC, OB, AED, and VR, respectively; all
p,0.001; Fig. 4). Duloxetine prevented the MDMA-induced
increase in circulating plasma NE levels, an endocrine marker for
sympathetic system activation (Table 1), and reduced the blood
pressure and heart rate response to MDMA (Table 1; Fig. 5).
MDMA-induced increases in plasma NE at 60 min correlated
with elevations in MAP (r =0.57, p,0.05) and increases in VAS
scores for ‘‘good drug effects,’’ ‘‘liking,’’ ‘‘open’’ (r = 0.65, 0.69,
0.77 and 0.63, respectively; all p,0.01), supporting the modula-
tory role of NE in these effects of MDMA. ANOVAs with period
as factor showed no effect of treatment order, confirming the
absence of period effects.
Pharmacokinetics
The robust decrease in the PD response to MDMA after
duloxetine was not the result of a pharmacokinetic interaction
between duloxetine and MDMA because duloxetine increased
exposure to MDMA. MDMA and duloxetine are both substrates
and inhibitors of CYP 2D6 [16]. The moderate CYP 2D6
inhibitor duloxetine increased both the Cmax and AUC0-6h of the
CYP 2D6 substrate MDMA by 1664% (mean 6 SEM;
F1,15 = 12.64, p,0.01) and 1865% (F1,15 = 8.95, p,0.01), respec-
tively (Fig. 6 and Table 2). Duloxetine had no effect on exposure to
MDA, the active metabolite of MDMA. Duloxetine decreased the
Cmax and AUC0-6h of the inactive CYP 2D6-formed MDMA
metabolite HMMA by 4666% (F1,15 = 70.03, p,0.001) and
4866% (F1,15 = 166.10, p,.001), respectively. Plasma duloxetine
concentrations nonsignificantly increased beginning 1 h after
Table 1. Pharmacodynamic peak drug effects.
Placebo-
placebo
Duloxetine-
placebo
Placebo-
MDMA
Duloxetine-
MDMA F3,45 = p,
Visual Analog Scales
Any drug effect Emax 3.8163.62 6.0062.52
### 86.6963.57*** 33.1967.74*** ### 74.47 0.001
Good drug effect Emax 4.5664.37 8.7565.01
### 89.3864.67*** 40.5669.50*** ### 42.89 0.001
Drug liking Emax 4.1364.06 7.5664.43
### 90.6964.82*** 38.3868.91*** ### 52.60 0.001
Drug high Emax 1.9461.94 4.8162.93
### 87.8164.85*** 28.9469.35** ### 55.45 0.001
Stimulated Emax 4.1361.94 5.1362.45
### 76.3166.84*** 22.2567.65### 46.25 0.001
Open Emax 1.3860.94 0.3860.38
### 32.1664.29*** 6.0063.26### 36.88 0.001
Closeness Emax 0.0060.00 0.0060.00
### 27.3163.87*** 4.6362.49### 37.32 0.001
Talkative Emax 1.1960.81 0.3160.31
### 28.8165.12*** 10.6963.73### 21.13 0.001
Adjective Mood Rating Scale
Well-being Emax 1.6660.49 0.3860.16
### 7.0661.01*** 3.5661.08## 18.0 0.001
Emotional excitation Emax 0.6960.35 0.6960.27
### 4.9460.97*** 1.3160.37### 14.7 0.001
Extroversion Emax 0.6360.24 0.3860.16
### 3.5060.61*** 1.4460.43### 17.5 0.001
Introversion Emax 0.3861.56 1.1360.30 2.6260.65** 1.6960.59 5.4 0.01
Dreaminess Emax 0.6360.33 1.3560.35 2.9460.66** 1.8160.48 4.1 0.05
Activity Emin 21,8860.50 22.6960.69 24.6961.04* 22.8160.78 2.6 0.06
Circulating catecholamines
Epinephrine (nM) Emax 0.4260.12 0.4660.10 0.5060.12 0.2660.10 ns
Norepinephrine (nM) Emax 20.2260.13 20.1860.07
### 0.4460.12*** 20.1960.10### 14.7 0.001
Physiologic effect
SBP (mm Hg) Emax 8.5661.75 6.1961.42
### 29.9463.41*** 10.9461.58### 24.6 0.001
DPB (mm Hg) Emax 6.2561.25 6.0060.97
### 22.1362.08*** 9.2261.57### 23.3 0.001
MAP (mm Hg) Emax 5.8061.27 5.1161.01
### 21.7662.73*** 8.5461.46### 20.3 0.001
Heart rate (beats/min) Emax 9.1961.29 5.0661.27
### 26.0662.77*** 11.0961.55### 25.5 0.001
Body temperature (uC) Emax 0.2360.04 0.1960.04### 0.5460.07** 0.3960.08 7.3 0.001
List of Complaints (total score)
Acute adverse effects at 3 h 20.0660.52 21.8161.09### 5.5661.72** 21.2561.49## 29.5 0.001
Sub-acute adverse effects at 24 h 21.0060.58 22.8861.35## 3.8861.09* 20.3861.32# 24.6 0.001
Ex vivo binding (IC50%)
NET .25 14.360.6*** ## 23.460.7 13.760.7*** ### 20.4 0.001
SERT .25 1.560.2 *** ### .25 1.460.2 *** ### 243.1 0.001
DAT .25 .25 .25 .25
Values are mean6SEM of changes from baseline of 16 subjects. *p,.05, **p,.01, and ***p,.001 vs. Placebo-placebo. #p,.05, ##p,.01, ###p,.001 vs. Placebo-
MDMA. SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure. IC50%, inhibition constant calculated as % of plasma sample dilution
with undiluted plasma set as 100%; NET, norepinephrine transporter; SERT, SERT, serotonin transporter; DAT, dopamine transporter; ns, nonsignificant.
doi:10.1371/journal.pone.0036476.t001
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Figure 2. Duloxetine inhibited the psychotropic effects of MDMA. MDMA produced stimulant-like (b–d) and ‘‘entactogenic’’ (e, f) effects
compared with placebo (p,0.001 for all scales). Duloxetine significantly inhibited MDMA-induced elevations in all of these subjective effects (a–f)
(p,0.001 for all scales). Values are expressed as mean+SEM (n =16).
doi:10.1371/journal.pone.0036476.g002
Figure 3. Duloxetine prevented the acute emotional effects of MDMA in the Adjective Mood Rating Scale. MDMA produced a state of
well-being (a), emotional excitation (b), increased introversion at drug onset at 1.25 h (d), increased extroversion at 2 h (c), increased dreaminess (e),
and decreased performance-oriented activity (f) (*p,0.05, **p,0.01, ***p,0.001, vs. placebo-placebo). Duloxetine prevented MDMA-induced
elevations in well-being, emotional excitation, and extroversion (a-c) (###p,0.001, placebo-MDMA vs. duloxetine-MDMA). Values are expressed as
mean+SEM (n =16).
doi:10.1371/journal.pone.0036476.g003
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MDMA administration (Fig. 5), consistent with the inhibitory
effect of MDMA on duloxetine metabolism via CYP 2D6.
Interindividual differences in CYP 2D6 activity also affected the
PK of MDMA. Lower CYP 2D6 function (i.e., a lower
dextromethorphan:dextrorphan urine concentration ratio) was
associated with a longer t1/2 of MDMA (r =0.65, p,0.01).
PK-PD Relationship
Fig. 7 shows the mean PD effects of MDMA plotted against
simultaneous plasma concentrations at the different time points
(hysteresis loops). The increases in ‘‘any drug effect’’ (Fig. 7a) and
MAP (Fig. 7b) returned to baseline within 6 h when MDMA
concentrations were still high. This clockwise hysteresis indicates
that a smaller MDMA effect was seen at a given plasma
concentration later in time, indicating rapid acute pharmacody-
namic tolerance, which was similarly described for cocaine [33].
Duloxetine robustly reduced the physical and subjective response
to MDMA, but it increased exposure to MDMA, illustrated by the
downward and rightward shift of the MDMA hysteresis loops
(Fig. 7).
Adverse Effects
MDMA produced adverse effects, such as sweating, difficulty
concentrating, thirst, and lack of appetite, resulting in an increase
in total LC scores at both 3 and 24 h after drug administration
(Table 1). Duloxetine produced daytime somnolence and moder-
ate insomnia. No severe adverse events were observed.
In vitro Studies
MDMA-induced 5-HT and NE release studies in vitro. MDMA
was nonsignificantly more potent in releasing NE via NET than 5-
HT via SERT (IC50 = 0.55 and 1.69 mM, respectively; Fig. 8;
Table 3), consistent with earlier work that used human [3,34] and
rat [2] transporters. MDA similarly released monoamines with
EC50 values of 0.85 and 2.77 mM for NE and 5-HT, respectively
(Fig. 8; Table 3). Thus, both amphetamines were active
transporter-mediated monoamine releasers and exhibited slightly
higher potency at NET than SERT. Duloxetine potently inhibited
the ability of MDMA and MDA to induce 5-HT release from
SERT and NE release from NET cells (Fig. 8). Duloxetine
(0.1 mM) decreased the Emax by approximately 50% and shifted
the concentration-effect curves to the right, consistent with a
mixed competitive and noncompetitive mode of inhibition. A high
concentration of duloxetine (10 mM) completely blocked the effects
of MDMA and MDA (Fig. 8). We then compared the inhibitory
effect of duloxetine on MDMA-induced monoamine release to the
inhibitory effects of the selective SERT inhibitor citalopram and
selective NET inhibitor reboxetine, each of which have been
shown to attenuate some of the effects of MDMA in humans
[7,10]. The potencies of duloxetine and citalopram to inhibit
MDA- and MDMA-induced 5-HT release were similar (Fig. S1;
Table 3). The potencies of duloxetine and reboxetine to block
MDMA-induced NE release were also similar (Fig. S1; Table 3).
These in vitro data indicate that duloxetine inhibited both SERT
and NET similarly to citalopram and reboxetine, respectively.
PK-PD and in vitro-in vivo relationship. Duloxetine
mainly affected the Emax of MDMA in the in vivo PK-PD
relationship of MDMA (Fig. 9a) consistent with a primarily
Figure 4. Duloxetine prevented the acute effects of MDMA in the Altered States of Consciousness (ASC) scale. MDMA significantly
increased the ASC sum score, Oceanic Boundlessness (OB), Anxious Ego Dissolution (AED), and Visionary Restructuralization (VR) dimensions, and
most of the subscales (*p,0.05, **p,0.01, ***p,0.001, placebo-placebo vs. placebo-MDMA). Duloxetine significantly reduced the effect of MDMA in
all dimensions and subscales (#p,0.05, ##p,0.01, ###p,0.001, placebo-MDMA vs. duloxetine-MDMA). Values are expressed as mean+SEM
(n = 16).
doi:10.1371/journal.pone.0036476.g004
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noncompetitive mode of inhibition and similar to the effect of
duloxetine on monoamine release produced by MDMA in vitro.
Duloxetine decreased the Emax from 93.867.3% to 20.864% for
placebo-MDMA compared with duloxetine-MDMA, respectively.
The EC50 values were 92.567.6 ng/mL (0.48 mM) and
83.8625 ng/mL (0.43 mM) for placebo-MDMA and duloxetine-
MDMA, respectively. The EC50 of the PK-PD curve of placebo-
MDMA in humans was 74 ng/ml (0.38 mM), similar to the EC50
values of MDMA to release 5-HT and NE in vitro. The plasma
concentrations of duloxetine (Cmax =112 ng/ml or 0.38 mM) were
also in the range of the concentrations that reduced MDMA-induced
5-HT and NE release in vitro. To relate our in vitro data to the PD of
MDMA in humans, we linked the concentration-effect relationship of
the in vitro effect of MDMA on 5-HT and NE release to the individual
concentration-time curves of our subjects (Fig. 9b). The observed
effect-time curve for MDMA in humans was predicted well by the in
vitro NE release model, assuming similar concentrations in plasma
and brain and no time lag. The 5-HT release model fitted, but 2- to
10-fold higher MDMA concentrations in the brain than in plasma
would be needed to obtain similar pharmacodynamic effects as NE.
The higher potency of MDMA to release NE vs. 5-HT in vitro also
predicted that NE release occurred at lower MDMA plasma and
brain concentrations and therefore sooner after MDMA administra-
tion, playing a predominant role during the initial drug effect (i.e.,
rush, stimulant effect). 5-HT release becomes relatively more
important later in time and predominantly mediates ‘‘entactogenic’’
effects, including feelings of being open and closer to others, that
prevail later. The model predicted that the half-maximal effects
would be reached at 4062 min and 70614 min for NE and 5-HT
release, respectively (Fig. 9b). The observed half-maximal subjective
drug effect of MDMA was reached 4464 min after drug adminis-
tration. At that time, the models predicted 4 (3–6)-fold higher NE
release compared with 5-HT release, consistent with the view of a
primary role for NE in the early effects of MDMA.
Monoamine transporter binding in vitro. The binding of
MDMA and MDA to monoamine transporters was weak (Table 4)
compared with the high potency of MDMA to release 5-HT and
NE. The binding profile of MDMA was consistent with other
binding studies that used human transporters [3] but different
from studies that used rat transporters [17]. Duloxetine showed
more than 100-fold higher affinity for both SERT and NET
compared with the affinity of MDMA for these transporters in the
same assay, supporting our approach of using duloxetine to
prevent MDMA from interacting with SERT and NET (Table 4).
Monoamine uptake inhibition in vitro. MDMA inhibited
NET three-fold more potently than SERT, consistent with previous
studies that used human transporters [3,35] but in contrast to data
derived frommouse and rat transporters [17,35,36] (Table 5). MDA
was equally potent to MDMA in inhibiting NET and SERT. Both
MDMA andMDA showed low potency to inhibit DAT. Duloxetine
was more potent in inhibiting SERT than NET (Table 5), which
was expected [13]. Because the selective SERT inhibitor citalopram
and selective NET inhibitor reboxetine have previously been shown
to attenuate the psychological effects of MDMA [7,10], we
compared duloxetine with these inhibitors. Duloxetine exhibited
similar potency as citalopram to inhibit SERT but 2- to 5-fold lower
potency as reboxetine to inhibit NET (Table 5).
Ex vivo Binding Studies
The ability of duloxetine to block monoamine transporters in
our study was confirmed with an ex vivo assay, in which plasma
from duloxetine-treated subjects inhibited ex vivo radioligand
binding to SERT and NET but not DAT (Table 1). We also
found a 10-fold higher affinity for SERT compared with NET,
Figure 5. Duloxetine reduced the cardiostimulant response to
MDMA. Duloxetine reduced the elevations in mean arterial blood
pressure (a) and heart rate (b) in response to MDMA. Duloxetine also
nonsignificantly lowered the MDMA-induced increase in body temper-
ature (c). Values are expressed as mean+SEM of 16 subjects.
doi:10.1371/journal.pone.0036476.g005
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Figure 6. Duloxetine increased MDMA exposure. Pharmacokinetics of MDMA, MDA, HMMA, and duloxetine (a–d). Duloxetine was administered 16 h
and 4 h before MDMA, which was administered at the 0 h time point. Duloxetine increased the Cmax and AUC0–6 of MDMA (a), had no significant effect on
MDA exposure (b), and decreased the Cmax and AUC0–6 of HMMA (c). Plasma duloxetine concentrations were similar in the duloxetine-placebo and duloxetine-
MDMA groups before MDMA administration (at –4 h and 0 h). Duloxetine concentrations increased 1 h after MDMA administration in the duloxetine-MDMA
vs. duloxetine-placebo group (d). Values are expressed as mean6SEM of 16 subjects. MDMA, 3,4-methylenedioxymethamphetamine; MDA, 3,4-
methylenedioxyamphetamine; HMMA, 4-hydroxy-3-methoxymethamphetamine.
doi:10.1371/journal.pone.0036476.g006
Table 2. Pharmacokinetic parameters of MDMA, MDA, HMMA, and duloxetine.
Cmax (ng/ml) Tmax (h) T1/2 (h) AUC0-6 (ng/ml h) AUC(0-‘) (ng/ml h)
MDMA
Placebo-MDMA 221.31611.63 2.3460.19 8.1760.74 952.75645.89 2908.556275.64
Duloxetine-MDMA 253.63613.60** 2.6660.29 7.1460.40 1106.87657.22** 2915.286154.27
MDA
Placebo-MDMA 11.7560.70 5.5060.22 – 46.6063.02 –
Duloxetine-MDMA 10.6760.72 5.2560.30 – 41.9563.38 –
HMMA
Placebo-MDMA 3.3660.34 1.8460.17 – 13.5761.58 –
Duloxetine-MDMA 2.0060.38*** 1.8960.25 – 8.1461.45*** –
Duloxetine
Duloxetine-placebo 106.77610.25 5.1460.29 10.9761.04 799.88674.40 1960.186229.54
Duloxetine-MDMA 111.6967.06 5.9560.39 11.3761.43 814.31652.73 2189.456297.99
Cmax, maximum plasma concentration; Tmax, time from drug administration to maximum plasma concentration; AUC0-‘, area under concentration-time curve
extrapolated to infinity. HMMA, 4-hydroxy-3-methoxymethamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MDA, 3,4-methylenedioxyamphetamine.
**p,.01, ***p,.001, vs. Placebo-MDMA. Values are mean6SEM (n = 16).
doi:10.1371/journal.pone.0036476.t002
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which was previously shown [13] and consistent with the in vitro
profile of duloxetine. We calculated the duloxetine concentration
in the plasma samples using the Ki values of duloxetine for SERT
and NET binding (Table 2) and the IC50 values derived from the
ex vivo binding in the duloxetine-placebo group (Table 1). The
values (mean 6 SE) obtained were 388636 nM and 576644 nM
duloxetine using SERT and NET binding, respectively, which was
well in agreement with the duloxetine plasma concentrations
determined by LC-MS/MS (31462.5 nM). Plasma from MDMA-
treated subjects did not differ from placebo-treated subjects with
regard to ex vivo radioligand binding to monoamine transporters
(Table 1). This finding is consistent with the relatively low in vitro
binding affinity of MDMA, which does not reflect the high
pharmacological activity of the drug. Our assay assessed binding to
Figure 7. Pharmacokinetic-pharmacodynamic (PK-PD) relationship. MDMA effects are plotted against simultaneous MDMA plasma
concentrations (a, b). The time of sampling is noted next to each point in minutes or hours after MDMA administration. The clockwise hysteresis
indicates acute tolerance to the effects of MDMA. Duloxetine pretreatment markedly reduced physical and subjective responses to MDMA in the
hysteresis loops (a, b).
doi:10.1371/journal.pone.0036476.g007
Figure 8. Duloxetine blocked MDMA- and MDA-induced 5-HT and NE efflux. Duloxetine inhibited SERT-mediated 5-HT release by MDMA
(a) and MDA (b). Duloxetine also inhibited NET-mediated NE release by MDMA (c) and MDA (d). Values are expressed as mean 6 SEM (n = 3–6) of
retained radiolabeled substrate following incubation with various concentrations of MDMA and MDA.
doi:10.1371/journal.pone.0036476.g008
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the SERT and NET binding site for [3H]-citalopram and [3H]-
nisoxetine, respectively. A possible explanation for the low affinity
of MDMA in this assay could be a binding site for MDMA that is
different from citalopram and nisoxetine at SERT and NET,
respectively, consistent with the noncompetitive mode of inhibition
of the MDMA-induced 5-HT and NE release by duloxetine.
Discussion
The present study showed that the dual SERT and NET
inhibitor duloxetine markedly decreased the psychotropic and
cardiovascular responses to MDMA in human subjects, confirm-
ing and extending previous work with selective SERT [7,8,9] and
NET [10] inhibitors. The inhibition of the effect of MDMA by
duloxetine in humans was pronounced and primarily noncompet-
itive. In vitro, duloxetine similarly blocked the interactive effects of
MDMA with SERT and NET to release 5-HT and NE. The
present findings provide further support for a central role of SERT
and NET as targets of MDMA with regard to its acute effects in
humans. Previous clinical data indicated that 5-HT release
primarily mediates the MDMA-typical ‘‘empathogenic’’ mood
effects of MDMA [7], whereas NE release may be responsible for
the stimulant and cardiovascular effects of the drug [10]. In the
present study, dual inhibition of 5-HT and NE release robustly
blocked both aspects of the MDMA effect, consistent with the role
of both 5-HT and NE. The precise mode of interaction of
amphetamine derivatives, including MDMA, with monoamine
transporters remains to be elucidated and may involve the
exchange of amphetamine with the transmitter, channel-like
conformational changes of the transporter [37], or transporter
internalization [38,39,40], MDMA is structurally similar to 5-HT,
and a common binding site has been proposed in transmembrane
domain 6 of SERT [41]. A distinct binding site was found for
SERT inhibitors, including citalopram and fluoxetine, proximal to
the 5-HT binding site [42]. Some SERT inhibitors may therefore
allosterically inhibit the interaction between MDMA and SERT to
release 5-HT. Consistent with these molecular data, our study
showed that duloxetine inhibited MDMA-induced 5-HT release,
NE release, and the response to MDMA in humans possibly
according to a noncompetitive inhibition mode. Both our in vitro
and in vivo findings may indicate acute allosteric inhibition of the
effects of MDMA by duloxetine. Prior work with rat brain
synaptosomes showed that indatraline competitively inhibited
MDMA-induced 5-HT release [5]. However, later studies
indicated that many SERT inhibitors also decreased the Emax
for different monoamine releasers, suggesting unique transporter
Table 3. Inhibition of MDMA-induced 5-HT or NE release by different inhibitors.
SERT NET
EC50 (mM) (95% CI)
Emax, % retained,
(95% CI) EC50 (mM) (95% CI)
Emax, % retained,
(95% CI)
MDMA alone 1.69 (1.07–2.66) 48 (42–55) 0.55 (0.17–1.81) 78 (73–82)
MDMA plus 0.1 mM duloxetine 3.51 (0.46–27) 82 (75–90) 0.59 (0.02–19) 90 (84–97)
MDMA plus 0.1 mM citalopram 3.17 (1.89–5.31) 72 (68–77) na na
MDMA plus 0.1 mM reboxetine na Na 3.35 (0.63–179) 78 (56–102)
MDA alone 2.77 (1.78–4.30) 48 (41–54) 0.85 (0.29–2.55) 73 (67–79)
MDA plus 0.1 mM duloxetine 6.86 (0.5–100) 83 (77–89) 2.06 (0.35–12.12) 80 (73–87)
MDA plus 0.1 mM citalopram 5.0 (1.28–19.6) 59 (44–75) na na
95% CI, 95% confidence interval; na, not assessed.
doi:10.1371/journal.pone.0036476.t003
Figure 9. Pharmacokinetic-pharmacodynamic modeling. Duloxetine lowered Emax in the MDMA concentration-effect curve (a) with little
effect on EC50, similar to the effect of MDMA on monoamine release in vitro. Diamonds and circles represent concentration-effect data pairs for
ascending concentrations for placebo-MDMA and duloxetine-MDMA, respectively (a). The solid lines show the fit of a sigmoid Emax PD model to the
observed PK data (a). Dashed lines indicate the 95% confidence interval (CI) of the estimation error (a). NE release predicted the observed subjective
effect of MDMA in vivo (b). Predicted effects are shown as curves (mean695% CI) that represent the fit of the in vitro concentration-effect data to the
16 individual plasma concentration-time curves (b). Observed values are expressed as mean6SEM of 16 subjects (b). MDMA, 3,4-
methylenedioxymethamphetamine; NE, norepinephrine; 5-HT, serotonin.
doi:10.1371/journal.pone.0036476.g009
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interactions for different inhibitor-releaser combinations [6]. This
indicates that different SERT inhibitors may also more or less
effectively reduce the effects of psychostimulants in humans.
Nevertheless, several of the present findings indicate that the effect
of duloxetine on the MDMA response was likely attributable to the
dual inhibition of SERT and NET and not only the result of
potent SERT inhibition alone. First, duloxetine blocked MDMA-
induced NE release in vitro and MDMA-induced increases in
plasma NE in vivo, similar to the selective NET inhibitor reboxetine
[10]. Second, we documented, ex vivo, NET binding in plasma
from duloxetine-treated subjects, and duloxetine has previously
been shown to effectively inhibit NET in humans [13]. Third,
potent and selective inhibition of SERT alone using citalopram in
a single high dose [7], fluoxetine for 5 days [8], or paroxetine for
3 days [9] failed to block the effects of MDMA in humans to the
extent seen here with dual SERT and NET inhibition. Conversely,
selectively blocking NET alone also did not as effectively reduce
the effects of MDMA in humans [10] as blocking both SERT and
NET. The importance of NE as a modulator of the acute effects of
MDMA is also supported by the fact that NE plasma levels after
MDMA treatment in the present study correlated with the
subjective effects and increases in blood pressure. Furthermore, we
compared our in vitro 5-HT and NE release data to clinical data in
humans and showed that the NE release link model better
predicted the ascending subjective effects of MDMA in humans
than the 5-HT release link model. A full assessment of the relative
efficacy of SERT and NET inhibitors to prevent the effects of
MDMA would require administration of SERT and NET
inhibitors alone and in combination and dose-response studies.
However, such studies were not ethically feasible because we did
not want to expose our MDMA-naive subjects to more than two
doses of MDMA in a crossover design.
The role of DA in the reinforcing effects of psychostimulants is
well established, but unknown is whether DA is critical for the
acute effects of MDMA. We found that MDMA exhibited higher
affinity for DAT than NET or SERT in vitro. However, MDMA
functionally exhibited significantly higher inhibition potency of the
SERT and NET compared with DAT, respectively. MDMA is
also more potent in releasing 5-HT and NE compared with DA in
vitro [3], and the magnitude of 5-HT release exceeded DA release
in the nucleus accumbens, striatum, and prefrontal cortex, assessed
with in vivo microdialysis in rats [43]. DAT inhibition did not affect
the acute response to MDMA in rhesus monkeys [44]. Addition-
ally, the D2 dopamine receptor antagonist haloperidol only weakly
attenuated MDMA-induced euphoria in humans and only at doses
that produced significant dysphoria [45]. Whether DAT (NET)
inhibitors, such as bupropion or methylphenidate, inhibit the
effects of MDMA in humans remains to be tested. Duloxetine is a
potent SERT and NET inhibitor but also weak DAT inhibitor
[13,46], which was confirmed in the present in vitro study. We
cannot exclude the possibility that the relatively high dose of
duloxetine used in the present study also inhibited MDMA-
induced DA release. Notably, the present ex vivo binding studies
further showed that the plasma from the subjects treated with
duloxetine exhibited binding to SERT and NET but not DAT.
The transporter-independent vesicular release of monoamines
could theoretically contribute to the mechanism of action of
MDMA. We recently showed that this is not the case for NE
because clonidine, which blocks transporter-independent vesicular
NE release, did not alter the effects of MDMA in humans [12].
Additionally, MDMA did not directly stimulate the Ca2+-
dependent vesicular release of DA [47]. Nevertheless, MDMA
may indirectly stimulate the DA system and induce the vesicular
release of DA by downstream 5-HT-DA or NE-DA system
interactions. For example, 5-HT release by MDMA stimulates DA
release via 5-HT2 receptor activation [48], and this indirect effect
on the DA system is also prevented by SERT inhibition [49].
Thus, downstream DA system activation may be a contributing
factor to MDMA-induced euphoria and the mechanism of action
of psychostimulants in general, even when SERT and NET may
be considered the primary pharmacological targets.
Finally, it is also possible that duloxetine induced adaptive
effects on monoamine systems that reduced the response to
MDMA in vivo. For example, decreases in SERT but not in NET
Table 4. Binding affinities to human monoamine
transporters.
SERT NET DAT
MDMA 13.360.47 22.4614.6 6.5262.24
MDA 18.762.76 17.864.06 26.464.24
Duloxetine 0.00560.002 0.0760.05 0.7060.07
Reboxetine 0.2460.02 0.01560.01 16.264.91
Citalopram 0.00560.001 5.0663.00 21.4610.5
Indatraline 0.0260.008 0.0360.02 0.0160.01
Paroxetine 0.00460.001 0.4260.17 0.7760.18
Values are mean6SD of Ki (mM) (n$3). Radioligands were 3[H]citalopram,
3[H]nisoxetine, and 3[H]-WIN35,428 for SERT, NET, and DAT, respectively.
doi:10.1371/journal.pone.0036476.t004
Table 5. Monoamine transport inhibition.
SERT NET DAT
Ki (mM) (95% CI) Ki (mM) (95% CI) Ki (mM) (95% CI)
MDMA* 1.40 (1.00–1.96) 0.470 (0.334–0.598) 16.7 (11.5–24)
MDA* 2.41 (1.49–3.92) 0.341 (0.253–0.461) 11 (7.5–17)
Duloxetine 0.050 (0.04–0.07)* 0.126 (0.099–0.161)* 2.26 (0.7–3.8)#
Reboxetine 2.07 (1.4–2.6)# 0.036 (0.030–0.044)* 16.4 (11.5–25.2)#
Citalopram* 0.045 (0.037–0.057) .20 .20
Indatraline# 0.09 (0.06–0.12) 0.043 (0.03–0.06) 0.025 (0.01–0.04)
Paroxetine# 0.014 (0.01–0.02) 1.12 (0.03–1.7) 4.83 (2.4–7.3)
*method A; #method B; 95% CI, 95% confidence interval; values are significantly different (p,0.05) if 95% CI do not operlap.
doi:10.1371/journal.pone.0036476.t005
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binding sites were documented following chronic administration of
duloxetine in rats [50].
In conclusion, the present study adds to a better understanding
of the mechanism of action of MDMA in humans. The data
support the roles of both NE and 5-HT in the acute effects of
MDMA. The robust and almost complete prevention of the effects
of MDMA by duloxetine suggests that dual transporter inhibitors
may be useful in the prevention of the acute and long-term
consequences of MDMA and potentially other psychostimulants in
addicted subjects.
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Figure S1 Potency and efficacy of MDMA- and MDA-
induced 5-HT and NE release inhibition by duloxetine,
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Sex Differences in the Effects of MDMA (Ecstasy) on
Plasma Copeptin in Healthy Subjects
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Basel, Switzerland
Background: 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) misuse is associated with
hyponatremia particularly in women. Hyponatremia is possibly due to inappropriate secretion of
plasma arginine vasopressin (AVP).
Objective: To assess whether MDMA increases plasma AVP and copeptin in healthy male and
female subjects and whether effects depend on MDMA-induced release of serotonin and norepi-
nephrine. Copeptin, theC-terminal part of theAVPprecursorpreprovasopressin, is cosecretedwith
AVP and can be determined more reliably.
Methods:We used a randomized placebo-controlled crossover design. Plasma and urine osmola-
lities as well as AVP and copeptin levels were measured in 16 healthy subjects (eight female, eight
male) at baseline and afterMDMA (125mg) administration. In addition,we testedwhether effects
ofMDMAonAVPandcopeptin secretioncanbepreventedbypretreatmentwith the serotoninand
norepinephrine transporter inhibitor duloxetine (120 mg), which blocks MDMA-induced trans-
porter-mediated release of serotonin and norepinephrine.
Results:MDMA significantly elevated plasma copeptin levels at 60 min and at 120 min compared
with placebo inwomenbut not inmen. The copeptin response toMDMA inwomenwas prevented
by duloxetine. MDMA also nonsignificantly increased plasma AVP levels in women, and the effect
was prevented by duloxetine. Although subjects drank more water after MDMA compared with
placebo administration, MDMA tended to increase urine sodium levels and urine osmolality com-
pared with placebo, indicating increased renal water retention.
Conclusion:MDMA increased plasma copeptin, a marker for AVP secretion, in women but not
in men. This sex difference in MDMA-induced AVP secretion may explain why hyponatremia is
typically reported in female ecstasy users. The copeptin response to MDMA is likely mediated
via MDMA-induced release of serotonin and/or norepinephrine because it was prevented by
duloxetine, which blocks the interaction of MDMA with the serotonergic and noradrenergic
system. (J Clin Endocrinol Metab 96: 2844–2850, 2011)
Abuseof3,4-methylenedioxymethamphetamine (MDMA,ecstasy) has been associated with the syndrome of
inappropriate secretion of antidiuretic hormone (SIADH)
(1, 2) and symptomatic hyponatremia particularly in
women (3, 4). Specifically, a case series of ecstasy-associ-
ated hyponatremia included 18 cases, of which 17 were
women (4). Another larger retrospective series of ecstasy
exposures reported to a poison center found hyponatre-
mia (Na!130mmol/liter) in 73 (38.8%) of 188 cases (3).
Of the 73 cases with hyponatremia, 55 (75.3%) were
women and 18 (24.7%) men (3). Thus, female sex was
significantly associated with increased odds of hypona-
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tremiaand increasedoddsof associated comaamong these
cases (3). A small nonblinded laboratory study showed
that MDMA significantly increased plasma concentra-
tions of arginine vasopressin (AVP) at 1–4 h after con-
trolled MDMA administration in eight healthy male
volunteers (5, 6). This study provides evidence for a stim-
ulatory effect of MDMA on AVP secretion. However, no
female subjects were included. We assessed MDMA ef-
fects on AVP system activation and associated changes in
plasma and urine osmolality as well as sodium levels in
resting healthy subjects with ad libitum water intake in a
controlled laboratory setting.
MDMA is a substrate of both the serotonin and nor-
epinephrine transporter (7). It enters presynaptic nerve
terminals andpotently releases serotonin andnorepineph-
rine through the transporter (7). AVP secretion is thought
to be regulated by serotonergic (8) and noradrenergic (9)
pathways, and these monoamines could act as mediators
for the effects ofMDMAon theAVPsystem.TheMDMA-
induced carrier-mediated release of serotonin and norepi-
nephrine can be reduced by serotonin and norepinephrine
transporter inhibitors, respectively (10, 11). We therefore
assessed whether blockade of both the serotonin and nor-
epinephrine transporter with duloxetine would prevent
potential effects of MDMA on AVP secretion in the pres-
ent study.
The reliable determination of plasma AVP is problem-
atic. We therefore measured copeptin in addition to AVP
levels. Copeptin is the C-terminal part of the AVP precur-
sor preprovasopressin. Copeptin is produced together
with AVP in equimolar ratio and exhibits similar kinetics
in response to osmotic changes (12–14). In contrast to
AVP, copeptin levels remain stable in serum or plasma
samples and can easily and reliably be measured (12).
Wehypothesized thatMDMAwould increaseAVPand
copeptin levels, particularly in women, and that pretreat-
ment with the serotonin-norepinephrine transport inhib-
itor duloxetine would prevent this effect.
Subjects and Methods
Study subjects
The study was performed in 16 healthy subjects (eight
women, eightmen).Womenwere (mean! SD) 29.0! 7.1 yr old.
Body weight was 59.0 ! 6.9 kg. Men were 23.3 ! 3.1 yr old.
Body weight was 79.5! 9.8 kg. Exclusion criteria included age
under 18 or over 45 yr, pregnancy (urine pregnancy test before
each test session), bodymass index below18.5 or over 25 kg/m2,
personal or family (first-degree relatives) history of psychiatric
disorder, regular use of medications, chronic or acute physical
illness (normal physical exam, normal electrocardiogram, and
standard hematological and chemical blood analyses), smoking,
lifetime prevalence of illicit drug use over five times (except for
tetrahydrocannabinol), illicit drug use within the last 2 months,
and illicit drug use during the study (urine tests before test ses-
sions). Subjects were asked to abstain from excessive alcohol
consumptionbetween test sessions and inparticular to limit their
use to one glass on the day before the test sessions. Subjects
abstained from caffeinated beverages on the test days. Female
subjects were investigated during the follicular phase (d 2–14) of
their menstrual cycle when the reactivity to amphetamines (15)
andosmotic sensitivity (16) are expected to be similar tomen.All
subjects gave theirwritten informed consent before participating
in the study, and subjects were paid for participation.
Study procedures
The study was conducted in accordance with the Declaration
of Helsinki and was approved by the Ethics Committee of Basel,
Switzerland. The use of MDMA in healthy subjects was autho-
rized by the Swiss Federal Office of Public Health, Bern, Swit-
zerland. The study was registered at www.clinicaltrials.gov
(number NCT00990067) with neuroendocrine measures as a
secondary outcome. We used a randomized placebo-controlled
crossover design with four conditions (placebo-MDMA, place-
bo-duloxetine, duloxetine-MDMA, and placebo-placebo) in
balanced order.Washout periods between sessions lasted 10–14
d. Duloxetine (120 mg) or placebo was administered twice 16
and 4 h before MDMA (125 mg) or placebo, respectively. We
assessed plasma and urine osmolality aswell as plasma and urine
sodium 4 h before and 120 min after MDMA/placebo adminis-
tration. Plasma levels of copeptinwere assessed 4 h before and at
60 and 120 min after MDMA/placebo. Plasma levels of AVP
were assessed 4 h before and 120 min after MDMA/placebo.
Subjects were not engaged in any physical activity andwere rest-
ing in hospital beds during the test session. Subjects had a small
standardizedbreakfast at thebeginningof each test session. Fluid
consumption was not restricted up to a total intake of 2000 ml
water during the session andwas recorded from4hbefore to120
min after MDMA/placebo administration when the last hor-
mone measurement was performed. In addition, saline was ad-
ministered via an iv catheter to keep catheters open for blood
sampling at a rate of 100 ml/h from 0–120 min after MDMA/
placebo administration. The study design also included addi-
tional assessments of subjective and cardiovascular effects,
blood drawings for pharmacokinetics, and monitoring of ad-
verse events for 6 h afterMDMA/placebo administration as will
bedescribedelsewhere (Simmler,L.D.,C.M.Hysek, J.Huwyler,
M. E. Liechti, unpublished data).
Measurements
Measurementswere done in duplicates in a blinded fashion in
a single batch. AVP was assessed in EDTA plasma using a RIA
(Direct Vasopressin RIA; Bu¨hlmann Laboratories AG, Scho¨nen-
buch/Basel, Switzerland). The lower detection limit was 0.82
pmol/liter, and the intraassay precisionwas 6.0%.Copeptin lev-
els were assessed using an immunoassay (LIA CT-proAVP;
B.R.A.H.M.S./ThermoFisher Scientific, Hennigsdorf/Berlin, Ger-
many) as described previously (12) and modified as described
previously (14).The lowerdetection limitwas0.4pmol/liter, and
the intraassay coefficient of variation was less than 5%. Sodium
concentrations were measured by indirect potentiometry (Hita-
chi 917; RocheDiagnostics, Rotkreuz, Switzerland).Osmolality
was measured by cryoscopy (Micro Osmometer; Advances In-
struments for Switzerland Instruments, Zurich, Switzerland).
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Study drugs
(!)MDMA hydrochloride (Lipomed AG, Arlesheim, Swit-
zerland) was obtained from the Swiss Federal Office of Public
Health and prepared as gelatin capsules (100 and 25 mg). Iden-
tical placebo (lactose) capsules were prepared. MDMA was ad-
ministered in a single absolute dose of 125 mg. This dose of
MDMA corresponds to a typical recreational dose of ecstasy,
and comparable doses of MDMA have previously been used in
controlled settings. Because MDMA was dosed in an absolute
dose of 125 mg, differences in body weight resulted in different
weight-adjusted relative MDMA doses of 1.6 ! 0.23 mg/kg
(range, 1.4–2.1 mg/kg) in men and 2.1 ! 0.25 mg/kg (range,
1.8–2.5 mg/kg) in women. Duloxetine (Cymbalta; Eli Lilly SA,
Vernier, Switzerland) was prepared as 60-mg gelatin capsules,
and identically looking placebo (lactose) capsules were similarly
prepared.
Statistical analysis
Repeated-measures ANOVAwith the factors drug (placebo-
placebo, duloxetine-placebo, placebo-MDMA, and duloxetine-
MDMA) and time (baseline, 60 min, and 120 min) stratified for
sex and followed by pairwise Tukey post hoc tests was used to
assess differences in the effects of the different drugs. Nonnor-
mally distributed variables were log nor-
malized before the ANOVA. Correlation
analyses were performed using Spearman’s
rankcorrelationsusing the total of all values
(n" 128). All tests were two tailed, and the
significance level was set to P " 0.05.
Results
ANOVA on plasma copeptin levels
yielded a significant drug # time # sex
interaction [F(6,84)" 3.93; P" 0.0017].
MDMAsignificantlyelevatedplasmaco-
peptin levels at60min (P$0.001)andat
120 min (P$ 0.01) compared with pla-
cebo in women (Fig. 1A) but not in men
(Fig. 1B). The MDMA-induced increase
in plasma copeptin in women was pre-
vented by duloxetine pretreatment
bothat 60min (P$0.001) and120min
(P $ 0.01) (Fig. 1A). A similar trend
was observed for AVP levels but drug
effects did not reach significance (Fig.
1, C and D). Oral liquid intake varied
across drug treatments, but there
were no sex differences [main effect of
drug: F(3,42) " 8.62; P $ 0.001, no
drug # sex interaction]. Oral liquid
intake (mean! SEM) was 612! 50 ml
after placebo-placebo, 1267! 118ml
after duloxetine-placebo (P $ 0.001
vs. placebo-placebo), 1198 ! 130 ml
after placebo-MDMA (P " 0.001 vs.
placebo-placebo), and 807 ! 83 ml after duloxetine-
MDMA (P " 0.02 vs. duloxetine-placebo, and P "
0.051 vs. placebo-MDMA). Urine osmolality decreased
significantly over time [main effect of time: F(1,14) "
62.69; P$ 0.001]. Urine osmolality tended to be higher
after placebo-MDMAor duloxetine-MDMA compared
with placebo-placebo or duloxetine-placebo as evi-
denced by a near-significant drug # time interaction in
the ANOVA [F(3,42) " 2.70; P " 0.058] (Fig. 2, A and
B). A similar trend was observed for urine sodium levels
[drug# time interaction: F(3,42)" 2.33;P" 0.088] (Fig.
2, C and D). There were no significant drug effects on
plasma sodium levels or plasma osmolality (Fig. 2,
E–H). Circulating copeptin levels correlated with AVP
levels (all: rs" 0.34, P$ 0.001; women: rs" 0.53, P$
0.001; men: rs " 0.28, P $ 0.05]. Copeptin levels were
also correlated with plasma and urine osmolality [rs "
0.22; P $ 0.05 and rs " 0.68; P $ 0.001, respectively]
as well as with plasma and urine sodium [rs " 0.18; P $
A              B              
C              D
FIG. 1. Mean values ! SEM for plasma levels of copeptin and AVP in eight female and eight
male healthy subjects 4 h before (PRE) and 60 and 120 min after MDMA (125 mg) or placebo.
A, MDMA significantly increased copeptin levels in women at 60 and 120 min after drug
administration compared with placebo. Duloxetine pretreatment prevented the MDMA-
induced elevation in circulating copeptin in women. B, MDMA did not alter copeptin levels in
men. C, Similar to its effects on MDMA-induced copeptin increases, duloxetine also prevented
the nonsignificant increase in AVP at 120 min after MDMA administration in women. D,
There were no drug effects on AVP levels in men. **, P $ 0.01; ***, P $ 0.001 vs. placebo-
placebo; ##, P $ 0.01; ###, P $ 0.001 vs. placebo-MDMA.
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0.05 and rs ! 0.28; P " 0.01, respectively]. Baseline co-
peptin levels were significantly lower in women than men
[F(1,14) ! 8.38; P ! 0.012]. The relative dose of MDMA
(inmilligrams per kilogrambodyweight) did not correlate
with the MDMA-induced increase in plasma copeptin
within the two sex groups. In the present study, MDMA
also producedmarked subjective and cardiovascular stim-
ulant effects aswill be reported separately elsewhere (Sim-
mler, L. D., C. M. Hysek, J. Huwyler, M. E. Liechti, un-
published data).
Discussion
We found that MDMA increased circulating copeptin, a
marker for AVP secretion, in women but not in men. This
sex difference inMDMA-induced AVP secretion is in line
with the clinical observation that ecstasy-associated hy-
ponatremia is typically reported in female users (3, 4).
Other sex differences in the response toMDMAor ecstasy
have previously been reported and include increased sub-
jective effects in women compared with men to equal
weight-adjusted doses of MDMA (18), more pronounced
depression after ecstasy use (19), and a potential increase
in serotonergic neurotoxicty in associationwith long-term
useof ecstasy inwomen (20).Thepresent findings indicate
that women may be at increased risk for developing hy-
ponatremia and associated neurotoxicity due to their sex-
specific stronger AVP response to MDMA. In addition,
the threshold levels of plasma sodium at which neurolog-
ical complications occur appear to be higher in women
than men (21, 22), and woman are more likely than men
to die from hyponatremic encephalopathy after surgery
(21, 23). Seizures and coma were also more frequently
reported in female cases of ecstasy-associated hypona-
tremia compared with men (3). However, ecstasy-asso-
ciated hyponatremia may have multiple causes, and
MDMA-induced AVP secretion may be only one of sev-
eral contributing factors. Dry mouth and physical ex-
ertion with sweating followed by hyperhydration with
electrolyte-free water may all contribute to the devel-
opment of hyponatremic states in recreational ecstasy
users. Even loss of sodium into the gastrointestinal tract
has been discussed (24).
The AVP system is activated by factors typically asso-
ciated with MDMA consumption in a party setting in-
A
E F G H
B C D
FIG. 2. Mean values # SEM for sodium and osmolality in urine and plasma in eight female and eight male healthy subjects 4 h before (PRE) and
120 min after MDMA (125 mg) or placebo. The two treatment conditions including MDMA (placebo-MDMA and duloxetine-MDMA) tended to
increase both urine osmolality (A and B) and urine sodium levels (C and D) in both sexes. There were no treatment effects on plasma osmolality or
plasma sodium levels (E–H).
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cluding dehydration (12–14), heat (25), and physical ac-
tivity (12, 26), all of which are potentially increasing the
risk of SIADH. Our results indicate that direct activation
of the AVP system by MDMA may play a crucial facili-
tating role in the development of ecstasy-associated
SIADH, in particular in women, because we controlled
carefully for confounding factors that may increase AVP.
Subjects werewell hydrated orally and iv and resting com-
fortably in hospital beds in a temperature-controlled re-
search environment. Of note, our subjects drank more
water after MDMA than after placebo administration
possibly due to a dry mouth and increased thirst after
MDMAadministration (18). Fluid consumptionwouldbe
expected to decrease copeptin secretion (13), counteract-
ing the effects of MDMA. However, copeptin levels were
actually increased during the MDMA condition, which
further supports the concept that MDMA activated the
AVP system via pharmacological stimulation, although
we cannot exclude an indirect effect via increased thirst
perception (14). Furthermore, urine osmolality and urine
sodium levels tended to be higher afterMDMA compared
with placebo administration despite the increase in oral
fluid intake. This finding indicates thatMDMA increased
renal fluid retention, which is consistent with an elevated
secretion of AVP.
The AVP response to MDMA in women was blocked
by duloxetine pretreatment. Duloxetine prevents the
transporter-mediated release of serotonin and norepi-
nephrine by MDMA. Thus, MDMA-induced AVP secre-
tion appears to bemediated by serotonin and norepineph-
rine. This clinical finding is in line with preclinical studies
indicating a role for central serotonin (8) and norepineph-
rine (9) systems in AVP secretion. The mediating role of
the serotonin system in AVP regulation is also supported
by the fact that several serotonergic medications are typ-
ically associatedwithan increased riskof SIADH(22).The
precise mechanism of the serotonin/norepinephrine-AVP
system interaction is not known. AVP and copeptin are
also hypothalamic stress hormones (27, 28), andMDMA
is a pharmacological stressor. MDMA activates the hy-
pothalamo-pituitary-adrenal axis and increases plasma
corticotropin and cortisol (29, 30). In addition, MDMA
increases aldosterone secretion in rats. Cortisol and min-
eralocorticoids also influence the electrolyte and body
fluid balance. We did not assess the role of steroids in the
present study. However, steroids increase renal sodium
reabsorption and would thereby antagonize AVP effects
on plasma osmolality.
In our study, MDMA (125 mg) had no effect on AVP
or copeptin plasma levels in male subjects, whereas an
earlier study showed an increase inAVP after a lower dose
of MDMA (47.5 mg) in eight healthy men (5, 6). This
discrepancy is likely due to differences in the study design
and setting. Importantly, subjects were free to drink as
much as they wanted in our study, and fluid consumption
was higher after MDMA than after placebo which could
have counteracted any MDMA effects on AVP secretion
and even abolished any MDMA effects in men. In addi-
tion, our subjectswere resting inhospital beds, eliminating
any contributing effects of physical activity on AVP se-
cretion. Nevertheless, it is surprising that our compara-
tively high dose ofMDMAdid not affect AVP or copeptin
secretion despite pronounced subjective and cardiovascu-
lar stimulant effects of MDMA in the same subjects (Sim-
mler, L. D., C. M. Hysek, J. Huwyler, M. E. Liechti, un-
published data). Interestingly, similar inconsistencies are
seen in the clinical reports on ecstasy-associated hypona-
tremia. Hyponatremia was found in 55 (52.4%) of 105
women and 18 (21.7%) of 83 men in ecstasy exposures
reported to the California Poison Control System (3).
However, other reports indicate that hyponatremia is a
relatively rare complication of ecstasy use. Ecstasy-asso-
ciated hyponatremiawas observed in only two (5%) of 40
monointoxications (31) or was not reported (32) accord-
ing to other poison center studies. Hyponatremiawas also
a rare medical complication according to a series of in-
toxication cases presenting to emergency rooms (17, 33,
34). Taken together, the available data point toward an
important role of additional contributing personal (sex,
menstrual phase, and genetic factors) and/or environmen-
tal (heat and hydration) factors that may contribute and
modulate the effects of MDMA on AVP secretion and
osmotic regulation.
Our studyhas several limitations.The study sample size
is relatively small. Only single doses of MDMA and du-
loxetine were used. However, the doses were selected in
the upper dose range and produced pronounced effects on
a variety of outcomes. Importantly, the absolute dose of
MDMAwas the same in both sexes and was not adjusted
for body weight, resulting in higher relative doses of
MDMAper kilogramof bodyweight inwomen compared
with men. Thus, we cannot exclude that the observed sex
difference was in fact a dose effect with women receiving
higher relative doses of MDMA than men. However, rel-
ative MDMA doses did not correlate with MDMA-in-
duced changes in copeptin levels within the male and fe-
male groups, supporting the view that our finding
represents a true sex difference and not a dose effect. Fur-
thermore, fluid consumption was different across treat-
ment conditions, which may have counteracted effects of
MDMA on AVP secretion because subjects consumed
more liquids after MDMA than after placebo administra-
tion. Finally, urine osmolality and associated AVP system
activationwas higher inmen thanwomen at the beginning
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of the study, which may have differentially affected the
response to MDMA.
With regard to the validity of theoutcomemeasures,we
documented a correlation of plasma AVP and copeptin,
confirmingprevious studies (12, 14). In addition, copeptin
plasma concentrations also weakly correlated with
plasma and urine osmolalities as expected based on os-
moregulation and as previously documented in hypo-,
iso-, and hyperosmolar states in healthy subjects (14). We
also confirmed the previously reported sex differences in
basal plasma copeptin concentration (12, 13).
In conclusion, we found thatMDMA increased copep-
tin plasma levels reflecting AVP system stimulation in
women but not in men. The finding is consistent with an
increased risk for the development of hyponatremia and
associated complications after recreational ecstasy use in
women compared with men. AVP system activation by
MDMAis likelydue to the serotonin- andnorepinephrine-
releasing properties of MDMA.
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Chapter 3: In vitro studies relevant for the pharmacological 
treatment of stimulant addiction 
Stimulant dependence comes along with the action of the questioned amphetamine-
type drugs at dopaminergic targets. In paper 3 we investigated the effects of different 
treatments on stimulant-induced DA release, which is directly responsible for the 
addictive properties of a drug. Namely, we assessed the potencies and suitability of 
the antidepressant and smoking-cessation aid bupropion, the ADHS medication 
methylphenidate, and the abused but highly potent DA uptake inhibitor MDPV to 
inhibit methamphetamine-induced DA release in vitro with relevance for 
methamphetamine dependence.  
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Bupropion, methylphenidate, and
3,4-methylenedioxypyrovalerone antagonize
methamphetamine-induced efflux of dopamine
according to their potencies as dopamine uptake
inhibitors: implications for the treatment of
methamphetamine dependence
Linda D Simmler, Rebecca Wandeler and Matthias E Liechti*
Abstract
Background: Methamphetamine-abuse is a worldwide health problem for which no effective therapy is available.
Inhibition of methamphetamine-induced transporter-mediated dopamine (DA) release could be a useful approach
to treat methamphetamine-addiction. We assessed the potencies of bupropion, methylphenidate, and 3,4-
methylenedioxypyrovalerone (MDPV) to block DA uptake or to inhibit methamphetamine-induced DA release in
HEK-293 cells expressing the human DA transporter.
Findings: Bupropion, methylphenidate, and MDPV inhibited methamphetamine-induced DA release with relative
potencies corresponding to their potencies to block DA uptake (potency ranks: MDPV >methylphenidate > bupropion).
Conclusions: Bupropion and methylphenidate antagonize the effects of methamphetamine in vitro and may be
potential candidates for the treatment of stimulant addiction. However, drugs that very potently antagonize the effect of
methamphetamine are likely to also exhibit considerable abuse liability (MDPV >methylphenidate > bupropion).
Keywords: Methamphetamine, Addiction, Dopamine, Dopamine transporter, Bupropion, Methylphenidate, MDPV
Findings
Background
Methamphetamine dependence is a major public health
problem. Currently, no medical treatments are approved
for stimulant dependence indicating the need to explore
potential candidates [1]. Methamphetamine releases
dopamine (DA) via the DA transporter (DAT) [2,3].
DA is thought to mediate the reinforcing effects of
psychostimulants, which lead to drug dependence [4,5].
Blocking the pronounced release of DA by methampheta-
mine may therefore be an interesting therapeutic option for
the treatment of methamphetamine dependence [1]. Bu-
propion and methylphenidate are DA uptake inhibitors that
interact with the same pharmacological target as metham-
phetamine [6-11]. Bupropion is used as an antidepressant
and smoking cessation aid [7,9]. Methylphenidate is effect-
ively used in the treatment of attention-deficit/hyperactivity
disorder [12,13]. In addition, small clinical studies indicated
promising beneficial effects for both medications in
methamphetamine dependence [1]. Bupropion reduced the
acute subjective effects of methamphetamine in a labora-
tory study [14] and methamphetamine use in dependent
patients with moderate drug use [15-18]. Methylphenidate
reduced amphetamine use in dependent patients [19] and it
is now being investigated in methamphetamine-addiction
(clinicaltrials.gov: NCT01044238). Bupropion also reduced
methamphetamine self-administration in rats [20] or rhesus
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monkeys [21]. In contrast, methylphenidate did not
affect methamphetamine self-administration in rhesus
monkeys [21].
The precise pharmacological mechanism of action of
bupropion and methylphenidate with regard to their
therapeutic effects in methamphetamine dependent pa-
tients is not known. Dopamine is thought to contribute to
the drug-high and euphoria produced by psychostimulants
and mediates the addictive properties of drugs of abuse
[4,22]. Amphetamines reverse the transport of DA through
the DAT and this effect is thought to play a key role in the
addictive potential of amphetamines [5]. The DA uptake
inhibitors bupropion and methylphenidate may therefore
prevent methamphetamine from interacting with the DAT
to release DA, and such an effect would antagonize effects
of methamphetamine. Several DA uptake inhibitors have
previously been shown to prevent DAT-mediated release of
DA by amphetamines in vitro. For example, bupropion and
methylphenidate [23] as well as GBR12909 [3] inhibited
DAT-mediated amphetamine- or methamphetamine
induced DA release from rat synaptosomes. In HEK-293
cells expressing human DAT, methylphenidate inhibited
DA efflux induced by methamphetamine [24]. These and
similar data suggest that bupropion and methylphenidate
block the interaction of methamphetamine with the
DAT to release DA and thereby act as antagonists of
amphetamine-like drugs.
The aim of the present study was to test and compare
the effects of bupropion and methylphenidate on
methamphetamine-induced DA efflux in HEK-293 cells
expressing human DAT in vitro. Bupropion and methyl-
phenidate were selected because of their availability as
licensed medications and the clinical data described above.
We also included 3,4-methylenedioxypyrovalerone (MDPV)
into the study because it has been shown to be a very
potent DAT inhibitor [10,25].
We hypothesized that 1) the DA uptake blockers would
prevent methamphetamine-induced DA release and 2)
the potencies of the drugs to inhibit methamphetamine-
induced DA release would correspond to their potencies
to block DA uptake.
Methods
Drugs
(±)-Bupropion hydrochloride was from Toronto Research
Chemicals (North York, Canada), d-methamphetamine,
(±)-methylphenidate, and (±)-MDPV were supplied as
hydrochloride salts by Lipomed (Arlesheim, Switzerland).
Inhibition of DA uptake
The potencies of the drugs to inhibit the DAT were
evaluated as previously described [26] in HEK-293 cells
(Invitrogen, Zug, Switzerland) stably transfected with
the human DAT [8].
Inhibition of methamphetamine-induced DA release
We performed DA transporter mediated release experi-
ments as previously published [25] with slight modification.
In brief, HEK-293 cells expressing the human DAT as
stated above were cultured in 48 well-plates. Cells were
filled with 3H-DA, washed, and incubated with 250 μL
buffer containing the drug alone or in combinations. Drug
combinations were 10 μM of methamphetamine with
bupropion, methamphetamine, or MDPV in different
concentrations. DA release was stopped after 15 min by
removing the release buffer from the cells. To quantify
the DA release we determined the radioactivity in the
cells after another wash step. The residual radioactivity
in the cells after methamphetamine alone defined 100%
DA release. Baseline (0% release) was defined as the
radioactivity remaining in the cells treated with bupro-
pion, methylphenidate, or MDPV alone at the highest
concentration used.
Results
Inhibition of DA uptake
Bupropion, methylphenidate, and MDPV inhibited
the uptake of DA. MDPV was the most potent DAT
inhibitor followed by methylphenidate and bupropion.
Methamphetamine blocked DA uptake with similar
potency to bupropion (Figure 1).
Inhibition of methamphetamine-induced DA release
Methamphetamine released DA with a potency (EC50) of
1.56 μM (0.9 μM-2.8 μM, 95% CI) as shown previously
[25]. DA release induced with 10 μM methamphetamine
was inhibited concentration-dependently by bupropion,
methylphenidate, and MDPV (Figure 2). MDPV was
the most potent inhibitor of the methamphetamine-
induced DA release followed by methylphenidate and
bupropion (Figure 2). The IC50 values are shown in
Table 1. The potencies (IC50 values) of the drugs to
block DA release correlated highly with the potencies to
block DA uptake (Figure 3) as confirmed by a correlation
coefficient of >0.99, p < 0.05.
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Figure 1 DA uptake inhibition by methamphetamine, bupropion,
methylphenidate, and MDPV. IC50 values are shown in Table 1. The
data are expressed as mean ± SEM of 3–4 independent experiments.
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Discussion
In the present study, the DA uptake inhibitor bupropion
inhibited DA release induced by methamphetamine.
This mechanism might underlie the reduction in the
methamphetamine-induced subjective drug high by bu-
propion pretreatment documented in a clinical laboratory
study [14] and the reduced methamphetamine consump-
tion in drug users treated with bupropion [15-18].
Methylphenidate also blocked the methamphetamine-
induced DA release similar to bupropion and this effect
may also antagonize the rewarding effects of metham-
phetamine and its use in dependent patients. In fact,
methylphenidate showed beneficial effects in amphet-
amine dependent patients [19] and is being investi-
gated for the treatment of methamphetamine addiction
(clinicaltrials.gov: NCT01044238). Thus, inhibition of
DA release might be a pharmacological mechanism
how DA uptake inhibitors reduced the subjective stimulant
drug effects or drug consumption in the clinical studies
noted above. In addition, methylphenidate and bupropion
also increase DA levels and therefore both drugs may also
act as substitution treatments for methamphetamine use.
In the present study we also included the very potent DA
uptake inhibitor MDPV to explore how the potency of a
drug as DA uptake inhibitor relates to its potency to
antagonize the pharmacological effect of methampheta-
mine. MDPV blocked methamphetamine-induced DA
release with high potency reflecting its high potency as an
uptake inhibitor. We found that the potencies of the drugs
to block methamphetamine-induced DA release correlated
closely and significantly with their potencies to act as DA
uptake inhibitors. The finding suggests that the more po-
tent a drug antagonizes the DA release produced by meth-
amphetamine the more potently it also blocks DA uptake.
This finding may have important clinical implications re-
garding the abuse liability of potential antagonist treatments
for methamphetamine dependence. With regard to the
drugs tested in the present study, the antidepressant bupro-
pion is a low-potency DA transporter inhibitor and it is
considered a drug that does not produce relevant euphoria
nor addiction [27,28]. Methylphenidate is an intermediate-
potency DA transporter inhibitor and is known to produce
euphoria at higher doses [29,30] and to have a relevant
abuse potential [31,32]. The cathinone MDPV is a high po-
tency DA transporter inhibitor and street designer drug
(“super coke”, “research chemical”, “bath salt”) with high
addiction potential similar to the DA releaser metham-
phetamine [25,33-35]. Our findings indicate that drugs that
potently and effectively antagonize the effect of metham-
phetamine are likely to exhibit high abuse liability them-
selves because they block DA uptake. In fact, the potency
of amphetamine-type stimulants to block DA uptake has
been shown to correlate with the doses used by humans
[25]. Furthermore, potent DA transport uptake inhibition is
sufficient to produce addiction because cocaine and MDPV
only block DA uptake and do not induce DA release as
methamphetamine [5,25]. It is therefore questionable
whether there are any compounds that do not activate the
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Figure 2 Methamphetamine-induced DA release is inhibited by
bupropion, methylphenidate and MDPV. The corresponding IC50
values are shown in Table 1. DA release was induced with 10 μM
methamphetamine (100% release) and blocked with different
concentration of the inhibitors bupropion, methylphenidate or MDPV.
Baseline (0% release) was defined as the radioactivity remaining in the
cells treated with bupropion, methylphenidate, or MDPV alone. The
data are expressed as mean ± SEM of 3–4 independent experiments.
Table 1 Potencies of drugs to block DA uptake or
methamphetamine-induced DA release
DA uptake Methamphetamine-induced
DA release
IC50 (μM) (95% CI) IC50 (μM) (95% CI)
Methamphetamine 1.05 (0.7-1.5) -
Bupropion 1.76 (1.1-2.8) 14.2 (9.7-21)
Methylphenidate 0.14 (0.1-0.2) 1.67 (0.7-4.0)
MDPV 0.031(0.03-0.04) 0.28 (0.1-0.6)
Values are means of 3–4 independent experiments and 95% confidence
intervals (CI).
Figure 3 The potencies of the drugs (log IC50 values) to
inhibit DA uptake correlate linearly with their potencies
to inhibit methamphetamine-induced DA release
(correlation coefficient > 0.99, p < 0.05, regression line and 95%
confidence intervals).
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DA system and lack abuse liability but effectively prevent
methamphetamine from interacting with DAT. On the
other hand, abuse liability of medications can be reduced
by using extended-release drug formulations.
Methamphetamine also has additional effects on the
DA system (e.g., on monoamine oxidase and the vesicular
monoamine transporter), which were not studied here.
These effects of methamphetamine take place within the
cells and are likely prevented by DAT inhibitors [36]
that block methamphetamine transport into the cell.
Methamphetamine also releases norepinephrine [2,3]
and norepinephrine is thought to contribute to the
acute effects of amphetamine-type drugs [3,37-39]. MDPV
[25] and methylphenidate [6,40], and to a lower extent
bupropion [7,11], block the norepinephrine transporter and
these drugs could also block methamphetamine-induced
norepinephrine release. We did not address potential drug
interactions at the norepinephrine transporter because in
contrast to DA, norepinephrine is not generally thought
to be a major mediator of the addictive properties of
psychostimulants. However, interactions at the norepin-
ephrine transporter could be expected to contribute to
any therapeutic effects of the drugs tested in the present
study. Finally, it should be noted that we assessed only a
small number of DAT inhibitors. However, the drugs were
selected to cover a wide range of DAT inhibition potencies
including also the very potent DAT inhibitor MDPV.
Conclusion
Our in vitro studies and the limited clinical data indi-
cate that the low- and intermediate-potency DA uptake
inhibitors bupropion and methylphenidate may be potential
candidates as treatments of amphetamine-type stimu-
lant dependence [1] due to their property to inhibit
methamphetamine-induced DA efflux. Their clinical
efficacy needs further confirmation.
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Discussion 
 
We assessed the pharmacology of amphetamine-type drugs in vitro and, using 
MDMA, also in humans. We found that these novel designer drugs overall resemble 
long known psychostimulant drugs like MDMA, methamphetamine, or cocaine. 
However, there is considerable variability in the pharmacological properties within 
cathinone designer drugs. We therefore classified the assessed novel designer drugs 
according to their pharmacology, which should also facilitate the prediction of their 
psychotropic effects, expected medical complications, and presumed addictive 
potential in humans. Currently abused novel designer drugs range from highly potent 
dopaminergic and noradrenergic drugs (e.g., MDPV) to selective serotonergic drugs 
(e.g., methedrone), thus displaying a wide range of potential effects in humans. We 
demonstrated that in vitro pharmacological profiling was a useful tool to gain a first 
and fast overview on the pharmacology of newly emerging designer drugs with action 
on the monoamine systems. We also highlighted the essentiality of clinical laboratory 
studies in humans to clarify the role of the different monoaminergic neurotransmitters 
and receptors in the psychotropic and clinical toxicological effects of these 
recreationally used drugs. Translating the in vitro to the clinical findings and back, we 
gained knowledge and certainty in the interpretation of pharmacological effects of 
amphetamine-type drugs. With the understanding of the drugs’ pharmacology, we 
took the next step to explore ways to combat drug-related problems such as stimulant 
dependence by pharmacological antagonism. 
 
Methodological problems and limitations 
During the establishment of the pharmacological in vitro assays, we were facing 
several methodological problems. I address here the most crucial issues.  
As shortly mentioned in the methods of paper 1a, in our hands, a pure uptake inhibitor 
induced slight “transporter-mediated” monoamine release from monoamine-preloaded 
cells. For example, mazindol and citalopram reduced radioactivity remaining in cells 
by ≤ 20% in HEK DAT and HEK SERT cells, respectively (see paper 1a). Some other 
research groups did not explicitly report this so-called apparent release both in HEK 
cell lines [1] and in synaptosomes [2]. However, there is an exemplary publication 
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that explains the cause of this apparent monoamine release by pure uptake inhibitors 
as methodological artifact. In their experiments with superfused HEK SERT cells, 
pure 5-HT uptake inhibitors like fluoxetine induced marked 5-HT release. This 
release was not as effective than the one induced by a substrate-type releaser such as 
para-chloroamphetamine. From their in vitro studies assessing the cause of this 
phenomenon, the authors concluded that intracellular 5-HT must penetrate the plasma 
membrane in a transporter-unspecific way, but in presence of a highly potent uptake 
blocker like fluoxetine there is no subsequent transporter-mediated 5-HT reuptake 
into the cell. This causes the nonspecific or apparent release observed when 
calculating monoamine efflux from a non-blocking vehicle control [3]. Scholze et al. 
proposed to use 1-methyl-4-phenylpyridinium (MPP+) as a substitute for 5-HT to 
circumvent this apparent release phenomenon. However, we and others decided to 
continue our experiments with the physiological substrates because MPP+ and 5-HT, 
NE, or DA do not have identical transport characteristics [3-5]. Considering apparent 
release in the experimental setting by subtraction or statistical analysis, we could keep 
on working with the natural neurotransmitters.  
A further difficulty in our methodology should be mentioned here. We preloaded cells 
with neurotransmitters prior to release-induction to ensure an intracellular reservoir of 
monoamines that could be released, thus modeling a transmitter-loaded presynapse of 
a neuron. For 5-HT release in HEK SERT cells, loading the cells with 10 nM 5-HT 
was sufficient for effective release. However, for DA and NE release, 1 µM DA and 
10 µM NE were required to obtain effective monoamine release. This was shown for 
DA before [6], but others succeeded using low DA or NE concentrations [1, 7, 8]. 
Amphetamines that induce monoamine release are generally thought to be substrates 
of the respective monoamine transporters [9]. Since the release assay remained to be 
difficult, we also tried to assess whether substances were transporter substrates to 
classify a drug as substrate-type releaser or as non-releaser. Thus, we quantified 
intracellular drugs after a 15 min period of uptake at 37 °C and on ice, with or without 
uptake inhibitors present. Unfortunately these attempts remained unsuccessful, as data 
were difficult to interpret due to high variability. It also seemed that uptake on ice 
could still take place, which would contradict the claim of active substrate transport 
[10]. Moreover, we could not distinguish between a releasing- and a non-releasing 
substance, as all drugs were transported to a certain extent, probably due to their 
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lipophilicity. Thus, we remained unsuccessful in quantifying substrate transport, but 
experimental optimizations (e.g. reduction of variability and passive transport) could 
indeed lead to interesting information on drugs’ transport characteristics and 
toxicological potential. These experiments are mentioned here for completeness but 
are not described in the result section where only more conclusive published or 
publishable data was presented.  
It should be noted here that attempts to characterize substrate uptake into human cells 
or synaptosomes and monoamine release experiments are in general considered 
methodologically complex and less reliable and valid than commonly used 
monoamine uptake assays. Release may therefore best be studied using in vivo 
microdialysis in freely moving rodents. However, this approach is very resource-
consuming and can only be used to evaluate a selection of compounds as recently 
done by other research groups [11, 12]. 
Using transfected cells as model to assess drugs’ pharmacology, we took advantage of 
the possibility to work with human transporters. This is not possible if synaptosomes 
were used, since they are derived from non-humans such as rhesus monkeys [2] or 
mice [13]. However, working with cells transfected with one respective gene, we do 
not take into account that genetic variants of SERT, DAT, and NET exist and that 
these variants might exert different effects as response on drug action [14-18]. To 
account for different geno- and phenotypes would, however, exceed this thesis’ 
possibilities. In addition, in transfected human cells only the target transporter or 
receptor of interest is evaluated in isolation whereas synaptosomes contain all 
molecules present in the synaptic membrane. We consider the in vitro models with 
human transporters and receptors an excellent starting point to rapidly screen for the 
pharmacological properties of newly emerging substances. These experiments can 
then be complemented by in vivo tests in rodents (locomotor behavior, cardiovascular 
stimulation, telemetry with body temperature recordings, and microdialysis) for 
selected compounds of interest, ultimately also using clinical studies for a subset of 
compounds that are more widely used recreationally. 
In this thesis, we hardly broach the issue of stereochemistry in the assessed drugs. All 
of the assessed substances exist as two enantiomers. For MDMA, amphetamine, and 
methamphetamine it is well known that their pharmacology and even 
pharmacokinetics are stereoselective [1, 2, 19]. Novel designer drugs like cathinone-
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derivatives are mainly commercially available as racemates only, therefore we 
worked, with the exception of amphetamine and methamphetamine, with the 
respective racemic mixture.  
Some of our studies, namely paper 1a, 1b and paper 2b in this thesis, provide binding 
affinity constants derived with assays which quantify the ability of a drug to displace 
a radiolabeled ligand from the binding site of the target. We admit that the 
significance of this information is limited if the radiolabeled ligand and the substance 
to assess do not share the same binding site and property. A close look at our data 
reveals that affinity data for transporter substrates do not correlate with their potency 
to inhibit the transporter. MDMA, for example, inhibits NE and 5-HT uptake with 
similar potencies than cocaine, but its binding is approximately 10 times weaker 
compared to cocaine (see paper 1a). This is a common phenomenon for binding 
studies using ligands that are also transporter substrates because transport of the 
substrate alters the apparent binding affinity [20-22]. Furthermore, the non-releaser 
cocaine and the substrate-type releaser MDMA do not share the same binding site at 
the transporters, which was shown nicely for SERT by the Blakely group [23].  
Obviously, if a substance is a substrate-type releaser, its binding affinities assessed by 
the described displacement assay will never be representative. In fact, we could even 
use the discrepancy of the binding affinities and uptake inhibition potencies as marker 
for the drug being a substrate and thus a monoamine releaser. 
 
Differentiation of releasers and non-releasers in relation to psycho-
stimulant effects in humans 
Throughout my PhD thesis, I distinguished monoamine-releasing drugs from pure 
monoamine uptake inhibitors, either in the characterization of their pharmacology or 
in the interpretation of their impact on humans. We came across the fact that MDPV 
exerts extremely pronounced psychostimulant effects in humans [24-26], but found it 
to be a pure uptake inhibitor. Before this finding, we have speculated that the 
releasing property of a drug might result in more potent effects compared to a 
non-releasing drug. However, whether a psychostimulant releases monoamines (such 
as MDMA or amphetamine) or acts primarily as an uptake inhibitor (such as cocaine 
or MDPV) may not be critically relevant with regard to the psychostimulant and 
addictive properties of a drug in vivo. With MDPV and cocaine we know two highly 
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effective and potent psychotropic but non-releasing drugs [27, 28], and also 
methylphenidate is a pure uptake inhibitor, which is frequently abused due to its 
stimulating properties [29]. On the other hand, at least with regard to the 5-HT and 
NE, an uptake inhibitor abolishes psychostimulant effects of the 5-HT/NE-releaser 
MDMA in humans, as shown in paper 2a and 2b as well as by Liechti et al. [30]. 
Thus, net monoamine accumulation should be lower in presence of a non-releasing 
drug compared to a releasing drug. For example, 5-HT concentrations in the synaptic 
cleft would not be increased by citalopram to the same extent as it would be by 
MDMA, although citalopram inhibits 5-HT uptake at SERT with higher potency than 
MDMA [2]. This was indeed observed with DA in two studies comparing 
extracellular DA concentrations measured by microdialysis. Cocaine provoked lower 
extracellular DA concentrations than equivalent amphetamine doses [31, 32]. In 
contrast, another study by Maisonneuve et al. claimed no differences between net DA 
concentrations after cocaine or amphetamine administration [33]. Due to the 
underrepresentation of studies comparing net extracellular neurotransmitter levels 
induced by non-releasing and releasing drugs, I hereby cannot draw final conclusions 
on the relevance to distinguish between a non-releasing and releasing psychoactive 
drug for its psychostimulant effects.  
The effects of a psychostimulant on the DA and NE systems appear to be the critical 
determinant of the psychostimulant effectiveness of a drug, regardless of its releasing 
or non-releasing properties. In fact, the DAT and NET but not the SERT inhibition 
potency of the psychotropic drugs investigated previously [2] or in this work (paper 
1a) correlated with the doses to induce psychostimulant effects in humans. 
Furthermore, release of DA, but also pure DA uptake blockade, is related to increased 
risk for addiction [34]. Rothman suggested over 20 years ago that there are uptake 
inhibitors like cocaine which produce addiction and euphoria and uptake inhibitors 
like bupropion which are equally potent DAT blockers, but do not have addictive or 
psychostimulant effects [35]. These kind of non-addictive and non-euphoriant uptake 
inhibitors could indeed be used as pharmacological treatment against addiction. We 
should also consider that dosing and pharmacokinetics are highly critical additional 
determinants of the abuse and euphoriant potential of psychostimulants. DA uptake 
inhibitors like methylphenidate may produce very pronounced and identical 
DISCUSSION___________________________________________________________________! !114!
psychostimulation and feelings of drug high to cocaine when administered in high 
doses, intravenously, or by the nasal route [29].  
Finally, we should always consider the increased toxic potential of a substrate-type 
releasing drug due to its intracellular accumulation [36]. A pure uptake-inhibiting 
drug could even prevent this toxicity by inhibiting the transporter-mediated uptake of 
the toxic drug into the presynaptic neuron [10]. 
 
Relevance of our findings for medical care 
For our society the main benefit from our research is the pharmacological 
characterization of so far poorly evaluated but recreationally used drugs of abuse. 
Knowing about the molecular pharmacology of these designer drugs, we can predict 
some of the acute clinical effects and medical complications. We can thereby advise 
physicians on the expected features of intoxications and which emergency treatment 
would be appropriate based on pharmacological considerations, in accordance e.g. to 
the recently reported recommendations by Mas-Morey et al. [37]. Moreover, we can 
estimate the addictive potential of a drug based on their dopaminergic versus 
serotonergic properties.  
As we saw in our study presented in paper 2c and in the work by others [38, 39], 
MDMA use is associated with SIADH and hyponatremia due to its 5-HT releasing 
properties. Thus, we expect all 5-HT releasing drugs to potentially produce SIADH. A 
recent report by Boulanger-Gobeil et al. [40] is in line with this interpretation. They 
found hyponatremia, resulting from SIADH, in a case that was exposed to methylone 
and ethcathinone. Indeed, we showed methylone to be a 5-HT releasing 
amphetamine-derivative (see paper 1a). For all intoxications with 5-HT releasing 
drugs, we would therefore advise emergency care personnel to consider hyponatremia 
if intoxication cases present with confusion, seizures or even comma. They should 
treat these intoxications primarily with water restriction [41].  
More common than hyponatremia-related toxicity are signs and symptoms associated 
with sympathomimetic overstimulation such as hypertension, tachycardia, 
hyperthermia, and agitation due to psychostimulant use [36, 42]. Indirect agonism at 
the adrenoreceptors α1 and β1-3 are responsible for cardiostimulant effects of NE 
uptake inhibiting and/or releasing drugs [36, 43-45]. Cardiostimulation results in high 
blood pressure, increased heart rate, and increased body temperature [36, 43]. 
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Drug-induced body temperature elevation is triggered by physical activity in hot 
environments such as dance parties [46, 47]. This kind of hyperthermia can be 
life-threatening because it might result in multi-organ failure [47, 48]. The clinical 
picture of amphetamine-associated sympathomimetic overstimulation including 
hyperthermia is typically seen with drugs stimulating the noradrenergic system [36, 
49]. In our in vitro profiling in chapter 1, all novel designer drugs inhibited NE uptake 
considerably. We therefore expect possible sympathomimetic intoxications with all 
assessed designer drugs. Medical personnel should be aware of treating these cases of 
sympathomimetic intoxication due to consumption of new designer drugs analog to 
intoxications with amphetamine, cocaine, and MDMA. Typical pharmacological 
intervention implies sedation with benzodiazepines [27, 37, 48]. Beta-blockers or 
α1-β-blockers are not commonly used in emergency care treatment of stimulant 
intoxications. One advises against the use of β-blockers due to observed unopposed 
α1-activation in response to cocaine which may result in enhanced vasoconstriction 
and tachycardia [50]. In MDMA, the β-blocker pindolol did not worsen drug-induced 
cardiovascular effects. It might be useful to improve MDMA-induced tachycardia, but 
not hypertension [51]. However, we showed that the α1-β-blocker carvedilol reduces 
MDMA-induced cardiostimulation and more importantly also the thermogenic effects 
of MDMA [44]. Apart from benzodiazepines, an α1-β-blocker could therefore also be 
useful in stimulant intoxications in particular in cases with severe hyperthermia that 
do not adequately respond to fluid administration and sedation.  
Amphetamine-induced psychotic symptoms such as paranoia and hallucinations 
derive mostly from DA release [36]. Among novel designer drugs, cathinone-
derivatives are characterized by pronounced activity at dopaminergic neurons (see 
chapter 1). We expect psychotic symptoms to arise from cathinones-use, which 
indeed is reported in the literature [26]. In severe cases, antagonism of psychosis with 
neuroleptics may be indicated, but benzodiazepines should be used first [27, 52].  
 
Within the scope of this thesis, we strongly focused on the medical risks that an 
amphetamine-type drug bears when misused for recreational purpose. However, I 
want to remind here that there are indeed positive medical aspects of some 
amphetamine-type drugs. Most notably, amphetamine and methylphenidate are 
effective and widely prescribed in the treatment of attention deficit hyperactivity 
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disorder [53]. Before illegalization, the entactogenic MDMA was widely used in 
psychotherapy to facilitate the therapist’s access to the patient. There is also a 
renewed research focus on the use of MDMA as adjunct to psychotherapy in the 
treatment of post-traumatic stress disorders (PTSD) [54, 55]. Recent clinical studies 
showed MDMA’s beneficial and catalytic effects for recovery from PTSD [56-58]. 
 
Outlook 
Accessible knowledge about the designer substances currently abused and their 
pharmacology and clinical toxicology is highly valuable. Thus, we keep on profiling 
the pharmacology of novel designer drugs in vitro. In collaboration with emergency 
care doctors and medical analysts, we will also collect and report cases requiring 
emergency care due to designer drug intoxications. These efforts will further improve 
the understanding of recently emerged drugs of abuse and support medical care 
personal to treat such intoxications, as well as to help health authorities in their 
decisions to schedule new drugs.  
Wherever the pharmacology of novel designer drugs is unknown, their toxic effects 
are unknown either and remain an object of concern. Since we now hold a 
comprehensive set of frequently abused drugs in our laboratory, we should take the 
chance and study their neurotoxicological potential as well. We could assess the 
implications of our designer drugs on mitochondrial dysfunction in vitro. After 
incubation with liver microsomes [59], we could also assess the toxic effects of their 
metabolites, which probably bear even higher toxicological potentials than the mother 
substances [60]. One could also study the in vitro potencies to inhibit enzymes 
involved in neurotransmitter synthesis and metabolism in particular with those drugs 
that are substrate-type releasers and thus transported into the cells.  
One should also take advantage of the mechanistic understanding of the drugs’ 
pharmacology and the contextual neuronal functions. In vitro, the direct antagonism 
of psychostimulant drugs’ targets is shown by us in paper 3 and by others [2, 61, 62], 
but one should intensify the investigations on the benefits of this antagonism in 
humans [63]. We need more data from clinical studies assessing for example the 
outcome from treatment with DAT inhibitors on stimulant dependence. Besides of 
direct interaction with stimulant targets, we also propose to further investigate indirect 
pharmacological modulation. Animal experiments showed the involvement of the 
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trace-amine associated receptor 1 in drug effects [13, 64]. We propose to keep on 
investigating the possibility to modulate effects of drugs of abuse via the 
pharmacological activation of this receptor. However, more mechanistic 
understanding of this pathway is needed before addressing this objective in humans. 
 
Irrespective of the different objectives proposed here for further investigations, the 
continuous use of a wide variety of psychostimulants points towards the essentiality 
of doing research on currently abused drugs. Manhood will never stop changing its 
perception by the ingestion of effective substances. Is this not reason enough for all 
efforts to understand the negative and positive consequences of drugs? 
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